Engineered meganucleases with specificity for recognition sequences within the dystrophin gene
Patent Information
- Application Number
- JP2023528230
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-08-16
- Filing Date
- 2021-11-12
- Publication Date
- 2024-11-20
- Estimated Expiration
- 2041-11-12
AI Technical Summary
Current treatments for Duchenne muscular dystrophy, such as gene replacement, exon skipping, and cell transplantation, face challenges like limited viral vector capacity, immune response, inefficiency, and the need for lifelong drug administration, with exon skipping being inefficient and transient.
Genetically engineered meganucleases are used to excise specific exons from the dystrophin gene by targeting intronic regions, restoring the reading frame and expressing a modified dystrophin protein with intact N-terminal and C-terminal domains, using a pair of engineered meganucleases to cleave and remove exons 45-55.
This approach provides a permanent treatment that reduces the severity of Duchenne muscular dystrophy to a milder Becker phenotype by ensuring the expression of a functional dystrophin protein without the non-essential rod domain, addressing the inefficiencies of existing methods.
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
Technical field
[0001] This application relates to the fields of genetically engineered meganucleases, molecular biology and recombinant nucleic acid technology. In certain aspects, the invention relates to genetically engineered meganucleases useful for removing exons from the dystrophin gene and treating subjects with Duchenne muscular dystrophy.
[0002] Reference to sequence listings submitted as text files via EFS-WEB This application contains a sequence listing submitted in ASCII format via EFS-Web, which is incorporated herein by reference in its entirety. The name of the above ASCII copy created on November 12, 2021 is P109070054WO00-SEQ-EPG and the size is 279,819 bytes. [Background technology]
[0003] Duchenne muscular dystrophy (DMD) is a rare X-linked muscular degenerative disorder that affects approximately 1 in 3,500 boys worldwide. The disease is caused by mutations in the dystrophin gene, the largest known gene. The dystrophin gene spans 2.2 Mb of the X chromosome and primarily encodes a 14 kb transcript derived from 79 exons. The full-length dystrophin protein, expressed in skeletal muscle, smooth muscle, and cardiomyocytes, is 3685 amino acids and has a molecular weight of 427 kD. Severe Duchenne phenotype is generally associated with loss of full-length dystrophin protein from skeletal and cardiac muscle, leading to debilitating muscle degeneration and ultimately heart failure. A number of different dystrophin gene mutations have been described, many of which result in either severe DMD or the milder form of Becker muscular dystrophy.
[0004] Several therapeutic strategies have been pursued for the treatment of DMD. First, "gene replacement" strategies are an active area of research (Non-Patent Documents 1-4). This approach involves delivering a functional copy of the dystrophin gene to the patient using a viral delivery vector, typically an adeno-associated virus (AAV). However, the large size of the dystrophin gene makes it incompatible with the limited carrying capacity of common viral vectors. This requires the use of the "microdystrophin" gene, in which most of the repetitive core of the gene is removed, leaving only a minimally functional protein. However, it is not clear that expression of "microdystrophin" is sufficient for clinical benefit. Furthermore, this approach suffers from the possibility of random gene integration into the patient's genome, which can result in insertional mutagenesis, and the possibility of an immune response to the delivery vector.
[0005] A second approach to treating DMD involves transplanting healthy muscle progenitor cells into the patient's muscle fibers (5, 6). This approach suffers from inefficient migration of transplanted myoblasts and potential immune rejection by the patient.
[0006] A third approach involves suppression of nonsense mutations using PTC124 (Non-Patent Document 7). However, this requires lifelong administration of the drug, and this approach has not yet shown any significant clinical benefit.
[0007] A fourth approach to treating DMD is called "exon skipping" (Non-Patent Documents 8-14). In general, the amino (N) and carboxy (C) terminal portions of the dystrophin gene, which are essential for its role as a "scaffolding" protein that maintains the membrane integrity of muscle fibers, contain 24 spectrin-like repeats. The central "rod domain" is at least partially dispensable. Indeed, the severe Duchenne phenotype is typically associated with mutations in the dystrophin gene that introduce frameshifts and / or premature stop codons, resulting in a truncated form of the dystrophin protein that lacks the essential C-terminal domain. Mutations of the central rod domain, including large deletions of entire exons, typically result in a much milder Becker phenotype if the reading frame is maintained such that the C-terminal domain of the protein is intact.
[0008] DMD is most frequently caused by the deletion of one or more entire exons, resulting in a reading frame shift. For example, exon 45 is frequently deleted in Duchenne patients. Exon 45 is 176 bp long, which is not divisible by 3, so deleting the exon shifts exons 46 to 79 into the wrong reading frame. The same is true for exon 44, which is 148 bp long. However, if exons 44 and 45 are deleted, the total size of the deletion is 324 bp, which is divisible by 3. Therefore, deletion of both exons does not result in a reading frame shift. Since these exons encode part of the nonessential rod domain of the dystrophin protein, deletion of them from the protein would be expected to result in a mild Becker-like phenotype. Therefore, patients with Duchenne phenotype due to deletion of one or more exons could potentially be treated by eliminating one or more adjacent exons to restore the reading frame. . This is behind 'exon skipping', which uses modified oligonucleotides to block the splice acceptor site of dystrophin pre-mRNA, ensuring that one or more specific exons are not present in the processed transcript. It is the principle. This approach has been used to restore dystrophin gene expression in an mdx mouse model by skipping exon 23, which has a disease-causing nonsense mutation (15). Oligonucleotide analogs that induce exon 51 skipping have also shown promise in early human clinical trials (16). The main limitations of this approach are: (1) the exon-skipping process is inefficient and results in relatively low levels of functional dystrophin expression; (2) exon-skipping oligonucleotides are relatively short Because it has a half-life, its effects are transient and require repeated and lifelong dosing. Thus, while exon-skipping approaches have shown some promise in clinical trials, improvements in disease progression are minimal and variable.
[0009] The present disclosure improves on current exon skipping approaches by correcting gene expression at the level of genomic DNA rather than pre-mRNA. The present invention is a permanent treatment for DMD that involves excising specific exons from the dystrophin coding sequence using a pair of genetically engineered site-specific homing endonucleases, often called meganucleases. By targeting such endonuclease pairs to sites in intronic regions flanking exons within the dystrophin gene, it is possible to permanently remove intervening fragments from the genome. The resulting cells and their progeny express a modified dystrophin in which a portion of the non-essential spectrin repeat domain has been removed, but the essential N-terminal and C-terminal domains are intact.
[0010] Homing endonucleases, or meganucleases, are a group of naturally occurring nucleases that recognize 15-40 base pair cleavage sites commonly found in plant and fungal genomes. They are often associated with parasitic DNA elements such as group 1 self-splicing introns and inteins. They naturally promote homologous recombination or gene insertion at specific locations in the host genome by creating double-strand breaks in the chromosome and recruit the cell's DNA repair machinery (17). Homing endonucleases are generally classified into four families: the LAGLIDADG family, the GIY-YIG family, the His-Cys box family, and the HNH family. These families are characterized by structural motifs that influence catalytic activity and recognition sequences. For example, members of the LAGLIDADG family are characterized by having either one or two copies of the conserved LAGLIDADG motif (Non-Patent Document 18). LAGLIDADG homing endonucleases with a single copy of the LAGLIDADG motif form homodimers, whereas members with two copies of the LAGLIDADG motif are found as monomers.
[0011] I-CreI (SEQ ID NO: 1) is a member of the LAGLIDADG family of homing endonucleases that recognizes and cleaves a 22 base pair recognition sequence in the chloroplast chromosome of the algae Chlamydomonas reinhardtii. Genetic selection techniques have been used to modify wild-type I-CreI cleavage site preference (Non-Patent Documents 19-22). Mono-LAGLIDADG homing allows I-CreI and other homing endonucleases to be comprehensively redesigned to target a wide variety of DNA sites, including sites in mammalian, yeast, plant, bacterial and viral genomes. A method for rationally designing endonucleases has been described (Patent Document 1).
[0012] As first described in US Pat. can be fused into a single polypeptide using short peptide linkers (23, 24). Thus, a functional "single-stranded" meganuclease can be expressed from a single transcript. By delivering genes encoding two different single-chain meganucleases into the same cell, it is possible to cleave two different sites simultaneously. This, combined with the extremely low frequency of off-target cleavage observed with genetically engineered meganucleases, makes them the preferred endonucleases for the present disclosure. [Prior art documents] [Patent document]
[0013] [Patent Document 1] International Publication WO2007 / 047859 [Patent Document 2] International Publication WO2009 / 059195 Publication [Non-patent literature]
[0014] [Non-patent document 1] Oshima et al. (2009) J.Am.Soc.Gene Ther.17:73-80 [Non-patent document 2] Liu et al.(2005)Mol.Ther.11:245-56 [Non-patent document 3] Lai et al.(2006)Hum Gene Ther.17:1036-42 [Non-patent document 4] Odom et al.(2008)Mol.Ther.16:1539-45 [Non-patent document 5] Peault et al.(2007)Mol.Ther.15:867-77 [Non-patent document 6] Skuk et al.(2007)Neuromuscul.Disord.17:38-46 [Non-patent document 7] Welch et al.(2007)Nature 447:87-91 [Non-patent document 8] Williams et al.(2008)BMC Biotechnol.8:35 [Non-patent document 9] Jearawiriyapaisarn et al. (2008) Mol Ther. 16:1624-29 [Non-patent document 10] Yokota et al.(2007)Acta Myol.26:179-84 [Non-patent document 11] van Deutekom et al.(2001)Hum.Mol.Gen.10:1547-54 [Non-patent document 12] Benedetti et al. (2013)FEBS J.280:4263-80 [Non-patent document 13] Rodino-Klapac(2013)Curr Neurol Neurosci Rep.13:332 [Non-patent document 14] Verhaart&Aartsma-Rus(2012)Curr Opin Neurol.25:588-96 [Non-patent document 15] Mann et al.(2001)Proc.Nat.Acad.Sci.USA 98:42-47 [Non-patent document 16] Benedetti et al. (2013)FEBS J.280:4263-80 [Non-patent document 17] Stoddard(2006)Q.Rev.Biophys.38:49-95 [Non-patent document 18] Chevalier et al. (2001) Nucleic Acids Res.29:3757-74 [Non-patent document 19] Sussman et al. (2004) J.Mol.Biol.342:31-41 [Non-patent document 20] Chames et al. (2005) Nucleic Acids Res.33:e178 [Non-patent document 21] Seligman et al. (2002) Nucleic Acids Res.30:3870-79 [Non-patent document 22] Arnould et al. (2006) J.Mol.Biol.355:443-58 [Non-patent document 23] Li et al. (2009) Nucleic Acids Res.37:1650-62 [Non-patent document 24] Grizot et al. (2009) Nucleic Acids Res.37:5405-19 [Summary of the invention] [Problem to be solved by the invention]
[0015] The present disclosure provides genetically engineered meganucleases that bind to and cleave recognition sequences within the dystrophin gene (e.g., the human dystrophin gene), as well as compositions containing such engineered meganucleases and methods of use thereof. provide. In some embodiments, the engineered meganuclease pair generates a first cleavage site in an intron upstream of a first exon and a second cleavage site in an intron downstream of a second exon. used to remove multiple exons from the dystrophin gene by generating In the specific example described herein, the first cleavage site is generated in an intron 5' upstream of exon 45 of the dystrophin gene, and the second cleavage site is generated in an intron 3' downstream of exon 55. Ru. This process allows excision and removal of exons 45-55 from the dystrophin gene after annealing of the two cleavage sites and repair of the genome. The recognition sequence targeted by the disclosed genetically engineered meganuclease is such that the first and second cleavage sites have complementary 4 base pair 3' overhangs that allow them to fully ligate to each other. , are selected to have identical four base pair central sequences (ie, each base of one overhang pair pairs with its complement on the other overhang). By removing exons 45-55 from a mutant dystrophin gene lacking one or more of these exons, this approach results in restoration of the normal (ie, wild-type) reading frame of the dystrophin gene. Cells so treated express a truncated, modified form of the dystrophin protein in which part of the central spectrin repeat domain is absent, but the N-terminal and C-terminal domains are intact. This often reduces the severity of the disease. In some cases, it results in a milder Becker phenotype. [Means to solve the problem]
[0016] Thus, in one aspect, the invention provides an engineered meganuclease that binds to and cleaves a recognition sequence within the dystrophin gene, the engineered meganuclease comprising a first subunit and a second subunit. unit, a first subunit binds to a first recognition half site of the recognition sequence, comprises a first hypervariable (HVR1) region, and a second subunit binds to a second recognition half site of the recognition sequence. Genetically engineered meganucleases are provided that bind to a half-site and include a second hypervariable (HVR2) region.
[0017] In some embodiments, the recognition sequence comprises SEQ ID NO:6.
[0018] In some such embodiments, the HVR1 region comprises at least 80%, 85%, 90%, 91%, 92% of the amino acid sequence corresponding to residues 24-79 of any one of SEQ ID NOs: 36-44. , 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher sequence identity. In some embodiments, the HVR1 region comprises residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75 of any one of SEQ ID NOs: 36-44. , and one or more residues corresponding to 77. In some embodiments, the HVR1 region comprises residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75 of any one of SEQ ID NOs: 36-44. , and residues corresponding to 77. In some embodiments, the HVR1 region includes Y, R, K, or D at the residue corresponding to residue 66 of any one of SEQ ID NOs: 36-44. In some embodiments, the HVR1 region comprises the remainder of any one of SEQ ID NOs: 36-44 with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 amino acid substitutions. Contains groups 24-79. In some embodiments, the HVR1 region comprises residues 24-79 of any one of SEQ ID NOs: 36-44.
[0019] In some such embodiments, the first subunit has at least 80%, 85%, 90%, 91%, 92%, 93 with residues 7-153 of any one of SEQ ID NOs: 36-44. %, 94%, 95%, 96%, 97%, 98%, 99% or higher sequence identity. In some embodiments, the first subunit includes a G, S, or A at the residue corresponding to residue 19 of any one of SEQ ID NOs: 36-44. In some embodiments, the first subunit comprises a residue corresponding to residue 19 of any one of SEQ ID NOs: 36-44. In some embodiments, the first subunit includes E, Q, or K at the residue corresponding to residue 80 of any one of SEQ ID NOs: 36-44. In some embodiments, the first subunit includes a residue corresponding to residue 80 of any one of SEQ ID NO: 38, 39, or 149. In some embodiments, the first subunit is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, Residues 7-153 of any one of SEQ ID NOs: 36-44 with up to 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acid substitutions. In some embodiments, the first subunit comprises residues 7-153 of any one of SEQ ID NOs: 36-44.
[0020] In some such embodiments, the HVR2 region comprises at least 80%, 85%, 90%, 91%, 92% of the amino acid sequence corresponding to residues 215-270 of any one of SEQ ID NOs: 36-44. , 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher sequence identity. In some embodiments, the HVR2 region comprises residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266 of any one of SEQ ID NOs: 36-44. , and one or more residues corresponding to 268. In some embodiments, the HVR2 region comprises residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266 of any one of SEQ ID NOs: 36-44. , and residues corresponding to 268. In some embodiments, the HVR2 region includes Y, R, K, or D at the residue corresponding to residue 257 of any one of SEQ ID NOs: 36-44. In some embodiments, the HVR2 region includes a residue corresponding to residue 236 of SEQ ID NO: 39. In some embodiments, the HVR2 region includes a residue corresponding to residue 239 of SEQ ID NO:37. In some embodiments, the HVR2 region includes a residue corresponding to residue 241 of any one of SEQ ID NOs: 36-37. In some embodiments, the HVR2 region includes a residue corresponding to residue 263 of SEQ ID NO:36. In some embodiments, the HVR2 region includes a residue corresponding to residue 264 of any one of SEQ ID NOs: 36-44. In some embodiments, the HVR2 region comprises the remainder of any one of SEQ ID NOs: 36-44 with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 amino acid substitutions. Contains groups 215-270. In some embodiments, the HVR2 region comprises residues 215-270 of any one of SEQ ID NOs: 36-44.
[0021] In some such embodiments, the second subunit comprises residues 198-344 of any one of SEQ ID NOs: 36-44 and at least 80%, 85%, 90%, 91%, 92%, 93 %, 94%, 95%, 96%, 97%, 98%, 99% or higher sequence identity. In some embodiments, the second subunit includes a G, S, or A at the residue corresponding to residue 210 of any one of SEQ ID NOs: 36-44. In some embodiments, the second subunit includes E, Q, or K at the residue corresponding to residue 271 of any one of SEQ ID NOs: 36-44. In some embodiments, the second subunit includes a residue corresponding to residue 271 of any one of SEQ ID NO: 36, 39, 40, 43, or 44. In some embodiments, the second subunit includes a residue corresponding to residue 330 of any one of SEQ ID NOs: 36-38 or 40-44. In some embodiments, the second subunit is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, Residues 198-344 of any one of SEQ ID NOs: 36-44 with up to 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acid substitutions. In some embodiments, the second subunit comprises residues 198-344 of any one of SEQ ID NOs: 36-44.
[0022] In some such embodiments, the genetically engineered meganuclease is a single chain meganuclease that includes a linker, the linker covalently joining the first subunit and the second subunit. In some embodiments, the genetically engineered meganuclease has at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, Contains amino acid sequences having 96%, 97%, 98%, 99% or higher sequence identity. In some embodiments, the genetically engineered meganuclease comprises an amino acid sequence of any one of SEQ ID NOs: 36-44. In some embodiments, the genetically engineered meganuclease is at least 80%, 85%, 90%, 91%, 92%, 93%, Encoded by nuclear sequences having 94%, 95%, 96%, 97%, 98%, 99% or higher sequence identity. In some embodiments, the genetically engineered meganuclease is encoded by a nucleic acid sequence set forth in any one of SEQ ID NOs: 60-68.
[0023] In some embodiments, the recognition sequence comprises SEQ ID NO:10.
[0024] In some such embodiments, the HVR1 region comprises at least 80%, 85%, 90%, 91%, 92% of the amino acid sequence corresponding to residues 24-79 of any one of SEQ ID NOs: 45-52. , 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher sequence identity. In some embodiments, the HVR1 region comprises residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75 of any one of SEQ ID NOs: 45-52. , and one or more residues corresponding to 77. In some embodiments, the HVR1 region comprises residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75 of any one of SEQ ID NOs: 45-52. , and residues corresponding to 77. In some embodiments, the HVR1 region includes Y, R, K, or D at the residue corresponding to residue 66 of any one of SEQ ID NOs: 45-52. In some embodiments, the HVR1 region comprises the remainder of any one of SEQ ID NOs: 45-52 with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 amino acid substitutions. Contains groups 24-79. In some embodiments, the HVR1 region comprises residues 24-79 of any one of SEQ ID NOs: 45-52.
[0025] In some such embodiments, the first subunit has at least 80%, 85%, 90%, 91%, 92%, 93 with residues 7-153 of any one of SEQ ID NOs: 45-52. %, 94%, 95%, 96%, 97%, 98%, 99% or higher sequence identity. In some embodiments, the first subunit includes a G, S, or A at the residue corresponding to residue 19 of any one of SEQ ID NOs: 45-52. In some embodiments, the first subunit comprises a residue corresponding to residue 19 of any one of SEQ ID NOs: 45-52. In some embodiments, the first subunit includes E, Q, or K at the residue corresponding to residue 80 of any one of SEQ ID NOs: 45-52. In some embodiments, the first subunit includes a residue corresponding to residue 80 of any one of SEQ ID NOs: 45-51. In some embodiments, the first subunit is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, Residues 7-153 of any one of SEQ ID NOs: 45-52 with up to 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acid substitutions. In some embodiments, the first subunit comprises residues 7-153 of any one of SEQ ID NOs: 45-52.
[0026] In some such embodiments, the HVR2 region comprises at least 80%, 85%, 90%, 91%, 92% of the amino acid sequence corresponding to residues 215-270 of any one of SEQ ID NOs: 45-52. , 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher sequence identity. In some embodiments, the HVR2 region comprises residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266 of any one of SEQ ID NOs: 45-52. , and one or more residues corresponding to 268. In some embodiments, the HVR2 region comprises residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266 of any one of SEQ ID NOs: 45-52. , and residues corresponding to 268. In some embodiments, the HVR2 region includes Y, R, K, or D at the residue corresponding to residue 257 of any one of SEQ ID NOs: 45-52. In some embodiments, the HVR2 region includes residues corresponding to residues 239, 241, and 264 of any one of SEQ ID NOs: 45-52. In some embodiments, the HVR2 region includes residues corresponding to residue 250 of SEQ ID NO:45. In some embodiments, the HVR2 region includes a residue corresponding to residue 263 of any one of SEQ ID NO: 45 or 46. In some embodiments, the HVR2 region comprises the remainder of any one of SEQ ID NOs: 45-52 with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 amino acid substitutions. Contains groups 215-270. In some embodiments, the HVR2 region comprises residues 215-270 of any one of SEQ ID NOs: 45-52.
[0027] In some such embodiments, the second subunit comprises residues 198-344 of any one of SEQ ID NOs: 45-52 and at least 80%, 85%, 90%, 91%, 92%, 93 %, 94%, 95%, 96%, 97%, 98%, 99% or higher sequence identity. In some embodiments, the second subunit includes a G, S, or A at the residue corresponding to residue 210 of any one of SEQ ID NOs: 45-52. In some embodiments, the second subunit includes E, Q, or K at the residue corresponding to residue 271 of any one of SEQ ID NOs: 45-52. In some embodiments, the second subunit includes a residue corresponding to residue 271 of SEQ ID NO: 52. In some embodiments, the second subunit comprises a residue corresponding to residue 330 of any one of SEQ ID NOs: 45-52. In some embodiments, the second subunit is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, Residues 198-344 of any one of SEQ ID NOs: 45-52 with up to 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acid substitutions. In some embodiments, the second subunit comprises residues 198-344 of any one of SEQ ID NOs: 45-52.
[0028] In some such embodiments, the genetically engineered meganuclease is a single chain meganuclease that includes a linker, the linker covalently joining the first subunit and the second subunit. In some embodiments, the genetically engineered meganuclease has at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, Contains amino acid sequences having 96%, 97%, 98%, 99% or higher sequence identity. In some embodiments, the genetically engineered meganuclease comprises an amino acid sequence of any one of SEQ ID NOs: 45-52. In some embodiments, the genetically engineered meganuclease is at least 80%, 85%, 90%, 91%, 92%, 93%, Encoded by nucleic acid sequences having 94%, 95%, 96%, 97%, 98%, 99% or higher sequence identity. In some embodiments, the genetically engineered meganuclease is encoded by a nucleic acid sequence set forth in any one of SEQ ID NOs: 69-76.
[0029] In some embodiments, the recognition sequence comprises SEQ ID NO:12.
[0030] In some such embodiments, the HVR1 region comprises at least 80%, 85%, 90%, 91%, 92% of the amino acid sequence corresponding to residues 24-79 of any one of SEQ ID NOs: 53-59. , 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher sequence identity. In some embodiments, the HVR1 region comprises residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75 of any one of SEQ ID NOs: 53-59. , and one or more residues corresponding to 77. In some embodiments, the HVR1 region comprises residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75 of any one of SEQ ID NOs: 53-59. , and residues corresponding to 77. In some embodiments, the HVR1 region includes Y, R, K, or D at the residue corresponding to residue 66 of any one of SEQ ID NOs: 53-59. In some embodiments, the HVR1 region includes a residue corresponding to residue 64 of SEQ ID NO:54. In some embodiments, the HVR1 region comprises the remainder of any one of SEQ ID NOs: 53-59 with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 amino acid substitutions. Contains groups 24-79. In some embodiments, the HVR1 region comprises residues 24-79 of any one of SEQ ID NOs: 53-59.
[0031] In some such embodiments, the first subunit comprises residues 7-153 of any one of SEQ ID NOs: 53-59 and at least 80%, 85%, 90%, 91%, 92%, 93 %, 94%, 95%, 96%, 97%, 98%, 99% or higher sequence identity. In some embodiments, the first subunit includes a G, S, or A at the residue corresponding to residue 19 of any one of SEQ ID NOs: 53-59. In some embodiments, the first subunit comprises a residue corresponding to residue 19 of any one of SEQ ID NOs: 53-59. In some embodiments, the first subunit includes E, Q, or K at the residue corresponding to residue 80 of any one of SEQ ID NOs: 53-59. In some embodiments, the first subunit includes a residue corresponding to residue 80 of any one of SEQ ID NOs: 53-55, 57, or 58. In some embodiments, the first subunit is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, Residues 7-153 of any one of SEQ ID NOs: 53-59 with up to 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acid substitutions. In some embodiments, the first subunit comprises residues 7-153 of any one of SEQ ID NOs: 53-59.
[0032] In some such embodiments, the HVR2 region comprises at least 80%, 85%, 90%, 91%, 92% of the amino acid sequence corresponding to residues 215-270 of any one of SEQ ID NOs: 53-59. , 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher sequence identity. In some embodiments, the HVR2 region comprises residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266 of any one of SEQ ID NOs: 53-59. , and one or more residues corresponding to 268. In some embodiments, the HVR2 region comprises residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266 of any one of SEQ ID NOs: 53-59. , and residues corresponding to 268. In some embodiments, the HVR2 region includes Y, R, K, or D at the residue corresponding to residue 257 of any one of SEQ ID NOs: 53-59. In some embodiments, the HVR2 region includes a residue corresponding to residue 239 of SEQ ID NO: 53 or SEQ ID NO: 55. In some embodiments, the HVR2 region includes a residue corresponding to residue 241 of any one of SEQ ID NOs: 53-55. In some embodiments, the HVR2 region includes a residue corresponding to residue 255 of SEQ ID NO: 55. In some embodiments, the HVR2 region includes a residue corresponding to residue 263 of any one of SEQ ID NOs: 56-59. In some embodiments, the HVR2 region includes a residue corresponding to residue 264 of any one of SEQ ID NOs: 53-59. In some embodiments, the HVR2 region comprises the remainder of any one of SEQ ID NOs: 53-59 with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 amino acid substitutions. Contains groups 215-270. In some embodiments, the HVR2 region comprises residues 215-270 of any one of SEQ ID NOs: 53-59.
[0033] In some such embodiments, the second subunit comprises residues 198-344 of any one of SEQ ID NOs: 53-59 and at least 80%, 85%, 90%, 91%, 92%, 93 %, 94%, 95%, 96%, 97%, 98%, 99% or higher sequence identity. In some embodiments, the second subunit includes a G, S, or A at the residue corresponding to residue 210 of any one of SEQ ID NOs: 53-59. In some embodiments, the second subunit includes E, Q, or K at the residue corresponding to residue 271 of any one of SEQ ID NOs: 53-59. In some embodiments, the second subunit comprises a residue corresponding to residue 271 of SEQ ID NO: 53 or any one of 55-59. In some embodiments, the second subunit comprises a residue corresponding to residue 330 of any one of SEQ ID NOs: 54-59. In some embodiments, the second subunit is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, Residues 198-344 of any one of SEQ ID NOs: 53-59 with up to 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acid substitutions. In some embodiments, the second subunit comprises residues 198-344 of any one of SEQ ID NOs: 53-59.
[0034] In some such embodiments, the genetically engineered meganuclease is a single chain meganuclease that includes a linker, the linker covalently joining the first subunit and the second subunit. In some embodiments, the genetically engineered meganuclease has at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, Contains amino acid sequences having 96%, 97%, 98%, 99% or higher sequence identity. In some embodiments, the genetically engineered meganuclease comprises an amino acid sequence of any one of SEQ ID NOs: 53-59. In some embodiments, the genetically engineered meganuclease is at least 80%, 85%, 90%, 91%, 92%, 93%, Encoded by nuclear sequences having 94%, 95%, 96%, 97%, 98%, 99% or higher sequence identity. In some embodiments, the genetically engineered meganuclease is encoded by a nuclear sequence set forth in any one of SEQ ID NOs: 77-83.
[0035] In each of the above embodiments, the genetically engineered meganuclease can include a nuclear localization signal. In some embodiments, the nuclear localization signal is at the N-terminus of the engineered meganuclease. In some embodiments, the nuclear localization signal comprises an amino acid sequence that has at least 80% or at least 90% sequence identity with SEQ ID NO:3. In some embodiments, the nuclear localization signal comprises SEQ ID NO:3.
[0036] In another aspect, the invention provides a polynucleotide comprising a nucleic acid sequence encoding a genetically engineered meganuclease as described herein. In some embodiments, the polynucleotide is mRNA.
[0037] In another aspect, the invention provides a recombinant DNA construct comprising a polynucleotide comprising a nucleic acid sequence encoding a genetically engineered meganuclease as described herein.
[0038] In some embodiments, the recombinant DNA construct encodes a recombinant virus that includes the polynucleotide. In some embodiments, the recombinant virus is a recombinant adenovirus, recombinant lentivirus, recombinant retrovirus, or recombinant AAV. In some embodiments, the recombinant virus is a recombinant AAV. In some embodiments, the recombinant AAV has a rh.74 capsid. In some embodiments, the recombinant AAV has an AAV9 capsid. In some embodiments, the rh.74 capsid is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% with SEQ ID NO: 182. , comprising amino acid sequences with 99% or higher identity. In some embodiments, the rh.74 capsid comprises the amino acid sequence of SEQ ID NO: 182. In some embodiments, the AAV9 capsid is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99 with SEQ ID NO: 183. % or higher identity. In some embodiments, the AAV9 capsid comprises the amino acid sequence of SEQ ID NO: 183. In some embodiments, the recombinant AAV has an AAV8 capsid.
[0039] In some embodiments, the nucleic acid sequence includes a promoter operably linked to a nucleic acid sequence encoding a genetically engineered meganuclease described herein. In some embodiments, the promoter is a muscle-specific promoter. In some embodiments, the muscle-specific promoter is the MCK promoter, C5-12 promoter, spc 5-12 promoter, MHCK7 promoter, CK8 promoter, SK-CRM4 promoter, SP-301 promoter, SP-817 promoter, or SP -905 promoter included. In some embodiments, the promoter is capable of expressing a genetically engineered meganuclease described herein in muscle progenitor cells (eg, satellite cells or stem cells).
[0040] In another aspect, the invention provides a recombinant virus comprising a polynucleotide comprising a nucleic acid sequence encoding a genetically engineered meganuclease as described herein.
[0041] In some embodiments, the recombinant virus is a recombinant adenovirus, recombinant lentivirus, recombinant retrovirus, or recombinant AAV. In some embodiments, the recombinant virus is a recombinant AAV. In some embodiments, the recombinant AAV has a rh.74 capsid. In some embodiments, the rh.74 capsid is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% with SEQ ID NO: 182. , comprising amino acid sequences with 99% or higher identity. In some embodiments, the rh.74 capsid comprises the amino acid sequence of SEQ ID NO: 182. In some embodiments, the recombinant AAV has an AAV9 capsid. In some embodiments, the AAV9 capsid is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99 with SEQ ID NO: 183. % or higher identity. In some embodiments, the AAV9 capsid comprises the amino acid sequence of SEQ ID NO: 183. In some embodiments, the recombinant AAV has an AAV8 capsid.
[0042] In some embodiments, the polynucleotide includes a promoter operably linked to a nucleic acid sequence encoding a genetically engineered meganuclease described herein. In some embodiments, the promoter is a muscle-specific promoter. In some embodiments, the muscle-specific promoter is the MCK promoter, C5-12 promoter, spc 5-12 promoter, MHCK7 promoter, CK8 promoter, SK-CRM4 promoter, SP-301 promoter, SP-817 promoter, or SP -905 promoter included. In some embodiments, the promoter is capable of expressing a genetically engineered meganuclease described herein in muscle progenitor cells (eg, satellite cells or stem cells).
[0043] In another aspect, the invention provides a lipid nanoparticle composition comprising a lipid nanoparticle comprising a polynucleotide comprising a nucleic acid sequence encoding a genetically engineered meganuclease as described herein. In some embodiments, the polynucleotide is mRNA.
[0044] In another aspect, the invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a genetically engineered meganuclease described herein.
[0045] In another aspect, the invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a polynucleotide described herein.
[0046] In another aspect, the invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a recombinant DNA construct described herein.
[0047] In another aspect, the invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a recombinant virus described herein.
[0048] In another aspect, the invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a lipid nanoparticle composition described herein.
[0049] In another aspect, the invention provides a polynucleotide comprising a first nucleic acid sequence encoding a first genetically engineered meganuclease and a second nucleic acid sequence encoding a second genetically engineered meganuclease. wherein the first genetically engineered meganuclease is a genetically engineered meganuclease described herein that binds to and cleaves a recognition sequence comprising SEQ ID NO: 6, and the second genetically engineered meganuclease The meganuclease is a genetically engineered meganuclease described herein that binds and cleaves a recognition sequence comprising SEQ ID NO: 10, or the second genetically engineered meganuclease comprises SEQ ID NO: 12. A genetically engineered meganuclease described herein that binds and cleaves a recognition sequence.
[0050] In some embodiments, the first genetically engineered meganuclease is a genetically engineered meganuclease described herein that binds to and cleaves a recognition sequence comprising SEQ ID NO: 6, and the second genetically engineered meganuclease An engineered meganuclease is a genetically engineered meganuclease described herein that binds and cleaves a recognition sequence comprising SEQ ID NO:10. In some embodiments, the first engineered meganuclease and the second engineered meganuclease are combinations of meganucleases (and variants thereof described herein) provided in Table 1. selected from.
[0051]
table 1
[0052] In some embodiments, the first genetically engineered meganuclease is DMD 19-20x.13 (SEQ ID NO: 36) or a variant thereof described herein and the second genetically engineered meganuclease is DMD 19-20x.13 (SEQ ID NO: 36) or a variant thereof described herein. The nuclease is DMD 35-36x.63 (SEQ ID NO: 45) or a variant thereof as described herein. In some embodiments, the first engineered meganuclease is 19-20x.87 (SEQ ID NO: 37) or a variant thereof described herein, and the second engineered meganuclease is DMD 35-36x.81 (SEQ ID NO: 46) or a variant thereof as described herein. In some embodiments, the first genetically engineered meganuclease is DMD 19-20x.13 (SEQ ID NO: 36) or a variant thereof described herein and the second genetically engineered meganuclease is DMD 19-20x.13 (SEQ ID NO: 36) or a variant thereof described herein. The nuclease is DMD 35-36x.81 (SEQ ID NO: 46), or a variant thereof as described herein. In some embodiments, the first engineered meganuclease is DMD 19-20x.87 (SEQ ID NO: 37) or a variant thereof described herein, and the second engineered meganuclease is DMD 19-20x.87 (SEQ ID NO: 37) or a variant thereof described herein. The nuclease is DMD 35-36x.63 (SEQ ID NO: 45) or a variant thereof as described herein. In some embodiments, the first engineered meganuclease is DMD 19-20L.249 (SEQ ID NO: 38) or a variant thereof described herein, and the second engineered meganuclease is DMD 19-20L.249 (SEQ ID NO: 38) or a variant thereof described herein. The nuclease is DMD 35-36L.195 (SEQ ID NO: 47) or a variant thereof as described herein. In some embodiments, the first genetically engineered meganuclease is DMD 19-20L.302 (SEQ ID NO: 39) or a variant thereof described herein and the second genetically engineered meganuclease is DMD 19-20L.302 (SEQ ID NO: 39) or a variant thereof described herein. The nuclease is DMD 35-36L.282 (SEQ ID NO: 48), or a variant thereof as described herein. In some embodiments, the first genetically engineered meganuclease is DMD 19-20L.329 (SEQ ID NO: 40) or a variant thereof described herein and the second genetically engineered meganuclease is DMD 19-20L.329 (SEQ ID NO: 40) or a variant thereof described herein. The nuclease is DMD 35-36L.282 (SEQ ID NO: 48) or a variant thereof as described herein. In some embodiments, the first genetically engineered meganuclease is DMD 19-20L.302 (SEQ ID NO: 39) or a variant thereof described herein and the second genetically engineered meganuclease is DMD 19-20L.302 (SEQ ID NO: 39) or a variant thereof described herein. The nuclease is DMD 35-36L.349 (SEQ ID NO: 49) or a variant thereof as described herein. In some embodiments, the first genetically engineered meganuclease is DMD 19-20L.329 (SEQ ID NO: 40) or a variant thereof described herein and the second genetically engineered meganuclease is DMD 19-20L.329 (SEQ ID NO: 40) or a variant thereof described herein. The nuclease is DMD 35-36L.349 (SEQ ID NO: 49), or a variant thereof as described herein.
[0053] In certain embodiments, the first genetically engineered meganuclease is a genetically engineered meganuclease described herein that binds to and cleaves a recognition sequence comprising SEQ ID NO: 6, and the second genetically engineered meganuclease A meganuclease described herein is a genetically engineered meganuclease that binds to and cleaves a recognition sequence comprising SEQ ID NO:12. In some embodiments, the first engineered meganuclease and the second engineered meganuclease are combinations of meganucleases (and variants thereof described herein) provided in Table 2. selected from.
[0054] [Table 2] TIFF2023549357000005.tif191148
[0055] In some embodiments, the first genetically engineered meganuclease is DMD 19-20x.13 (SEQ ID NO: 36) or a variant thereof described herein and the second genetically engineered meganuclease is DMD 19-20x.13 (SEQ ID NO: 36) or a variant thereof described herein. The nuclease is DMD 37-38x.15 (SEQ ID NO: 53) or a variant thereof as described herein. In some embodiments, the first engineered meganuclease is DMD 19-20x.87 (SEQ ID NO: 37) or a variant thereof described herein, and the second engineered meganuclease is DMD 19-20x.87 (SEQ ID NO: 37) or a variant thereof described herein. The nuclease is DMD 37-38x.15 (SEQ ID NO: 53) or a variant thereof as described herein. In some embodiments, the first genetically engineered meganuclease is DMD 19-20x.13 (SEQ ID NO: 36) or a variant thereof described herein and the second genetically engineered meganuclease is DMD 19-20x.13 (SEQ ID NO: 36) or a variant thereof described herein. The nuclease is DMD 37-38x.66 (SEQ ID NO: 54) or a variant thereof as described herein. In some embodiments, the first engineered meganuclease is DMD 19-20x.87 (SEQ ID NO: 37) or a variant thereof described herein, and the second engineered meganuclease is DMD 19-20x.87 (SEQ ID NO: 37) or a variant thereof described herein. The nuclease is DMD 37-38x.66 (SEQ ID NO: 54) or a variant thereof as described herein. In some embodiments, the first genetically engineered meganuclease is DMD 19-20x.13 (SEQ ID NO: 36) or a variant thereof described herein and the second genetically engineered meganuclease is DMD 19-20x.13 (SEQ ID NO: 36) or a variant thereof described herein. The nuclease is DMD 37-38x.79 (SEQ ID NO: 55) or a variant thereof as described herein. In some embodiments, the first engineered meganuclease is DMD 19-20x.87 (SEQ ID NO: 37) or a variant thereof described herein, and the second engineered meganuclease is DMD 19-20x.87 (SEQ ID NO: 37) or a variant thereof described herein. The nuclease is DMD 37-38x.79 (SEQ ID NO: 55) or a variant thereof as described herein. In some embodiments, the first engineered meganuclease is DMD 19-20L.249 (SEQ ID NO: 38) or a variant thereof described herein, and the second engineered meganuclease is DMD 19-20L.249 (SEQ ID NO: 38) or a variant thereof described herein. The nuclease is DMD 37-38L.166 (SEQ ID NO: 56), or a variant thereof as described herein.
[0056] In some embodiments, the polynucleotide is mRNA. In some embodiments, the first nucleic acid sequence and the second nucleic acid sequence are separated by an IRES or 2A sequence. In certain embodiments, the 2A sequence is a T2A, P2A, E2A or F2A sequence.
[0057] In another aspect, the invention comprises a polynucleotide as described herein (i.e., a first nucleic acid sequence encoding a first genetically engineered meganuclease and a second genetically engineered meganuclease). and a second nucleic acid sequence encoding a recombinant DNA construct.
[0058] In some embodiments, the first nucleic acid sequence and the second nucleic acid sequence are separated by an IRES or 2A sequence. In certain embodiments, the 2A sequence is a T2A, P2A, E2A or F2A sequence.
[0059] In some embodiments, the polynucleotide includes a promoter operably linked to the first nucleic acid sequence and the second nucleic acid sequence. In some embodiments, the promoter is a muscle-specific promoter. In some embodiments, the muscle-specific promoter is the MCK promoter, C5-12 promoter, spc 5-12 promoter, MHCK7 promoter, CK8 promoter, SK-CRM4 promoter, SP-301 promoter, SP-817 promoter, or SP -905 promoter included. In some embodiments, the promoter is capable of expressing the first and second genetically engineered meganucleases described herein in muscle progenitor cells (eg, satellite cells or stem cells).
[0060] In some embodiments, the polynucleotide includes a first promoter operably linked to a first nucleic acid sequence and a second promoter operably linked to a second nucleic acid sequence. In some embodiments, the first promoter and the second promoter are muscle-specific promoters. In some embodiments, the muscle-specific promoter is MCK promoter, C5-12 promoter, spc 5-12 promoter, MHCK7 promoter, CK8 promoter, SK-CRM4 promoter, SP-301 promoter, SP-817 promoter, SP- 905 promoter, or a combination thereof. In some embodiments, the promoter is capable of expressing the first and second genetically engineered meganucleases described herein in muscle progenitor cells (eg, satellite cells or stem cells).
[0061] In some embodiments, the recombinant DNA construct encodes a recombinant virus that includes the polynucleotide. In some embodiments, the recombinant virus is a recombinant adenovirus, recombinant lentivirus, recombinant retrovirus, or recombinant AAV. In some embodiments, the recombinant virus is a recombinant AAV. In some embodiments, the recombinant AAV has a rh.74 capsid. In some embodiments, the recombinant AAV has an AAV9 capsid. In some embodiments, the rh.74 capsid is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% with SEQ ID NO: 182. , comprising amino acid sequences with 99% or higher identity. In some embodiments, the rh.74 capsid comprises the amino acid sequence of SEQ ID NO: 182. In some embodiments, the AAV9 capsid is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99 with SEQ ID NO: 183. % or higher identity. In some embodiments, the AAV9 capsid comprises the amino acid sequence of SEQ ID NO: 183. In some embodiments, the recombinant AAV has an AAV8 capsid.
[0062] In another aspect, the invention comprises a polynucleotide as described herein (i.e., a first nucleic acid sequence encoding a first genetically engineered meganuclease and a second genetically engineered meganuclease). and a second nucleic acid sequence encoding the recombinant virus.
[0063] In some embodiments, the polynucleotide includes a promoter operably linked to the first nucleic acid sequence and the second nucleic acid sequence. In some embodiments, the first nucleic acid sequence and the second nucleic acid sequence are separated by an IRES or 2A sequence. In certain embodiments, the 2A sequence is a T2A, P2A, E2A or F2A sequence.
[0064] In some embodiments, the promoter is a muscle-specific promoter. In some embodiments, the muscle-specific promoter is the MCK promoter, C5-12 promoter, spc 5-12 promoter, MHCK7 promoter, CK8 promoter, SK-CRM4 promoter, SP-301 promoter, SP-817 promoter, or SP -905 promoter included. In some embodiments, the promoter is capable of expressing a genetically engineered meganuclease described herein in muscle progenitor cells (eg, satellite cells or stem cells).
[0065] In some embodiments, the polynucleotide includes a first promoter operably linked to a first nucleic acid sequence and a second promoter operably linked to a second nucleic acid sequence. In some embodiments, the first promoter and the second promoter are muscle-specific promoters. In some embodiments, the muscle-specific promoter is MCK promoter, C5-12 promoter, spc 5-12 promoter, MHCK7 promoter, CK8 promoter, SK-CRM4 promoter, SP-301 promoter, SP-817 promoter, SP- 905 promoter, or a combination thereof. In some embodiments, the promoter is capable of expressing a genetically engineered meganuclease described herein in muscle progenitor cells (eg, satellite cells or stem cells). In some embodiments, the recombinant virus is a recombinant adenovirus, recombinant lentivirus, recombinant retrovirus, or recombinant AAV. In some embodiments, the recombinant virus is a recombinant AAV. In some embodiments, the recombinant AAV has a rh.74 capsid. In some embodiments, the recombinant AAV has an AAV9 capsid. In some embodiments, the rh.74 capsid is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% with SEQ ID NO: 182. , comprising amino acid sequences with 99% or higher identity. In some embodiments, the rh.74 capsid comprises the amino acid sequence of SEQ ID NO: 182. In some embodiments, the AAV9 capsid is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99 with SEQ ID NO: 183. % or higher identity. In some embodiments, the AAV9 capsid comprises the amino acid sequence of SEQ ID NO: 183. In some embodiments, the recombinant AAV has an AAV8 capsid.
[0066] In another aspect, the invention comprises a polynucleotide as described herein (i.e., a first nucleic acid sequence encoding a first genetically engineered meganuclease and a second genetically engineered meganuclease). and a second nucleic acid sequence encoding a lipid nanoparticle composition.
[0067] In some embodiments, the polynucleotide is an mRNA described herein. In some embodiments, the polynucleotide is a recombinant DNA construct described herein.
[0068] In another aspect, the invention comprises a pharmaceutically acceptable carrier and a polynucleotide as described herein (i.e., a first nucleic acid sequence encoding a first genetically engineered meganuclease; a second nucleic acid sequence encoding a genetically engineered meganuclease of No. 2).
[0069] In some embodiments, the polynucleotide comprises an mRNA described herein. In some embodiments, the polynucleotide comprises a recombinant DNA construct described herein. In some embodiments, the pharmaceutical composition comprises a recombinant virus described herein. In some embodiments, the pharmaceutical composition comprises a lipid nanoparticle composition described herein.
[0070] In another aspect, the invention provides a method for producing a genetically modified eukaryotic cell having a modified target sequence in the dystrophin gene of the genetically modified eukaryotic cell, comprising: introducing a polynucleotide comprising a nucleic acid sequence encoding a meganuclease into a eukaryotic cell, the genetically engineered meganuclease being expressed in the eukaryotic cell, the genetically engineered meganuclease comprising SEQ ID NO: 6; A method of generating a cleavage site within the dystrophin gene at the recognition sequence is provided. In some embodiments, the eukaryotic cell is a mammalian cell. In some embodiments, the mammalian cell is a muscle cell. In some embodiments, the muscle cells are muscle progenitor cells (eg, satellite cells or stem cells), skeletal muscle cells, or cardiomyocytes. In some embodiments, the mammalian cell is a human cell. In some embodiments, polynucleotides are introduced into eukaryotic cells by lipid nanoparticles, mRNA, or recombinant viruses (eg, recombinant AAV).
[0071] In another aspect, the invention provides a method for producing a genetically modified eukaryotic cell having a modified target sequence in the dystrophin gene of the genetically modified eukaryotic cell, comprising: 6, the genetically engineered meganuclease produces a cleavage site within the dystrophin gene at a recognition sequence comprising SEQ ID NO: 6. In some embodiments, the eukaryotic cell is a mammalian cell. In some embodiments, the mammalian cell is a muscle cell. In some embodiments, the muscle cells are muscle progenitor cells (eg, satellite cells or stem cells), skeletal muscle cells, or cardiomyocytes. In some embodiments, the mammalian cell is a human cell.
[0072] In another aspect, the invention provides a method for producing a genetically modified eukaryotic cell comprising an exogenous sequence of interest inserted into the dystrophin gene of the genetically modified eukaryotic cell, the method comprising: a first nucleic acid sequence encoding a genetically engineered meganuclease (wherein the engineered meganuclease is expressed in a eukaryotic cell) and a second nucleic acid sequence containing a sequence of interest (the genetically engineered meganuclease is expressed in a eukaryotic cell); a meganuclease generates a cleavage site within the dystrophin gene at a recognition sequence comprising SEQ ID NO: 6, and the sequence of interest is inserted into the dystrophin gene at the cleavage site), injecting one or more polynucleotides into a eukaryotic cell. A method is provided, including introducing. In some embodiments, the second nucleic acid sequence comprises a nucleic acid sequence homologous to the nucleic acid sequence adjacent to the cleavage site, and the sequence of interest is inserted into the cleavage site by homologous recombination. In some embodiments, the eukaryotic cell is a mammalian cell. In some embodiments, the mammalian cell is a muscle cell. In some embodiments, the muscle cells are muscle progenitor cells (eg, satellite cells or stem cells), skeletal muscle cells, or cardiomyocytes. In some embodiments, the mammalian cell is a human cell. In some embodiments, one or more polynucleotides are introduced into eukaryotic cells by lipid nanoparticles, mRNA, or recombinant viruses (eg, recombinant AAV).
[0073] In another aspect, the invention provides a method for producing a genetically modified eukaryotic cell comprising an exogenous sequence of interest inserted into the dystrophin gene of the genetically modified eukaryotic cell, the method comprising: comprising introducing into a eukaryotic cell a genetically engineered meganuclease and a polynucleotide comprising a sequence of interest, the genetically engineered meganuclease producing a cleavage site within the dystrophin gene at a recognition sequence comprising SEQ ID NO: 6; and provides a method in which a sequence of interest is inserted into the dystrophin gene at the cleavage site. In some embodiments, the polynucleotide comprises a nucleic acid sequence homologous to the nucleic acid sequence flanking the cleavage site, and the sequence of interest is inserted into the cleavage site by homologous recombination. In some embodiments, the eukaryotic cell is a mammalian cell. In some embodiments, the mammalian cell is a muscle cell. In some embodiments, the muscle cells are muscle progenitor cells (eg, satellite cells or stem cells), skeletal muscle cells, or cardiomyocytes. In some embodiments, the mammalian cell is a human cell. In some embodiments, polynucleotides are introduced into eukaryotic cells by lipid nanoparticles, mRNA, or recombinant viruses (eg, recombinant AAV).
[0074] In another aspect, the invention provides a method for producing a genetically modified eukaryotic cell having a modified target sequence in the dystrophin gene of the genetically modified eukaryotic cell, comprising: introducing into a eukaryotic cell a polynucleotide comprising a nucleic acid sequence encoding a meganuclease, wherein the genetically engineered meganuclease is expressed in the eukaryotic cell, the genetically engineered meganuclease comprising SEQ ID NO: 10. A method of generating a cleavage site within the dystrophin gene at the recognition sequence is provided. In some embodiments, the eukaryotic cell is a mammalian cell. In some embodiments, the mammalian cell is a muscle cell. In some embodiments, the muscle cells are muscle progenitor cells (eg, satellite cells or stem cells), skeletal muscle cells, or cardiomyocytes. In some embodiments, the mammalian cell is a human cell. In some embodiments, polynucleotides are introduced into eukaryotic cells by lipid nanoparticles, mRNA, or recombinant viruses (eg, recombinant AAV).
[0075] In another aspect, the invention provides a method for producing a genetically modified eukaryotic cell having a modified target sequence in the dystrophin gene of the genetically modified eukaryotic cell, comprising: 10, wherein the genetically engineered meganuclease produces a cleavage site within the dystrophin gene at a recognition sequence comprising SEQ ID NO: 10. In some embodiments, the eukaryotic cell is a mammalian cell. In some embodiments, the mammalian cell is a muscle cell. In some embodiments, the muscle cells are muscle progenitor cells (eg, satellite cells or stem cells), skeletal muscle cells, or cardiomyocytes. In some embodiments, the mammalian cell is a human cell.
[0076] In another aspect, the invention provides a method for producing a genetically modified eukaryotic cell comprising an exogenous sequence of interest inserted into the dystrophin gene of the genetically modified eukaryotic cell, the method comprising: a first nucleic acid sequence encoding a genetically engineered meganuclease (wherein the genetically engineered meganuclease is expressed in a eukaryotic cell) and a second nucleic acid sequence comprising a sequence of interest (the genetically engineered meganuclease is expressed in a eukaryotic cell); a meganuclease generates a cleavage site within the dystrophin gene at a recognition sequence comprising SEQ ID NO: 10, and the sequence of interest is inserted into the dystrophin gene at the cleavage site), injecting one or more polynucleotides into a eukaryotic cell. A method is provided, including introducing. In some embodiments, the second nucleic acid sequence comprises a nucleic acid sequence homologous to the nucleic acid sequence adjacent to the cleavage site, and the sequence of interest is inserted into the cleavage site by homologous recombination. In some embodiments, the eukaryotic cell is a mammalian cell. In some embodiments, the mammalian cell is a muscle cell. In some embodiments, the muscle cells are muscle progenitor cells (eg, satellite cells or stem cells), skeletal muscle cells, or cardiomyocytes. In some embodiments, the mammalian cell is a human cell. In some embodiments, one or more polynucleotides are introduced into eukaryotic cells by lipid nanoparticles, mRNA, or recombinant viruses (eg, recombinant AAV).
[0077] In another aspect, the invention provides a method for producing a genetically modified eukaryotic cell comprising an exogenous sequence of interest inserted into the dystrophin gene of the genetically modified eukaryotic cell, the method comprising: comprising introducing into a eukaryotic cell a genetically engineered meganuclease and a polynucleotide comprising a sequence of interest, wherein the genetically engineered meganuclease produces a cleavage site within the dystrophin gene at a recognition sequence comprising SEQ ID NO: 10. and provides a method in which a sequence of interest is inserted into the dystrophin gene at the cleavage site. In some embodiments, the polynucleotide comprises a nucleic acid sequence homologous to the nucleic acid sequence flanking the cleavage site, and the sequence of interest is inserted into the cleavage site by homologous recombination. In some embodiments, the eukaryotic cell is a mammalian cell. In some embodiments, the mammalian cell is a muscle cell. In some embodiments, the muscle cells are muscle progenitor cells (eg, satellite cells or stem cells), skeletal muscle cells, or cardiomyocytes. In some embodiments, the mammalian cell is a human cell. In some embodiments, polynucleotides are introduced into eukaryotic cells by lipid nanoparticles, mRNA, or recombinant viruses (eg, recombinant AAV).
[0078] In another aspect, the invention provides a method for producing a genetically modified eukaryotic cell having a modified target sequence in the dystrophin gene of the genetically modified eukaryotic cell, comprising: introducing into a eukaryotic cell a polynucleotide comprising a nucleic acid sequence encoding a meganuclease, wherein the genetically engineered meganuclease is expressed in the eukaryotic cell, the genetically engineered meganuclease comprising SEQ ID NO: 12. A method of generating a cleavage site within the dystrophin gene at the recognition sequence is provided. In some embodiments, the eukaryotic cell is a mammalian cell. In some embodiments, the mammalian cell is a muscle cell. In some embodiments, the muscle cells are muscle progenitor cells (eg, satellite cells or stem cells), skeletal muscle cells, or cardiomyocytes. In some embodiments, the mammalian cell is a human cell. In some embodiments, polynucleotides are introduced into eukaryotic cells by lipid nanoparticles, mRNA, or recombinant viruses (eg, recombinant AAV).
[0079] In another aspect, the invention provides a method for producing a genetically modified eukaryotic cell having a modified target sequence in the dystrophin gene of the genetically modified eukaryotic cell, comprising: 12, wherein the genetically engineered meganuclease produces a cleavage site within the dystrophin gene at a recognition sequence comprising SEQ ID NO: 12. In some embodiments, the eukaryotic cell is a mammalian cell. In some embodiments, the mammalian cell is a muscle cell. In some embodiments, the muscle cells are muscle progenitor cells (eg, satellite cells or stem cells), skeletal muscle cells, or cardiomyocytes. In some embodiments, the mammalian cell is a human cell.
[0080] In another aspect, the invention provides a method for producing a genetically modified eukaryotic cell comprising an exogenous sequence of interest inserted into the dystrophin gene of the genetically modified eukaryotic cell, the method comprising: a first nucleic acid sequence encoding a genetically engineered meganuclease (wherein the engineered meganuclease is expressed in a eukaryotic cell) and a second nucleic acid sequence containing a sequence of interest (the genetically engineered meganuclease is expressed in a eukaryotic cell); a meganuclease generates a cleavage site within the dystrophin gene at a recognition sequence comprising SEQ ID NO: 12, and the sequence of interest is inserted into the dystrophin gene at the cleavage site), injecting one or more polynucleotides into a eukaryotic cell. A method is provided, including introducing. In some embodiments, the second nucleic acid sequence comprises a nucleic acid sequence homologous to the nucleic acid sequence adjacent to the cleavage site, and the sequence of interest is inserted into the cleavage site by homologous recombination. In some embodiments, the eukaryotic cell is a mammalian cell. In some embodiments, the mammalian cell is a muscle cell. In some embodiments, the muscle cells are muscle progenitor cells (eg, satellite cells or stem cells), skeletal muscle cells, or cardiomyocytes. In some embodiments, the mammalian cell is a human cell. In some embodiments, one or more polynucleotides are introduced into eukaryotic cells by lipid nanoparticles, mRNA, or recombinant viruses (eg, recombinant AAV).
[0081] In another aspect, the invention provides a method for producing a genetically modified eukaryotic cell comprising an exogenous sequence of interest inserted into the dystrophin gene of the genetically modified eukaryotic cell, the method comprising: comprising introducing into a eukaryotic cell a genetically engineered meganuclease and a polynucleotide comprising a sequence of interest, wherein the genetically engineered meganuclease produces a cleavage site within the dystrophin gene at a recognition sequence comprising SEQ ID NO: 12. and provides a method in which a sequence of interest is inserted into the dystrophin gene at the cleavage site. In some embodiments, the polynucleotide comprises a nucleic acid sequence homologous to the nucleic acid sequence flanking the cleavage site, and the sequence of interest is inserted into the cleavage site by homologous recombination. In some embodiments, the eukaryotic cell is a mammalian cell. In some embodiments, the mammalian cell is a muscle cell. In some embodiments, the muscle cells are muscle progenitor cells (eg, satellite cells or stem cells), skeletal muscle cells, or cardiomyocytes. In some embodiments, the mammalian cell is a human cell. In some embodiments, polynucleotides are introduced into eukaryotic cells by lipid nanoparticles, mRNA, or recombinant viruses (eg, recombinant AAV).
[0082] In another aspect, the invention provides a method for producing a genetically modified eukaryotic cell comprising a modified dystrophin gene, comprising a first nucleic acid sequence encoding a first genetically engineered nuclease and a second gene. introducing into a eukaryotic cell one or more polynucleotides comprising a second nucleic acid sequence encoding an engineered nuclease, wherein the first engineered nuclease is in an intron 5' upstream of exon 45. a second genetically engineered nuclease binds to and cleaves a recognition sequence in an intron 3´ downstream of exon 55, the first genetically engineered nuclease and the second genetically engineered a first engineered nuclease produces a first cleavage site within the dystrophin gene at its recognition sequence, and a second engineered nuclease produces a first cleavage site within the dystrophin gene at its recognition sequence. producing a second cleavage site within the dystrophin gene, the first cleavage site and the second cleavage site having a complementary overhang between the first cleavage site and the second cleavage site; intervening genomic DNA is excised from the dystrophin gene and the dystrophin genes are annealed to generate a modified dystrophin gene.
[0083] In some embodiments, the first genetically engineered nuclease is a genetically engineered meganuclease described herein that binds to and cleaves a recognition sequence comprising SEQ ID NO: 6, and the second genetically engineered nuclease The engineered nuclease is a genetically engineered meganuclease described herein that binds and cleaves a recognition sequence comprising SEQ ID NO:10. In some embodiments, the first engineered meganuclease and the second engineered meganuclease are combinations of meganucleases (and variants thereof described herein) provided in Table 1. selected from. In such embodiments, the first cleavage site and the second cleavage site have complementary 3' overhangs. In some embodiments, the first engineered meganuclease is DMD 19-20x.13 (SEQ ID NO: 36) or a variant thereof described herein, and the second engineered meganuclease is DMD 19-20x.13 (SEQ ID NO: 36) or a variant thereof described herein. The nuclease is DMD 35-36x.63 (SEQ ID NO: 45) or a variant thereof as described herein. In some embodiments, the first engineered meganuclease is 19-20x.87 (SEQ ID NO: 37) or a variant thereof described herein, and the second engineered meganuclease is DMD 35-36x.81 (SEQ ID NO: 46) or a variant thereof as described herein. In some embodiments, the first engineered meganuclease is DMD 19-20x.13 (SEQ ID NO: 36) or a variant thereof described herein, and the second engineered meganuclease is DMD 19-20x.13 (SEQ ID NO: 36) or a variant thereof described herein. The nuclease is DMD 35-36x.81 (SEQ ID NO: 46), or a variant thereof as described herein. In some embodiments, the first engineered meganuclease is DMD 19-20x.87 (SEQ ID NO: 37) or a variant thereof described herein, and the second engineered meganuclease is DMD 19-20x.87 (SEQ ID NO: 37) or a variant thereof described herein. The nuclease is DMD 35-36x.63 (SEQ ID NO: 45) or a variant thereof as described herein. In some embodiments, the first engineered meganuclease is DMD 19-20L.249 (SEQ ID NO: 38) or a variant thereof described herein, and the second engineered meganuclease is DMD 19-20L.249 (SEQ ID NO: 38) or a variant thereof described herein. The nuclease is DMD 35-36L.195 (SEQ ID NO: 47) or a variant thereof as described herein. In some embodiments, the first genetically engineered meganuclease is DMD 19-20L.302 (SEQ ID NO: 39) or a variant thereof described herein and the second genetically engineered meganuclease is DMD 19-20L.302 (SEQ ID NO: 39) or a variant thereof described herein. The nuclease is DMD 35-36L.282 (SEQ ID NO: 48), or a variant thereof as described herein. In some embodiments, the first genetically engineered meganuclease is DMD 19-20L.329 (SEQ ID NO: 40) or a variant thereof described herein and the second genetically engineered meganuclease is DMD 19-20L.329 (SEQ ID NO: 40) or a variant thereof described herein. The nuclease is DMD 35-36L.282 (SEQ ID NO: 48) or a variant thereof as described herein. In some embodiments, the first genetically engineered meganuclease is DMD 19-20L.302 (SEQ ID NO: 39) or a variant thereof described herein and the second genetically engineered meganuclease is DMD 19-20L.302 (SEQ ID NO: 39) or a variant thereof described herein. The nuclease is DMD 35-36L.349 (SEQ ID NO: 49) or a variant thereof as described herein. In some embodiments, the first genetically engineered meganuclease is DMD 19-20L.329 (SEQ ID NO: 40) or a variant thereof described herein and the second genetically engineered meganuclease is DMD 19-20L.329 (SEQ ID NO: 40) or a variant thereof described herein. The nuclease is DMD 35-36L.349 (SEQ ID NO: 49), or a variant thereof as described herein.
[0084] In some embodiments, the first genetically engineered nuclease is a genetically engineered meganuclease described herein that binds to and cleaves a recognition sequence comprising SEQ ID NO: 6, and the second genetically engineered nuclease The engineered nuclease is a genetically engineered meganuclease described herein that binds and cleaves a recognition sequence comprising SEQ ID NO:12. In such embodiments, the first cleavage site and the second cleavage site have complementary 3' overhangs. In some embodiments, the first engineered meganuclease and the second engineered meganuclease are combinations of meganucleases (and variants thereof described herein) provided in Table 2. selected from. In some embodiments, the first engineered meganuclease is DMD 19-20x.13 (SEQ ID NO: 36) or a variant thereof described herein, and the second engineered meganuclease is DMD 19-20x.13 (SEQ ID NO: 36) or a variant thereof described herein. The nuclease is DMD 37-38x.15 (SEQ ID NO: 53) or a variant thereof as described herein. In some embodiments, the first engineered meganuclease is DMD 19-20x.87 (SEQ ID NO: 37) or a variant thereof described herein, and the second engineered meganuclease is DMD 19-20x.87 (SEQ ID NO: 37) or a variant thereof described herein. The nuclease is DMD 37-38x.15 (SEQ ID NO: 53) or a variant thereof as described herein. In some embodiments, the first engineered meganuclease is DMD 19-20x.13 (SEQ ID NO: 36) or a variant thereof described herein, and the second engineered meganuclease is DMD 19-20x.13 (SEQ ID NO: 36) or a variant thereof described herein. The nuclease is DMD 37-38x.66 (SEQ ID NO: 54) or a variant thereof as described herein. In some embodiments, the first engineered meganuclease is DMD 19-20x.87 (SEQ ID NO: 37) or a variant thereof described herein, and the second engineered meganuclease is DMD 19-20x.87 (SEQ ID NO: 37) or a variant thereof described herein. The nuclease is DMD 37-38x.66 (SEQ ID NO: 54) or a variant thereof as described herein. In some embodiments, the first engineered meganuclease is DMD 19-20x.13 (SEQ ID NO: 36) or a variant thereof described herein, and the second engineered meganuclease is DMD 19-20x.13 (SEQ ID NO: 36) or a variant thereof described herein. The nuclease is DMD 37-38x.79 (SEQ ID NO: 55) or a variant thereof as described herein. In some embodiments, the first engineered meganuclease is DMD 19-20x.87 (SEQ ID NO: 37) or a variant thereof described herein, and the second engineered meganuclease is DMD 19-20x.87 (SEQ ID NO: 37) or a variant thereof described herein. The nuclease is DMD 37-38x.79 (SEQ ID NO: 55) or a variant thereof as described herein. In some embodiments, the first engineered meganuclease is DMD 19-20L.249 (SEQ ID NO: 38) or a variant thereof described herein, and the second engineered meganuclease is DMD 19-20L.249 (SEQ ID NO: 38) or a variant thereof described herein. The nuclease is DMD 37-38L.166 (SEQ ID NO: 56), or a variant thereof as described herein.
[0085] In some embodiments, complementary overhangs (eg, 3' overhangs) of the first cleavage site and the second cleavage site are fully connected to each other.
[0086] In some embodiments, the dystrophin gene comprises the nucleic acid sequence set forth in SEQ ID NO: 32 or 34. In some embodiments, the dystrophin gene comprises the nucleic acid sequence set forth in SEQ ID NO:32. In some embodiments, the dystrophin gene comprises the nucleic acid sequence set forth in SEQ ID NO:34.
[0087] In some embodiments, the normal reading frame is restored in the modified dystrophin gene as compared to the full-length wild-type dystrophin gene.
[0088] In some embodiments, the modified dystrophin gene encodes a modified dystrophin polypeptide that lacks the amino acids encoded by exons 45-55 of the wild-type dystrophin gene. In some embodiments, the modified dystrophin polypeptide comprises the amino acid sequence set forth in SEQ ID NO:5.
[0089] In some embodiments, the method includes a first polynucleotide comprising a first nucleic acid sequence encoding a first genetically engineered meganuclease and a second polynucleotide encoding a second genetically engineered meganuclease. introducing into a eukaryotic cell a second polynucleotide comprising a nucleic acid sequence of. In some embodiments, the first polynucleotide is the first mRNA. In some embodiments, the second polynucleotide is a second mRNA. In some embodiments, the first mRNA and / or the second mRNA is an mRNA described herein (ie, encodes a genetically engineered meganuclease described herein). In some embodiments, the first polynucleotide is a first recombinant DNA construct. In some embodiments, the second polynucleotide is a second recombinant DNA construct. In some embodiments, the first recombinant DNA construct and / or the second recombinant DNA construct is a recombinant DNA construct described herein (i.e., a genetically engineered DNA construct described herein). containing a nucleic acid sequence encoding a meganuclease). In some embodiments, the first polynucleotide and the second polynucleotide are introduced into the eukaryotic cell by one or more lipid nanoparticles. In some embodiments, the first polynucleotide is introduced into the eukaryotic cell by the first lipid nanoparticle. In some embodiments, the second polynucleotide is introduced into the eukaryotic cell by a second lipid nanoparticle. In some embodiments, the first polynucleotide is introduced into the eukaryotic cell by a first recombinant virus. In some embodiments, the second polynucleotide is introduced into the eukaryotic cell by a second recombinant virus. In some embodiments, the first recombinant virus and / or the second recombinant virus is a recombinant virus described herein (i.e., a genetically engineered meganuclease described herein). (including polynucleotides containing a nucleic acid sequence encoding a polynucleotide).
[0090] In some embodiments, the method comprises a polynucleotide comprising a first nucleic acid sequence encoding a first genetically engineered meganuclease and a second nucleic acid sequence encoding a second genetically engineered meganuclease. involves introducing into eukaryotic cells. In some embodiments, the polynucleotide is mRNA. In some embodiments, the mRNA is an mRNA described herein (ie, comprises first and second nucleic acid sequences each encoding a meganuclease described herein). In some embodiments, the polynucleotide is a recombinant DNA construct. In some embodiments, the recombinant DNA construct is a recombinant DNA construct described herein (i.e., comprises first and second nucleic acid sequences each encoding a meganuclease described herein). ). In some embodiments, polynucleotides are introduced into eukaryotic cells by lipid nanoparticles. In some embodiments, polynucleotides are introduced into eukaryotic cells by recombinant viruses. In some embodiments, the recombinant virus is a recombinant virus described herein (i.e., a polynucleotide comprising first and second nucleic acid sequences each encoding a meganuclease described herein). including).
[0091] In some embodiments, the eukaryotic cell is a mammalian cell. In some embodiments, the mammalian cell is a muscle cell. In some embodiments, the muscle cells are muscle progenitor cells (eg, satellite cells or stem cells), skeletal muscle cells, or cardiomyocytes. In some embodiments, the mammalian cell is a human cell.
[0092] In another aspect, the invention provides a method for modifying the dystrophin gene in a target cell of a subject, wherein the dystrophin gene is characterized by a mutation that changes the reading frame of the dystrophin gene from the wild type; delivering to a target cell one or more polynucleotides comprising a first nucleic acid sequence encoding a first engineered nuclease and a second nucleic acid sequence encoding a second engineered nuclease; a first engineered nuclease binds to and cleaves a recognition sequence in an intron 5´ upstream of exon 45, and a second engineered nuclease binds to and cleaves a recognition sequence in an intron 3´ downstream of exon 55. bind and cleave, the first engineered nuclease and the second engineered nuclease are expressed in the target cell, and the first engineered nuclease binds and cleaves the first engineered nuclease within the dystrophin gene in its recognition sequence. a second engineered nuclease generates a second cleavage site within the dystrophin gene at its recognition sequence, and the first cleavage site and the second cleavage site form a complementary overhang. The intervening genomic DNA between the first and second cleavage sites is excised from the dystrophin gene, the dystrophin gene is annealed, and the normal reading frame of the dystrophin gene is converted into the full-length wild-type dystrophin gene. Provides a way to recover compared to.
[0093] In some embodiments, the first genetically engineered nuclease is a genetically engineered meganuclease described herein that binds to and cleaves a recognition sequence comprising SEQ ID NO: 6, and the second genetically engineered nuclease The engineered nuclease is a genetically engineered meganuclease described herein that binds and cleaves a recognition sequence comprising SEQ ID NO:10. In some embodiments, the first engineered meganuclease and the second engineered meganuclease are combinations of meganucleases (and variants thereof described herein) provided in Table 1. selected from. In such embodiments, the first cleavage site and the second cleavage site have complementary 3' overhangs. In some embodiments, the first engineered meganuclease is DMD 19-20x.13 (SEQ ID NO: 36) or a variant thereof described herein, and the second engineered meganuclease is DMD 19-20x.13 (SEQ ID NO: 36) or a variant thereof described herein. The nuclease is DMD 35-36x.63 (SEQ ID NO: 45) or a variant thereof as described herein. In some embodiments, the first engineered meganuclease is 19-20x.87 (SEQ ID NO: 37) or a variant thereof described herein, and the second engineered meganuclease is DMD 35-36x.81 (SEQ ID NO: 46) or a variant thereof as described herein. In some embodiments, the first engineered meganuclease is DMD 19-20x.13 (SEQ ID NO: 36) or a variant thereof described herein, and the second engineered meganuclease is DMD 19-20x.13 (SEQ ID NO: 36) or a variant thereof described herein. The nuclease is DMD 35-36x.81 (SEQ ID NO: 46), or a variant thereof as described herein. In some embodiments, the first engineered meganuclease is DMD 19-20x.87 (SEQ ID NO: 37) or a variant thereof described herein, and the second engineered meganuclease is DMD 19-20x.87 (SEQ ID NO: 37) or a variant thereof described herein. The nuclease is DMD 35-36x.63 (SEQ ID NO: 45) or a variant thereof as described herein. In some embodiments, the first engineered meganuclease is DMD 19-20L.249 (SEQ ID NO: 38) or a variant thereof described herein, and the second engineered meganuclease is DMD 19-20L.249 (SEQ ID NO: 38) or a variant thereof described herein. The nuclease is DMD 35-36L.195 (SEQ ID NO: 47) or a variant thereof as described herein. In some embodiments, the first genetically engineered meganuclease is DMD 19-20L.302 (SEQ ID NO: 39) or a variant thereof described herein and the second genetically engineered meganuclease is DMD 19-20L.302 (SEQ ID NO: 39) or a variant thereof described herein. The nuclease is DMD 35-36L.282 (SEQ ID NO: 48), or a variant thereof as described herein. In some embodiments, the first genetically engineered meganuclease is DMD 19-20L.329 (SEQ ID NO: 40) or a variant thereof described herein and the second genetically engineered meganuclease is DMD 19-20L.329 (SEQ ID NO: 40) or a variant thereof described herein. The nuclease is DMD 35-36L.282 (SEQ ID NO: 48) or a variant thereof as described herein. In some embodiments, the first genetically engineered meganuclease is DMD 19-20L.302 (SEQ ID NO: 39) or a variant thereof described herein and the second genetically engineered meganuclease is DMD 19-20L.302 (SEQ ID NO: 39) or a variant thereof described herein. The nuclease is DMD 35-36L.349 (SEQ ID NO: 49) or a variant thereof as described herein. In some embodiments, the first genetically engineered meganuclease is DMD 19-20L.329 (SEQ ID NO: 40) or a variant thereof described herein and the second genetically engineered meganuclease is DMD 19-20L.329 (SEQ ID NO: 40) or a variant thereof described herein. The nuclease is DMD 35-36L.349 (SEQ ID NO: 49), or a variant thereof as described herein.
[0094] In some embodiments, the first genetically engineered nuclease is a genetically engineered meganuclease described herein that binds to and cleaves a recognition sequence comprising SEQ ID NO: 6, and the second genetically engineered nuclease The engineered nuclease is a genetically engineered meganuclease described herein that binds and cleaves a recognition sequence comprising SEQ ID NO:12. In some embodiments, the first engineered meganuclease and the second engineered meganuclease are combinations of meganucleases (and variants thereof described herein) provided in Table 2. selected from. In such embodiments, the first cleavage site and the second cleavage site have complementary 3' overhangs. In some embodiments, the first engineered meganuclease is DMD 19-20x.13 (SEQ ID NO: 36) or a variant thereof described herein, and the second engineered meganuclease is DMD 19-20x.13 (SEQ ID NO: 36) or a variant thereof described herein. The nuclease is DMD 37-38x.15 (SEQ ID NO: 53) or a variant thereof as described herein. In some embodiments, the first engineered meganuclease is DMD 19-20x.87 (SEQ ID NO: 37) or a variant thereof described herein, and the second engineered meganuclease is DMD 19-20x.87 (SEQ ID NO: 37) or a variant thereof described herein. The nuclease is DMD 37-38x.15 (SEQ ID NO: 53) or a variant thereof as described herein. In some embodiments, the first engineered meganuclease is DMD 19-20x.13 (SEQ ID NO: 36) or a variant thereof described herein, and the second engineered meganuclease is DMD 19-20x.13 (SEQ ID NO: 36) or a variant thereof described herein. The nuclease is DMD 37-38x.66 (SEQ ID NO: 54) or a variant thereof as described herein. In some embodiments, the first engineered meganuclease is DMD 19-20x.87 (SEQ ID NO: 37) or a variant thereof described herein, and the second engineered meganuclease is DMD 19-20x.87 (SEQ ID NO: 37) or a variant thereof described herein. The nuclease is DMD 37-38x.66 (SEQ ID NO: 54) or a variant thereof as described herein. In some embodiments, the first engineered meganuclease is DMD 19-20x.13 (SEQ ID NO: 36) or a variant thereof described herein, and the second engineered meganuclease is DMD 19-20x.13 (SEQ ID NO: 36) or a variant thereof described herein. The nuclease is DMD 37-38x.79 (SEQ ID NO: 55) or a variant thereof as described herein. In some embodiments, the first engineered meganuclease is DMD 19-20x.87 (SEQ ID NO: 37) or a variant thereof described herein, and the second engineered meganuclease is DMD 19-20x.87 (SEQ ID NO: 37) or a variant thereof described herein. The nuclease is DMD 37-38x.79 (SEQ ID NO: 55) or a variant thereof as described herein. In some embodiments, the first engineered meganuclease is DMD 19-20L.249 (SEQ ID NO: 38) or a variant thereof described herein, and the second engineered meganuclease is DMD 19-20L.249 (SEQ ID NO: 38) or a variant thereof described herein. The nuclease is DMD 37-38L.166 (SEQ ID NO: 56), or a variant thereof as described herein.
[0095] In some embodiments, complementary overhangs (eg, 3' overhangs) of the first cleavage site and the second cleavage site are fully connected to each other.
[0096] In some embodiments, the dystrophin gene comprises the nucleic acid sequence set forth in SEQ ID NO: 32 or 34. In some embodiments, the dystrophin gene comprises the nucleic acid sequence set forth in SEQ ID NO:32. In some embodiments, the dystrophin gene comprises the nucleic acid sequence set forth in SEQ ID NO:34.
[0097] In some embodiments, the dystrophin gene encodes a modified dystrophin polypeptide that lacks the amino acids encoded by exons 45-55 of the wild-type dystrophin gene. In some embodiments, the modified dystrophin polypeptide comprises the amino acid sequence set forth in SEQ ID NO:5. In some embodiments, the subject is converted to a Becker muscular dystrophy phenotype.
[0098] In some embodiments, the method comprises a first polynucleotide comprising a first nucleic acid encoding a first genetically engineered meganuclease and a second polynucleotide encoding a second genetically engineered meganuclease. delivering a second polynucleotide comprising a nucleic acid sequence to a target cell. In some embodiments, the first polynucleotide is the first mRNA. In some embodiments, the second polynucleotide is a second mRNA. In some embodiments, the first mRNA and / or the second mRNA are described herein (ie, encode a genetically engineered meganuclease described herein). In some embodiments, the first polynucleotide is a first recombinant DNA construct. In some embodiments, the second polynucleotide is a second recombinant DNA construct. In some embodiments, the first recombinant DNA construct and / or the second recombinant DNA construct is a recombinant DNA construct described herein (i.e., a genetically engineered DNA construct described herein). containing a nucleic acid sequence encoding a meganuclease). In some embodiments, the first polynucleotide and the second polynucleotide are delivered to the target cell by one or more lipid nanoparticles. In some embodiments, the first polynucleotide is delivered to the target cell by the first lipid nanoparticle. In some embodiments, the second polynucleotide is delivered to the target cell by a second lipid nanoparticle. In some embodiments, the first polynucleotide is delivered to the target cell by a first recombinant virus. In some embodiments, the second polynucleotide is delivered to the target cell by a second recombinant virus. In some embodiments, the first recombinant virus and / or the second recombinant virus is a recombinant virus described herein (i.e., a genetically engineered meganuclease described herein). (including polynucleotides containing a nucleic acid sequence encoding a polynucleotide).
[0099] In some embodiments, the method comprises a polynucleotide comprising a first nucleic acid encoding a first genetically engineered meganuclease and a second nucleic acid sequence encoding a second genetically engineered meganuclease. delivery to target cells. In some embodiments, the polynucleotide is mRNA. In some embodiments, the mRNA is an mRNA described herein (ie, comprises first and second nucleic acid sequences each encoding a meganuclease described herein). In some embodiments, the polynucleotide is a recombinant DNA construct. In some embodiments, the recombinant DNA construct is a recombinant DNA construct described herein (i.e., comprises first and second nucleic acid sequences each encoding a meganuclease described herein). ). In some embodiments, polynucleotides are delivered to target cells by lipid nanoparticles. In some embodiments, polynucleotides are delivered to target cells by recombinant viruses. In some embodiments, the recombinant virus is a recombinant virus described herein (i.e., a polynucleotide comprising first and second nucleic acid sequences each encoding a meganuclease described herein). including).
[0100] In some embodiments, the subject is a mammal. In some embodiments, the target cell is a muscle cell. In some embodiments, the muscle cells are muscle progenitor cells (eg, satellite cells or stem cells), skeletal muscle cells, or cardiomyocytes. In some embodiments, the subject is a human.
[0101] In another aspect, the invention provides a method for treating DMD in a subject in need thereof, wherein the DMD alters the reading frame of the dystrophin gene as compared to the full-length wild-type dystrophin gene. an effective amount characterized by a mutation in the dystrophin gene and comprising a first nucleic acid sequence encoding a first genetically engineered nuclease and a second nucleic acid sequence encoding a second genetically engineered nuclease; or administering to a subject a plurality of polynucleotides, a first engineered nuclease binds to and cleaves a recognition sequence in an intron 5' upstream of exon 45, and a second engineered nuclease binds to and cleaves a recognition sequence in an intron 5' upstream of exon 45; The first engineered nuclease and the second engineered nuclease bind and cleave a recognition sequence in an intron 3′ downstream of 55, and the one or more polynucleotides are delivered to the target cell of interest. is expressed in the target cell, a first engineered nuclease produces a first cleavage site within the dystrophin gene at its recognition sequence, and a second engineered nuclease produces a first cleavage site within the dystrophin gene at its recognition sequence. producing a second cleavage site, the first cleavage site and the second cleavage site having complementary overhangs, and intervening genomic DNA between the first cleavage site and the second cleavage site; is excised from the dystrophin gene, the dystrophin genes are annealed, and the normal reading frame of the dystrophin gene is restored as compared to the full-length wild-type dystrophin gene.
[0102] In some embodiments, the first genetically engineered nuclease is a genetically engineered meganuclease described herein that binds to and cleaves a recognition sequence comprising SEQ ID NO: 6, and the second genetically engineered nuclease The engineered nuclease is a genetically engineered meganuclease described herein that binds and cleaves a recognition sequence comprising SEQ ID NO:10. In some embodiments, the first engineered meganuclease and the second engineered meganuclease are combinations of meganucleases (and variants thereof described herein) provided in Table 1. selected from. In such embodiments, the first cleavage site and the second cleavage site have complementary 3' overhangs. In some embodiments, the first engineered meganuclease is DMD 19-20x.13 (SEQ ID NO: 36) or a variant thereof described herein, and the second engineered meganuclease is DMD 19-20x.13 (SEQ ID NO: 36) or a variant thereof described herein. The nuclease is DMD 35-36x.63 (SEQ ID NO: 45) or a variant thereof as described herein. In some embodiments, the first engineered meganuclease is 19-20x.87 (SEQ ID NO: 37) or a variant thereof described herein, and the second engineered meganuclease is DMD 35-36x.81 (SEQ ID NO: 46) or a variant thereof as described herein. In some embodiments, the first engineered meganuclease is DMD 19-20x.13 (SEQ ID NO: 36) or a variant thereof described herein, and the second engineered meganuclease is DMD 19-20x.13 (SEQ ID NO: 36) or a variant thereof described herein. The nuclease is DMD 35-36x.81 (SEQ ID NO: 46), or a variant thereof as described herein. In some embodiments, the first engineered meganuclease is DMD 19-20x.87 (SEQ ID NO: 37) or a variant thereof described herein, and the second engineered meganuclease is DMD 19-20x.87 (SEQ ID NO: 37) or a variant thereof described herein. The nuclease is DMD 35-36x.63 (SEQ ID NO: 45) or a variant thereof as described herein. In some embodiments, the first engineered meganuclease is DMD 19-20L.249 (SEQ ID NO: 38) or a variant thereof described herein, and the second engineered meganuclease is DMD 19-20L.249 (SEQ ID NO: 38) or a variant thereof described herein. The nuclease is DMD 35-36L.195 (SEQ ID NO: 47) or a variant thereof as described herein. In some embodiments, the first genetically engineered meganuclease is DMD 19-20L.302 (SEQ ID NO: 39) or a variant thereof described herein and the second genetically engineered meganuclease is DMD 19-20L.302 (SEQ ID NO: 39) or a variant thereof described herein. The nuclease is DMD 35-36L.282 (SEQ ID NO: 48), or a variant thereof as described herein. In some embodiments, the first genetically engineered meganuclease is DMD 19-20L.329 (SEQ ID NO: 40) or a variant thereof described herein and the second genetically engineered meganuclease is DMD 19-20L.329 (SEQ ID NO: 40) or a variant thereof described herein. The nuclease is DMD 35-36L.282 (SEQ ID NO: 48) or a variant thereof as described herein. In some embodiments, the first genetically engineered meganuclease is DMD 19-20L.302 (SEQ ID NO: 39) or a variant thereof described herein and the second genetically engineered meganuclease is DMD 19-20L.302 (SEQ ID NO: 39) or a variant thereof described herein. The nuclease is DMD 35-36L.349 (SEQ ID NO: 49) or a variant thereof as described herein. In some embodiments, the first genetically engineered meganuclease is DMD 19-20L.329 (SEQ ID NO: 40) or a variant thereof described herein and the second genetically engineered meganuclease is DMD 19-20L.329 (SEQ ID NO: 40) or a variant thereof described herein. The nuclease is DMD 35-36L.349 (SEQ ID NO: 49), or a variant thereof as described herein.
[0103] In some embodiments, the first genetically engineered nuclease is a genetically engineered meganuclease described herein that binds to and cleaves a recognition sequence comprising SEQ ID NO: 6, and the second genetically engineered nuclease The engineered nuclease is a genetically engineered meganuclease described herein that binds and cleaves a recognition sequence comprising SEQ ID NO:12. In some embodiments, the first engineered meganuclease and the second engineered meganuclease are combinations of meganucleases (and variants thereof described herein) provided in Table 2. selected from. In such embodiments, the first cleavage site and the second cleavage site have complementary 3' overhangs. In some embodiments, the first engineered meganuclease is DMD 19-20x.13 (SEQ ID NO: 36) or a variant thereof described herein, and the second engineered meganuclease is DMD 19-20x.13 (SEQ ID NO: 36) or a variant thereof described herein. The nuclease is DMD 37-38x.15 (SEQ ID NO: 53) or a variant thereof as described herein. In some embodiments, the first engineered meganuclease is DMD 19-20x.87 (SEQ ID NO: 37) or a variant thereof described herein, and the second engineered meganuclease is DMD 19-20x.87 (SEQ ID NO: 37) or a variant thereof described herein. The nuclease is DMD 37-38x.15 (SEQ ID NO: 53) or a variant thereof as described herein. In some embodiments, the first engineered meganuclease is DMD 19-20x.13 (SEQ ID NO: 36) or a variant thereof described herein, and the second engineered meganuclease is DMD 19-20x.13 (SEQ ID NO: 36) or a variant thereof described herein. The nuclease is DMD 37-38x.66 (SEQ ID NO: 54) or a variant thereof as described herein. In some embodiments, the first engineered meganuclease is DMD 19-20x.87 (SEQ ID NO: 37) or a variant thereof described herein, and the second engineered meganuclease is DMD 19-20x.87 (SEQ ID NO: 37) or a variant thereof described herein. The nuclease is DMD 37-38x.66 (SEQ ID NO: 54) or a variant thereof as described herein. In some embodiments, the first engineered meganuclease is DMD 19-20x.13 (SEQ ID NO: 36) or a variant thereof described herein, and the second engineered meganuclease is DMD 19-20x.13 (SEQ ID NO: 36) or a variant thereof described herein. The nuclease is DMD 37-38x.79 (SEQ ID NO: 55) or a variant thereof as described herein. In some embodiments, the first engineered meganuclease is DMD 19-20x.87 (SEQ ID NO: 37) or a variant thereof described herein, and the second engineered meganuclease is DMD 19-20x.87 (SEQ ID NO: 37) or a variant thereof described herein. The nuclease is DMD 37-38x.79 (SEQ ID NO: 55) or a variant thereof as described herein. In some embodiments, the first engineered meganuclease is DMD 19-20L.249 (SEQ ID NO: 38) or a variant thereof described herein, and the second engineered meganuclease is DMD 19-20L.249 (SEQ ID NO: 38) or a variant thereof described herein. The nuclease is DMD 37-38L.166 (SEQ ID NO: 56), or a variant thereof as described herein.
[0104] In some embodiments, complementary overhangs (eg, 3' overhangs) of the first cleavage site and the second cleavage site are fully connected to each other.
[0105] In some embodiments, the dystrophin gene comprises the nucleic acid sequence set forth in SEQ ID NO: 32 or 34. In some embodiments, the dystrophin gene comprises the nucleic acid sequence set forth in SEQ ID NO:32. In some embodiments, the dystrophin gene comprises the nucleic acid sequence set forth in SEQ ID NO:34.
[0106] In some embodiments, the dystrophin gene encodes a modified dystrophin polypeptide that lacks the amino acids encoded by exons 45-55 of the wild-type dystrophin gene. In some embodiments, the modified dystrophin polypeptide comprises the amino acid sequence set forth in SEQ ID NO:5. In some embodiments, the subject is converted to a Becker muscular dystrophy phenotype.
[0107] In some embodiments, the method comprises a first polynucleotide comprising a first nucleic acid encoding a first genetically engineered meganuclease and a second polynucleotide encoding a second genetically engineered meganuclease. comprising administering to the subject a second polynucleotide comprising the nucleic acid sequence. In some embodiments, the first polynucleotide is the first mRNA. In some embodiments, the second polynucleotide is a second mRNA. In some embodiments, the first mRNA and / or the second mRNA is an mRNA described herein (ie, encodes a genetically engineered meganuclease described herein). In some embodiments, the first polynucleotide is a first recombinant DNA construct. In some embodiments, the second polynucleotide is a second recombinant DNA construct. In some embodiments, the first recombinant DNA construct and / or the second recombinant DNA construct is a recombinant DNA construct described herein (i.e., a genetically engineered DNA construct described herein). containing a nucleic acid sequence encoding a meganuclease). In some embodiments, the first polynucleotide and the second polynucleotide are administered to the subject via lipid nanoparticles. In some embodiments, the first polynucleotide is administered to the subject via the first lipid nanoparticle. In some embodiments, the second polynucleotide is administered to the subject via a second lipid nanoparticle. In some embodiments, the first polynucleotide is administered to the subject by a first recombinant virus. In some embodiments, the second polynucleotide is administered to the subject by a second recombinant virus. In some embodiments, the first recombinant virus and / or the second recombinant virus is a recombinant virus described herein (i.e., a genetically engineered meganuclease described herein). (including polynucleotides containing a nucleic acid sequence encoding a polynucleotide).
[0108] In some embodiments, the method comprises a polynucleotide comprising a first nucleic acid encoding a first genetically engineered meganuclease and a second nucleic acid sequence encoding a second genetically engineered meganuclease. Including administering to a subject. In some embodiments, the polynucleotide is mRNA. In some embodiments, the mRNA is an mRNA described herein (ie, comprises first and second nucleic acid sequences each encoding a meganuclease described herein). In some embodiments, the polynucleotide is a recombinant DNA construct. In some embodiments, the recombinant DNA construct is a recombinant DNA construct described herein (i.e., comprises first and second nucleic acid sequences each encoding a meganuclease described herein). ). In some embodiments, polynucleotides are administered to a subject via lipid nanoparticles. In some embodiments, the polynucleotide is administered to the subject by a recombinant virus. In some embodiments, the recombinant virus is a recombinant virus described herein (i.e., a polynucleotide comprising first and second nucleic acid sequences each encoding a meganuclease described herein). including).
[0109] In some embodiments, the subject is a mammal. In some embodiments, the target cell is a muscle cell. In some embodiments, the muscle cells are muscle progenitor cells (eg, satellite cells or stem cells), skeletal muscle cells, or cardiomyocytes. In some embodiments, the subject is a human.
[0110] In another aspect, the invention provides a polynucleotide comprising the nucleic acid sequence set forth in SEQ ID NO: 32 or SEQ ID NO: 34.
[0111] In some embodiments, the polynucleotide comprises the nucleic acid sequence set forth in SEQ ID NO:32. In some embodiments, the polynucleotide is the dystrophin gene in the genome of a cell (eg, a human muscle cell) that includes the nucleic acid sequence set forth in SEQ ID NO: 32. In some embodiments, the polynucleotide is a precursor mRNA in a cell (eg, a human muscle cell) that includes the nucleic acid sequence set forth in SEQ ID NO: 32.
[0112] In some embodiments, the polynucleotide comprises the nucleic acid sequence set forth in SEQ ID NO:34. In some embodiments, the polynucleotide is the dystrophin gene in the genome of a cell (eg, a human muscle cell) that includes the nucleic acid sequence set forth in SEQ ID NO: 34. In some embodiments, the polynucleotide is a precursor mRNA in a cell (eg, a human muscle cell) that includes the nucleic acid sequence set forth in SEQ ID NO: 34.
[0113] In another aspect, the invention provides a genetically modified eukaryotic cell comprising a modified dystrophin gene in its genome, wherein the modified dystrophin gene has exons 45-55 deleted, and the modified dystrophin gene has exons 44 and 55 deleted. It comprises the nucleic acid sequence shown in SEQ ID NO: 32 or the nucleic acid sequence shown in SEQ ID NO: 34 located within the intron between exon 56.
[0114] In some embodiments, the nucleic acid sequence comprises SEQ ID NO:32. In some embodiments, the nucleic acid sequence comprises SEQ ID NO:34.
[0115] In some embodiments, the genetically modified eukaryotic cell is a mammalian cell. In some embodiments, the genetically modified eukaryotic cell is a human cell. In some embodiments, the genetically modified eukaryotic cell is a muscle cell. In some embodiments, the muscle cells are muscle progenitor cells (eg, satellite cells or stem cells), skeletal muscle cells, or cardiomyocytes.
[0116] In another aspect, the present invention provides SEQ ID NO. provides a polypeptide comprising an amino acid sequence having higher sequence identity than Contains the C-terminal domain of the protein. In some embodiments, the polypeptide comprises the amino acid sequence set forth in SEQ ID NO:5.
[0117] In another aspect, the invention provides a genetically engineered meganuclease as described herein, or a polynucleotide as described herein encoding a genetically engineered meganuclease, or a gene as described herein, for use as a medicament. Cells described herein that express engineered meganucleases are provided.
[0118] In some embodiments, the medicament is useful for producing a modified dystrophin gene in a subject. In some embodiments, the medicament is useful for treating DMD.
[0119] In another aspect, the invention provides a method for treating DMD, for increasing levels of a modified dystrophin protein (i.e., lacking amino acids encoded by exons 45-55 of the dystrophin gene), or for treating symptoms associated with DMD. A genetically engineered meganuclease as described herein, or a polynucleotide as disclosed herein encoding a genetically engineered meganuclease, or a genetically engineered meganuclease, in the manufacture of a medicament for the purpose of Provided are uses of the cells described herein that express. [Brief explanation of drawings]
[0120]
Figure 1
Figure 2
[0121] A brief explanation of arrays
[0122] SEQ ID NO: 1 shows the amino acid sequence of wild type I-CreI meganuclease from Chlamydomonas reinhardtii.
[0123] SEQ ID NO: 2 shows the amino acid sequence of the LAGLIDADG motif.
[0124] SEQ ID NO: 3 shows the amino acid sequence of the nuclear localization signal.
[0125] SEQ ID NO: 4 shows the amino acid sequence of wild type dystrophin protein CCDS48091.1 (gene ID 1756).
[0126] SEQ ID NO: 5 shows the amino acid sequence of wild-type dystrophin protein CCDS48091.1 (gene ID 1756) lacking the amino acids encoded by exons 45-55.
[0127] SEQ ID NO: 6 shows the nucleic acid sequence of the sense strand of the DMD 19-20 recognition sequence.
[0128] SEQ ID NO: 7 shows the nucleic acid sequence of the antisense strand of the DMD 19-20 recognition sequence.
[0129] SEQ ID NO: 8 shows the nucleic acid sequence of the sense strand of the DMD 29-30 recognition sequence.
[0130] SEQ ID NO: 9 shows the nucleic acid sequence of the antisense strand of the DMD 29-30 recognition sequence.
[0131] SEQ ID NO: 10 shows the nucleic acid sequence of the sense strand of the DMD 35-36 recognition sequence.
[0132] SEQ ID NO: 11 shows the nucleic acid sequence of the antisense strand of the DMD 35-36 recognition sequence.
[0133] SEQ ID NO: 12 shows the nucleic acid sequence of the sense strand of the DMD 37-38 recognition sequence.
[0134] SEQ ID NO: 13 shows the nucleic acid sequence of the antisense strand of the DMD 37-38 recognition sequence.
[0135] SEQ ID NO: 14 shows the nucleic acid sequence of the first half sense strand of the DMD 19-20 recognition sequence.
[0136] SEQ ID NO: 15 shows the nucleic acid sequence of the first half antisense strand of the DMD 19-20 recognition sequence.
[0137] SEQ ID NO: 16 shows the nucleic acid sequence of the first half sense strand of the DMD 29-30 recognition sequence.
[0138] SEQ ID NO: 17 shows the nucleic acid sequence of the first half antisense strand of the DMD 29-30 recognition sequence.
[0139] SEQ ID NO: 18 shows the nucleic acid sequence of the first half sense strand of the DMD 35-36 recognition sequence.
[0140] SEQ ID NO: 19 shows the nucleic acid sequence of the first half antisense strand of the DMD 35-36 recognition sequence.
[0141] SEQ ID NO: 20 shows the nucleic acid sequence of the first half sense strand of the DMD 37-38 recognition sequence.
[0142] SEQ ID NO: 21 shows the nucleic acid sequence of the first half antisense strand of the DMD 37-38 recognition sequence.
[0143] SEQ ID NO: 22 shows the nucleic acid sequence of the second half sense strand of the DMD 19-20 recognition sequence.
[0144] SEQ ID NO: 23 shows the nucleic acid sequence of the second half-antisense strand of the DMD 19-20 recognition sequence.
[0145] SEQ ID NO: 24 shows the nucleic acid sequence of the second half sense strand of the DMD 29-30 recognition sequence.
[0146] SEQ ID NO: 25 shows the nucleic acid sequence of the second half-antisense strand of the DMD 29-30 recognition sequence.
[0147] SEQ ID NO: 26 shows the nucleic acid sequence of the second half sense strand of the DMD 35-36 recognition sequence.
[0148] SEQ ID NO: 27 shows the nucleic acid sequence of the second half-antisense strand of the DMD 35-36 recognition sequence.
[0149] SEQ ID NO: 28 shows the nucleic acid sequence of the second half sense strand of the DMD 37-38 recognition sequence.
[0150] SEQ ID NO: 29 shows the nucleic acid sequence of the second half-antisense strand of the DMD 37-38 recognition sequence.
[0151] SEQ ID NO: 30 shows the nucleic acid sequence of the ligated hybrid DMD 19-20 / 29-30 sense strand.
[0152] SEQ ID NO: 31 shows the nucleic acid sequence of the ligated hybrid DMD 19-20 / 29-30 sense strand.
[0153] SEQ ID NO: 32 shows the nucleic acid sequence of the ligated hybrid DMD 19-20 / 35-36 sense strand.
[0154] SEQ ID NO: 33 shows the nucleic acid sequence of the ligated hybrid DMD 19-20 / 35-36 sense strand.
[0155] SEQ ID NO: 34 shows the nucleic acid sequence of the ligated hybrid DMD 19-20 / 37-38 sense strand.
[0156] SEQ ID NO: 35 shows the nucleic acid sequence of the ligated hybrid DMD 19-20 / 37-38 sense strand.
[0157] SEQ ID NO: 36 shows the amino acid sequence of DMD 19-20x.13 genetically engineered meganuclease.
[0158] SEQ ID NO: 37 shows the amino acid sequence of DMD 19-20x.87 genetically engineered meganuclease.
[0159] SEQ ID NO: 38 shows the amino acid sequence of DMD 19-20L.249 genetically engineered meganuclease.
[0160] SEQ ID NO: 39 shows the amino acid sequence of DMD 19-20L.302 genetically engineered meganuclease.
[0161] SEQ ID NO: 40 shows the amino acid sequence of DMD 19-20L.329 genetically engineered meganuclease.
[0162] SEQ ID NO: 41 shows the amino acid sequence of DMD 19-20L.374 genetically engineered meganuclease.
[0163] SEQ ID NO: 42 shows the amino acid sequence of DMD 19-20L.375 genetically engineered meganuclease.
[0164] SEQ ID NO: 43 shows the amino acid sequence of DMD 19-20L.431 genetically engineered meganuclease.
[0165] SEQ ID NO: 44 shows the amino acid sequence of DMD 19-20L.458 genetically engineered meganuclease.
[0166] SEQ ID NO: 45 shows the amino acid sequence of DMD 35-36x.63 genetically engineered meganuclease.
[0167] SEQ ID NO: 46 shows the amino acid sequence of DMD 35-36x.81 genetically engineered meganuclease.
[0168] SEQ ID NO: 47 shows the amino acid sequence of DMD 35-36L.195 genetically engineered meganuclease.
[0169] SEQ ID NO: 48 shows the amino acid sequence of DMD 35-36L.282 genetically engineered meganuclease.
[0170] SEQ ID NO: 49 shows the amino acid sequence of DMD 35-36L.349 genetically engineered meganuclease.
[0171] SEQ ID NO: 50 shows the amino acid sequence of DMD 35-36L.376 genetically engineered meganuclease.
[0172] SEQ ID NO: 51 shows the amino acid sequence of DMD 35-36L.457 genetically engineered meganuclease.
[0173] SEQ ID NO: 52 shows the amino acid sequence of DMD 35-36L.469 genetically engineered meganuclease.
[0174] SEQ ID NO: 53 shows the amino acid sequence of DMD 37-38x.15 genetically engineered meganuclease.
[0175] SEQ ID NO: 54 shows the amino acid sequence of DMD 37-38x.66 genetically engineered meganuclease.
[0176] SEQ ID NO: 55 shows the amino acid sequence of DMD 37-38x.79 genetically engineered meganuclease.
[0177] SEQ ID NO: 56 shows the amino acid sequence of DMD 37-38L.166 genetically engineered meganuclease.
[0178] SEQ ID NO: 57 shows the amino acid sequence of DMD 37-38L.478 genetically engineered meganuclease.
[0179] SEQ ID NO: 58 shows the amino acid sequence of DMD 37-38L.512 genetically engineered meganuclease.
[0180] SEQ ID NO: 59 shows the amino acid sequence of DMD 37-38L.528 genetically engineered meganuclease.
[0181] SEQ ID NO: 60 shows the nucleic acid sequence encoding the DMD 19-20x.13 genetically engineered meganuclease.
[0182] SEQ ID NO: 61 shows the nucleic acid sequence encoding the DMD 19-20x.87 genetically engineered meganuclease.
[0183] SEQ ID NO: 62 shows the nucleic acid sequence encoding the DMD 19-20L.249 genetically engineered meganuclease.
[0184] SEQ ID NO: 64 shows the nucleic acid sequence encoding the DMD 19-20L.302 genetically engineered meganuclease.
[0185] SEQ ID NO: 64 shows the nucleic acid sequence encoding the DMD 19-20L.329 genetically engineered meganuclease.
[0186] SEQ ID NO: 65 shows the nucleic acid sequence of DMD 19-20L.374 genetically engineered meganuclease.
[0187] SEQ ID NO: 66 shows the nucleic acid sequence of DMD 19-20L.375 genetically engineered meganuclease.
[0188] SEQ ID NO: 67 shows the nucleic acid sequence of DMD 19-20L.431 genetically engineered meganuclease.
[0189] SEQ ID NO: 68 shows the nucleic acid sequence of DMD 19-20L.458 genetically engineered meganuclease.
[0190] SEQ ID NO: 69 shows the nucleic acid sequence encoding the DMD 35-36x.63 genetically engineered meganuclease.
[0191] SEQ ID NO: 70 shows the nucleic acid sequence encoding the DMD 35-36x.81 genetically engineered meganuclease.
[0192] SEQ ID NO: 71 shows the nucleic acid sequence encoding the DMD 35-36L.195 genetically engineered meganuclease.
[0193] SEQ ID NO: 72 shows the nucleic acid sequence encoding the DMD 35-36L.282 genetically engineered meganuclease.
[0194] SEQ ID NO: 73 shows the nucleic acid sequence encoding the DMD 35-36L.349 genetically engineered meganuclease.
[0195] SEQ ID NO: 74 shows the nucleic acid sequence encoding the DMD 35-36L.376 genetically engineered meganuclease.
[0196] SEQ ID NO: 75 shows the nucleic acid sequence encoding the DMD 35-36L.457 genetically engineered meganuclease.
[0197] SEQ ID NO: 76 shows the nucleic acid sequence encoding the DMD 35-36L.469 genetically engineered meganuclease.
[0198] SEQ ID NO: 77 shows the nucleic acid sequence encoding the DMD 37-38x.15 genetically engineered meganuclease.
[0199] SEQ ID NO: 78 shows the nucleic acid sequence encoding the DMD 37-38x.66 genetically engineered meganuclease.
[0200] SEQ ID NO: 79 shows the nucleic acid sequence encoding the DMD 37-38x.79 genetically engineered meganuclease.
[0201] SEQ ID NO: 80 shows the nucleic acid sequence encoding the DMD 37-38L.166 genetically engineered meganuclease.
[0202] SEQ ID NO: 81 shows the nucleic acid sequence encoding the DMD 37-38L.478 genetically engineered meganuclease.
[0203] SEQ ID NO: 82 shows the nucleic acid sequence encoding the DMD 37-38L.512 genetically engineered meganuclease.
[0204] SEQ ID NO: 83 shows the nucleic acid sequence encoding the DMD 37-38L.528 genetically engineered meganuclease.
[0205] SEQ ID NO: 84 shows the amino acid sequence of the DMD 19-20x.13 genetically engineered meganuclease DMD19 binding subunit.
[0206] SEQ ID NO: 85 shows the amino acid sequence of the DMD 19-20x.87 genetically engineered meganuclease DMD19 binding subunit.
[0207] SEQ ID NO: 86 shows the amino acid sequence of the DMD 19-20L.249 genetically engineered meganuclease DMD19 binding subunit.
[0208] SEQ ID NO: 87 shows the amino acid sequence of the DMD 19-20L.302 genetically engineered meganuclease DMD19 binding subunit.
[0209] SEQ ID NO: 88 shows the amino acid sequence of the DMD 19-20L.329 genetically engineered meganuclease DMD19 binding subunit.
[0210] SEQ ID NO: 89 shows the amino acid sequence of the DMD 19-20L.374 genetically engineered meganuclease DMD19 binding subunit.
[0211] SEQ ID NO: 90 shows the amino acid sequence of the DMD 19-20L.375 genetically engineered meganuclease DMD19 binding subunit.
[0212] SEQ ID NO: 91 shows the amino acid sequence of the DMD 19-20L.431 genetically engineered meganuclease DMD19 binding subunit.
[0213] SEQ ID NO: 92 shows the amino acid sequence of the DMD 19-20L.458 genetically engineered meganuclease DMD19 binding subunit.
[0214] SEQ ID NO: 93 shows the amino acid sequence of the DMD 35-36x.63 genetically engineered meganuclease DMD35 binding subunit.
[0215] SEQ ID NO: 94 shows the amino acid sequence of the DMD 35-36x.81 genetically engineered meganuclease DMD35 binding subunit.
[0216] SEQ ID NO: 95 shows the amino acid sequence of the DMD 35-36L.195 genetically engineered meganuclease DMD35 binding subunit.
[0217] SEQ ID NO: 96 shows the amino acid sequence of the DMD 35-36L.282 genetically engineered meganuclease DMD35 binding subunit.
[0218] SEQ ID NO: 97 shows the amino acid sequence of DMD 35-36L.349 genetically engineered meganuclease DMD35 binding subunit.
[0219] SEQ ID NO: 98 shows the amino acid sequence of the DMD 35-36L.376 genetically engineered meganuclease DMD35 binding subunit.
[0220] SEQ ID NO: 99 shows the amino acid sequence of the DMD 35-36L.457 genetically engineered meganuclease DMD35 binding subunit.
[0221] SEQ ID NO: 100 shows the amino acid sequence of DMD 35-36L.469 genetically engineered meganuclease DMD35 binding subunit.
[0222] SEQ ID NO: 101 shows the amino acid sequence of the DMD 37-38x.15 genetically engineered meganuclease DMD37 binding subunit.
[0223] SEQ ID NO: 102 shows the amino acid sequence of the DMD 37-38x.66 genetically engineered meganuclease DMD37 binding subunit.
[0224] SEQ ID NO: 103 shows the amino acid sequence of the DMD 37-38x.79 genetically engineered meganuclease DMD37 binding subunit.
[0225] SEQ ID NO: 104 shows the amino acid sequence of the DMD 37-38L.166 genetically engineered meganuclease DMD37 binding subunit.
[0226] SEQ ID NO: 105 shows the amino acid sequence of DMD 37-38L.478 genetically engineered meganuclease DMD37 binding subunit.
[0227] SEQ ID NO: 106 shows the amino acid sequence of DMD 37-38L.512 genetically engineered meganuclease DMD37 binding subunit.
[0228] SEQ ID NO: 107 shows the amino acid sequence of DMD 37-38L.528 genetically engineered meganuclease DMD37 binding subunit.
[0229] SEQ ID NO: 108 shows the amino acid sequence of the DMD 19-20x.13 genetically engineered meganuclease DMD20 binding subunit.
[0230] SEQ ID NO: 109 shows the amino acid sequence of the DMD 19-20x.87 genetically engineered meganuclease DMD20 binding subunit.
[0231] SEQ ID NO: 110 shows the amino acid sequence of DMD 19-20L.249 genetically engineered meganuclease DMD20 binding subunit.
[0232] SEQ ID NO: 111 shows the amino acid sequence of the DMD 19-20L.302 genetically engineered meganuclease DMD20 binding subunit.
[0233] SEQ ID NO: 112 shows the amino acid sequence of the DMD 19-20L.329 genetically engineered meganuclease DMD20 binding subunit.
[0234] SEQ ID NO: 113 shows the amino acid sequence of the DMD 19-20L.374 genetically engineered meganuclease DMD20 binding subunit.
[0235] SEQ ID NO: 114 shows the amino acid sequence of the DMD 19-20L.375 genetically engineered meganuclease DMD20 binding subunit.
[0236] SEQ ID NO: 115 shows the amino acid sequence of the DMD 19-20L.431 genetically engineered meganuclease DMD20 binding subunit.
[0237] SEQ ID NO: 116 shows the amino acid sequence of the DMD 19-20L.458 genetically engineered meganuclease DMD20 binding subunit.
[0238] SEQ ID NO: 117 shows the amino acid sequence of the DMD 35-36x.63 genetically engineered meganuclease DMD36 binding subunit.
[0239] SEQ ID NO: 118 shows the amino acid sequence of the DMD 35-36x.81 genetically engineered meganuclease DMD36 binding subunit.
[0240] SEQ ID NO: 119 shows the amino acid sequence of the DMD 35-36L.195 genetically engineered meganuclease DMD36 binding subunit.
[0241] SEQ ID NO: 120 shows the amino acid sequence of the DMD 35-36L.282 genetically engineered meganuclease DMD36 binding subunit.
[0242] SEQ ID NO: 121 shows the amino acid sequence of DMD 35-36L.349 genetically engineered meganuclease DMD36 binding subunit.
[0243] SEQ ID NO: 122 shows the amino acid sequence of the DMD 35-36L.376 genetically engineered meganuclease DMD36 binding subunit.
[0244] SEQ ID NO: 123 shows the amino acid sequence of DMD 35-36L.457 genetically engineered meganuclease DMD36 binding subunit.
[0245] SEQ ID NO: 124 shows the amino acid sequence of DMD 35-36L.469 genetically engineered meganuclease DMD36 binding subunit.
[0246] SEQ ID NO: 125 shows the amino acid sequence of the DMD 37-38x.15 genetically engineered meganuclease DMD38 binding subunit.
[0247] SEQ ID NO: 126 shows the amino acid sequence of the DMD 37-38x.66 genetically engineered meganuclease DMD38 binding subunit.
[0248] SEQ ID NO: 127 shows the amino acid sequence of the DMD 37-38x.79 genetically engineered meganuclease DMD38 binding subunit.
[0249] SEQ ID NO: 128 shows the amino acid sequence of the DMD 37-38L.166 genetically engineered meganuclease DMD38 binding subunit.
[0250] SEQ ID NO: 129 shows the amino acid sequence of the DMD 37-38L.478 genetically engineered meganuclease DMD38 binding subunit.
[0251] SEQ ID NO: 130 shows the amino acid sequence of the DMD 37-38L.512 genetically engineered meganuclease DMD38 binding subunit.
[0252] SEQ ID NO: 131 shows the amino acid sequence of the DMD 37-38L.528 genetically engineered meganuclease DMD38 binding subunit.
[0253] SEQ ID NO: 132 shows the amino acid sequence of the linker sequence.
[0254] SEQ ID NO: 133 shows the nucleic acid sequence of a probe used in a ddPCR assay to detect indels in the DMD 19-20 recognition sequence.
[0255] SEQ ID NO: 134 shows the nucleic acid sequence of the forward PCR primer used in the ddPCR assay to detect indels in the DMD 19-20 recognition sequence.
[0256] SEQ ID NO: 135 shows the nucleic acid sequence of the forward PCR primer used in the ddPCR assay to detect indels in the DMD 19-20 recognition sequence.
[0257] SEQ ID NO: 136 shows the nucleic acid sequence of a probe used as a reference in a ddPCR assay to detect indels.
[0258] SEQ ID NO: 137 shows the nucleic acid sequence of the forward PCR primer used as a reference in the ddPCR assay to detect indels.
[0259] SEQ ID NO: 138 shows the nucleic acid sequence of the forward PCR primer used as a reference in the ddPCR assay to detect indels.
[0260] SEQ ID NO: 139 shows the nucleic acid sequence of a probe used in a ddPCR assay to detect indels in the DMD 37-38 recognition sequence.
[0261] SEQ ID NO: 140 shows the nucleic acid sequence of the forward PCR primer used in the ddPCR assay to detect indels in the DMD 37-38 recognition sequence.
[0262] SEQ ID NO: 141 shows the nucleic acid sequence of the forward PCR primer used in the ddPCR assay to detect indels in the DMD 37-38 recognition sequence.
[0263] SEQ ID NO: 142 shows the nucleic acid sequence of a probe used in a ddPCR assay to detect indels in the DMD 35-36 recognition sequence.
[0264] SEQ ID NO: 143 shows the nucleic acid sequence of the forward PCR primer used in the ddPCR assay to detect indels in the DMD 35-36 recognition sequence.
[0265] SEQ ID NO: 144 shows the nucleic acid sequence of the forward PCR primer used in the ddPCR assay to detect indels in the DMD 35-36 recognition sequence.
[0266] SEQ ID NO: 145 shows the nucleic acid sequence of a probe used in a ddPCR assay to detect indels in the DMD 29-30 recognition sequence.
[0267] SEQ ID NO: 146 shows the nucleic acid sequence of the forward PCR primer used in the ddPCR assay to detect indels in the DMD 29-30 recognition sequence.
[0268] SEQ ID NO: 147 shows the nucleic acid sequence of the forward PCR primer used in the ddPCR assay to detect indels in the DMD 29-30 recognition sequence.
[0269] SEQ ID NO: 148 shows the nucleic acid sequence of the forward PCR primer used in the PCR amplification assay of the ligated recognition sequences of DMD 19-20 to DMD 35-36.
[0270] SEQ ID NO: 149 shows the nucleic acid sequence of the reverse PCR primer used in the PCR amplification assay of the ligated recognition sequences of DMD 19-20 to DMD 35-36.
[0271] SEQ ID NO: 150 shows the nucleic acid sequence of the forward PCR primer used in the PCR amplification assay of the ligated recognition sequences of DMD 19-20 to DMD 35-36.
[0272] SEQ ID NO: 151 shows the nucleic acid sequence of the reverse PCR primer used in the PCR amplification assay of the ligated recognition sequences of DMD 19-20 to DMD 35-36.
[0273] SEQ ID NO: 152 shows the nucleic acid sequence of the forward PCR primer used in the PCR amplification assay of the ligated recognition sequences of DMD 19-20 to DMD 29-30.
[0274] SEQ ID NO: 153 shows the nucleic acid sequence of the reverse PCR primer used in the PCR amplification assay of the ligated recognition sequences of DMD 19-20 to DMD 29-30.
[0275] SEQ ID NO: 154 shows the nucleic acid sequence of the forward PCR primer used in the PCR amplification assay of the ligated recognition sequences of DMD 19-20 to DMD 29-30.
[0276] SEQ ID NO: 155 shows the nucleic acid sequence of the reverse PCR primer used in the PCR amplification assay of the ligated recognition sequences of DMD 19-20 to DMD 29-30.
[0277] SEQ ID NO: 156 shows the nucleic acid sequence of the forward PCR primer used in the PCR amplification assay of the ligated recognition sequences of DMD 19-20 to DMD 37-38.
[0278] SEQ ID NO: 157 shows the nucleic acid sequence of the reverse PCR primer used in the PCR amplification assay of the ligated recognition sequences of DMD 19-20 to DMD 37-38.
[0279] SEQ ID NO: 158 shows the nucleic acid sequence of the forward PCR primer used in the PCR amplification assay of the ligated recognition sequences of DMD 19-20 to DMD 37-38.
[0280] SEQ ID NO: 159 shows the nucleic acid sequence of the reverse PCR primer used in the PCR amplification assay of the ligated recognition sequences of DMD 19-20 to DMD 37-38.
[0281] SEQ ID NO: 160 shows the nucleic acid sequence of the probe used in the ddPCR assay for the ligated recognition sequences of DMD 19-20 to DMD 37-38.
[0282] SEQ ID NO: 161 shows the nucleic acid sequence of the forward PCR primer used in the ddPCR assay of the ligated recognition sequences of DMD 19-20 to DMD 37-38.
[0283] SEQ ID NO: 162 shows the nucleic acid sequence of the reverse PCR primer used in the ddPCR assay of the ligated recognition sequences of DMD 19-20 to DMD 37-38.
[0284] SEQ ID NO: 163 shows the nucleic acid sequence of the probe used in the ddPCR assay for the ligated recognition sequences of DMD 19-20 to DMD 35-36.
[0285] SEQ ID NO: 164 shows the nucleic acid sequence of the forward PCR primer used in the ddPCR assay of the ligated recognition sequences of DMD 19-20 to DMD 35-36.
[0286] SEQ ID NO: 165 shows the nucleic acid sequence of the reverse PCR primer used in the ddPCR assay of the ligated recognition sequences of DMD 19-20 to DMD 35-36.
[0287] SEQ ID NO: 166 shows the nucleic acid sequence of the probe used in the ddPCR assay for the ligated recognition sequences of DMD 19-20 to DMD 29-30.
[0288] SEQ ID NO: 167 shows the nucleic acid sequence of the forward PCR primer used in the ddPCR assay of the ligated recognition sequences of DMD 19-20 to DMD 29-30.
[0289] SEQ ID NO: 168 shows the nucleic acid sequence of the reverse PCR primer used in the ddPCR assay of the ligated recognition sequences of DMD 19-20 to DMD 29-30.
[0290] SEQ ID NO: 169 shows the nucleic acid sequence of the C5-12 promoter sequence.
[0291] SEQ ID NO: 170 shows the nucleic acid sequence of the mouse MCK promoter and enhancer sequence.
[0292] SEQ ID NO: 171 shows the nucleic acid sequence of the human MCK promoter sequence.
[0293] SEQ ID NO: 172 shows the nucleic acid sequence of the wild type MCK enhancer sequence.
[0294] SEQ ID NO: 173 shows the nucleic acid sequence of the modified MCK enhancer sequence.
[0295] SEQ ID NO: 174 shows the nucleic acid sequence of the spc 5-12 promoter sequence.
[0296] SEQ ID NO: 175 shows the nucleic acid sequence of the MHCK7 promoter sequence.
[0297] SEQ ID NO: 176 shows the nucleic acid sequence of the CK8 promoter sequence.
[0298] SEQ ID NO: 177 shows the nucleic acid sequence of the SK-CRM4 promoter sequence.
[0299] SEQ ID NO: 178 shows the nucleic acid sequence of the SP-301 promoter sequence.
[0300] SEQ ID NO: 179 shows the nucleic acid sequence of the SP-817 promoter sequence.
[0301] SEQ ID NO: 180 shows the nucleic acid sequence of the SP-905 promoter sequence.
[0302] SEQ ID NO: 181 shows the nucleic acid sequence of the muscle hybrid promoter sequence.
[0303] SEQ ID NO: 182 shows the amino acid sequence of rh.74 AAV capsid.
[0304] SEQ ID NO: 183 shows the amino acid sequence of AAV9 capsid.
[0305] SEQ ID NO: 184 shows the nucleic acid sequence of the forward primer.
[0306] SEQ ID NO: 185 shows the nucleic acid sequence of the reverse primer.
[0307] SEQ ID NO: 186 shows the nucleic acid sequence of the probe.
[0308] SEQ ID NO: 187 shows the nucleic acid sequence of the forward primer.
[0309] SEQ ID NO: 188 shows the nucleic acid sequence of the reverse primer.
[0310] SEQ ID NO: 189 shows the nucleic acid sequence of the probe.
[0311] SEQ ID NO: 190 shows the nucleic acid sequence of the forward primer.
[0312] SEQ ID NO: 191 shows the nucleic acid sequence of the reverse primer.
[0313] SEQ ID NO: 192 shows the nucleic acid sequence of the probe.
[0314] SEQ ID NO: 193 shows the nucleic acid sequence of the reverse primer. Detailed description of the invention
[0315] 1.1 References and definitions The patent and scientific literature referred to herein establishes the knowledge available to those skilled in the art. References cited herein, including issued U.S. patents, allowed applications, published foreign applications, and GenBank database sequences, are each specifically and individually indicated to be incorporated by reference. are incorporated herein by reference to the same extent.
[0316] This disclosure may be embodied in different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art. For example, features illustrated with respect to one embodiment may be incorporated into other embodiments, and features illustrated with respect to a particular embodiment may be deleted from that embodiment. Furthermore, numerous variations and additions to the embodiments proposed herein will be apparent to those skilled in the art in light of this disclosure and do not depart from the invention.
[0317] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used in the description of the invention herein is for the purpose of describing particular embodiments only and is not intended to limit the invention.
[0318] All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety.
[0319] As used herein, "a", "an", or "the" can mean one or more than one. For example, "a" cell can mean a single cell or multiple cells.
[0320] As used herein, unless stated otherwise, the word "or" is used in the inclusive sense of "and / or" and not in the exclusive sense of "either / or."
[0321] As used herein, the terms "nuclease" and "endonuclease" are used interchangeably to refer to naturally occurring or genetically engineered enzymes that cleave phosphodiester bonds within polynucleotide chains. be done. Genetically engineered nucleases can include, but are not limited to, engineered meganucleases, zinc finger nucleases, TALENs, compact TALENs, CRISPR system nucleases, and mega TALs. Additionally, any genetically engineered nuclease capable of generating an overhang at its cleavage site is envisioned.
[0322] As used herein, the term "cleavage" or "cleavage" refers to the backbone of a recognition sequence within a target sequence that results in a double-stranded break within the target sequence, herein referred to as the "cleavage site." Refers to the hydrolysis of phosphodiester bonds within.
[0323] As used herein, the term "meganuclease" refers to an endonuclease that binds to double-stranded DNA with a recognition sequence greater than 12 base pairs. In some embodiments, the recognition sequence of a meganuclease of the present disclosure is 22 base pairs. The meganuclease may be an endonuclease derived from I-CreI (SEQ ID NO: 1), e.g. It may refer to a genetically engineered variant of I-CreI that has been modified against. Methods for producing such modified variants of I-CreI are known in the art (eg, WO 2007 / 047859, which is incorporated by reference in its entirety). As used herein, meganucleases bind double-stranded DNA as heterodimers. A meganuclease can also be a "single chain meganuclease" in which a pair of DNA binding domains are joined into a single polypeptide using a peptide linker. The term "homing endonuclease" is synonymous with the term "meganuclease." The meganucleases of the present disclosure are substantially non-toxic when expressed in the target cells described herein, and therefore have an effect on cell viability when measured using the methods described herein. Cells can be transfected and maintained at 37°C without observing any deleterious effects of or significant reduction in meganuclease cleavage activity.
[0324] As used herein, the term "single chain meganuclease" refers to a polypeptide that includes a pair of nuclease subunits connected by a linker. Single-chain meganucleases have the following structure: N-terminal subunit-linker-C-terminal subunit. The two meganuclease subunits generally do not have identical amino acid sequences and bind to non-identical DNA sequences. Therefore, single-chain meganucleases typically cleave pseudopalindromic or non-palindromic recognition sequences. Although single-chain meganucleases are sometimes referred to as "single-chain heterodimers" or "single-chain heterodimeric meganucleases," they are not actually dimers. For clarity, unless otherwise stated, the term "meganuclease" can refer to dimeric or single-chain meganucleases.
[0325] As used herein, the term "linker" refers to an exogenous peptide sequence used to join two nuclease subunits into a single polypeptide. The linker may have a sequence found in a naturally occurring protein, or it may be an artificial sequence not found in any naturally occurring protein. The linker may be flexible and lack secondary structure, or may have a tendency to form a particular three-dimensional structure under physiological conditions. Linkers can include, without limitation, those covered by US Pat. In some embodiments, the linker represents residues 154-195 of any one of SEQ ID NO: 36-59, at least 80%, at least 85%, at least 90%, at least 91%, at least 92 %, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity.
[0326] As used herein, the term "recombinant" or "genetically engineered" with respect to proteins refers to the addition of amino acids that have been changed as a result of the application of genetic engineering techniques to the nucleic acid encoding the protein and the cells or organisms expressing the protein. It means having an array. With respect to nucleic acids, the term "recombinant" or "genetically engineered" means having a nucleic acid sequence altered as a result of the application of genetic engineering techniques. Genetic engineering techniques include, but are not limited to, PCR and DNA cloning techniques; transfection, transformation and other gene transfer techniques; homologous recombination; site-directed mutagenesis; and gene fusion. According to this definition, a protein that has the same amino acid sequence as a naturally occurring protein but is produced by cloning and expression in a heterologous host is not considered to be recombinant or genetically engineered.
[0327] As used herein, the term "wild type" refers to the most common naturally occurring allele in a population of alleles of the same type of gene, in which the polypeptide encoded by the wild type allele has its original function. Refers to a gene (ie, a polynucleotide sequence). The term "wild type" also refers to a polypeptide encoded by a wild type allele. Wild-type alleles (i.e., polynucleotides) and polypeptides include mutant or variant alleles and polypeptides that contain one or more mutations and / or substitutions compared to the wild-type sequence(s). It is possible to distinguish from While a wild-type allele or polypeptide can confer a normal phenotype in an organism, a mutant or variant allele or polypeptide can, in some cases, confer an altered phenotype. Wild-type nucleases are distinguishable from recombinant or non-naturally occurring nucleases. The term "wild-type" can also refer to cells, organisms, and / or subjects that have a wild-type allele of a particular gene, or that are used for comparison purposes.
[0328] As used herein, the term "genetically modified" refers to a cell or organism whose genomic DNA sequence (or in its ancestor) has been intentionally modified by recombinant techniques. As used herein, the term "genetically modified" includes the term "transgenic."
[0329] As used herein, the term "modification" with respect to a recombinant protein refers to any insertion, deletion, or substitution of amino acid residues within a recombinant sequence relative to a reference sequence (e.g., a wild-type or native sequence). means.
[0330] As used herein, the term "recognition sequence" or "recognition site" refers to a DNA sequence that is bound and cleaved by a nuclease. For meganucleases, the recognition sequence comprises a pair of inverted 9 base pair "half sites" separated by 4 base pairs. For single-chain meganucleases, the N-terminal domain of the protein contacts the first half-site, and the C-terminal domain of the protein contacts the second half-site. Cleavage with the meganuclease results in a 4 base pair 3' overhang. "Overhangs" or "sticky ends" are short single-stranded DNA segments that can be produced by endonucleolytic cleavage of double-stranded DNA sequences. In the case of I-Crel derived meganucleases and single-chain meganucleases, the overhang includes bases 10-13 of the 22 base pair recognition sequence.
[0331] As used herein, the term "target site" or "target sequence" refers to the region of a cell's chromosomal DNA that contains the recognition sequence for a nuclease.
[0332] As used herein, the term "DNA binding affinity" or "binding affinity" refers to the tendency of a nuclease to non-covalently bind a reference DNA molecule (eg, a recognition sequence or any sequence). Binding affinity is measured by the dissociation constant, Kd. As used herein, a nuclease has an "altered" binding affinity if the Kd of the nuclease for a reference recognition sequence increases or decreases by a statistically significant percentage change relative to the reference nuclease.
[0333] As used herein, the term "specificity" refers to the ability of a nuclease to bind to double-stranded DNA molecules only at a particular sequence of base pairs, called a recognition sequence, or only at a particular set of recognition sequences. It means the ability to cut. A set of recognition sequences shares certain conserved positions or sequence motifs, but can be degenerate at one or more positions. Highly specific nucleases can cleave only one or a small number of recognition sequences. Specificity can be determined by any method known in the art.
[0334] As used herein, the term "dystrophin gene" refers to the gene related to National Center for Biotechnology Information (NCBI) gene ID 1756, as well as natural variants thereof. The term "dystrophin" refers to the polypeptide encoded by the dystrophin gene. The dystrophin isoform expressed in muscle cells and muscle progenitor cells is known as the Dp 427m dystrophin variant. The amino acid sequence of the full-length wild-type Dp427m dystrophin polypeptide is shown in SEQ ID NO:4. NCBI reference numbers NM_004006.3 and NP_003997.2 refer to dystrophin Dp427m mRNA and polypeptide, respectively. In some embodiments described herein, the dystrophin gene is edited with a pair of genetically engineered meganucleases, resulting in excision of exons 45-55 and subsequent complete ligation of the dystrophin gene. Removal of exons 45-55 from the wild-type dystrophin gene can result in a dystrophin polypeptide comprising the amino acid sequence shown in SEQ ID NO:5.
[0335] As used herein, the term "complete ligation" refers to all four of the 3' overhangs of the first cleavage site within the dystrophin gene after cleavage by a pair of genetically engineered meganucleases of the invention. refers to the ligation (i.e., annealing) of the base with all four bases of the complementary 3' overhang of the second cleavage site. The recognition sequences targeted by the disclosed engineered meganucleases have identical 4 base pair centers such that the first and second cleavage sites have complementary 4 base pair 3' overhangs. sequence (eg GTAT). Thus, each base pair on the first 3' overhang pairs with its complementary base pair on the second 3' overhang and ligation occurs via the DNA ligase enzyme. Examples of sequences resulting from such complete ligations are SEQ ID NO: 32 (i.e., complete ligation of DMD 19-20 and DMD 35-36 recognition sequences) and SEQ ID NO: 34 (i.e., DMD 19-20 and DMD 37-38 recognition sequences). Complete ligation of sequences).
[0336] As used herein, the term "Becker muscular dystrophy phenotype" refers to a less severe form of muscular dystrophy compared to DMD. Individuals with Becker muscular dystrophy still contain mutations within the dystrophin gene, but have more functional dystrophin protein in muscle cells (e.g., muscle progenitors, skeletal muscle cells, and cardiomyocytes) compared to individuals with DMD. ) and generally confers a better clinical prognosis.
[0337] As used herein, the term "homologous recombination" or "HR" refers to the natural cellular process in which double-stranded DNA breaks are repaired using a homologous DNA sequence as a repair template (e.g. (See Cahill et al. (2006) Front. Biosci. 11:1958-76). The homologous DNA sequence can be an endogenous chromosomal sequence or an exogenous nucleic acid delivered to the cell.
[0338] As used herein, the term "non-homologous end joining" or "NHEJ" refers to a natural cellular process in which double-stranded DNA breaks are repaired by direct joining of two non-homologous DNA segments (e.g. , see Cahill et al. (2006)). DNA repair by non-homologous end joining is error-prone and frequently results in untemplated addition or deletion of DNA sequences at the repair site. In some instances, cleavage at the target recognition sequence results in NHEJ at the target recognition site. Nuclease-induced cleavage of target sites in a gene's coding sequence followed by DNA repair by non-homologous end joining (NHEJ) can introduce mutations into the coding sequence, such as frameshift mutations, that disrupt gene function. . Thus, genetically engineered nucleases can be used to effectively knock out genes in a population of cells.
[0339] As used herein, the term "homologous arm" or "sequence homologous to the sequence flanking a nuclease cleavage site" refers to a nucleic acid molecule that facilitates insertion of a nucleic acid molecule into a cleavage site generated by a nuclease. refers to the sequences adjacent to the 5' and 3' ends of Generally, homologous arms may be at least 50 base pairs, preferably at least 100 base pairs, up to 2000 base pairs or longer, and are at least 90%, preferably at least 95% or more long than their corresponding sequences in the genome. It is possible to have higher sequence homology than that. In some embodiments, homologous arms are about 500 base pairs.
[0340] As used herein, with respect to both amino acid sequences and nucleic acid sequences, terms such as "percent identity," "sequence identity," "percentage similarity," and "sequence similarity" refer to the alignment of aligned amino acid sequences. An alignment of sequences that maximizes the similarity between residues or nucleotides and is a function of the number of identical or similar residues or nucleotides, the total number of residues or nucleotides, and the presence and length of gaps in the sequence alignment. refers to a measure of the degree of similarity between two sequences based on Various algorithms and computer programs are available for determining sequence similarity using standard parameters. As used herein, sequence similarity is determined using the BLASTp program for amino acid sequences and the BLASTn program for nucleic acid sequences, both available from the National Center for Biotechnology Information (www. .ncbi.nlm.nih.gov / ), e.g. Altschul et al. (1990) J.Mol.Biol.215:403-10; Gish&States (1993) Nature Genet.3:266-72; Madden et al. (1996) )Meth.Enzymol.266:131-41; Altschul et al. (1997) Nucleic Acids Res.25:3389-3402; and Zhang et al. (2000) J.Comput.Biol.7:203-14. ing. As used herein, the percent similarity of two amino acid sequences is a score based on the following parameters for the BLASTp algorithm: word size = 3; gap opening penalty = -11; gap extension penalty = -1; Score matrix = BLOSUM 62. As used herein, the percent similarity of two nucleic acid sequences is a score based on the following parameters for the BLASTn algorithm: word size = 11; gap opening penalty = -5; gap extension penalty = -2; Match reward = 1; mismatch penalty = -3.
[0341] As used herein, the term "corresponds to" with respect to modifications of two proteins or amino acid sequences means that a particular modification of the first protein is a substitution of the same amino acid residue as a modification of the second protein. that, and when the two proteins are subjected to standard sequence alignment (e.g., using the BLASTp program), the amino acid position of the modification in the first protein corresponds to the amino acid position of the modification in the second protein. Used to indicate that the Therefore, modification of residue "X" to amino acid "A" in the first protein, despite the fact that X and Y can be different numbers, if residues X and Y correspond to each other in the sequence alignment. First, it corresponds to the modification of residue "Y" to amino acid "A" in the second protein.
[0342] As used herein, the term "recognition half-site," "recognition sequence half-site," or simply "half-site" means Refers to a nucleic acid sequence within a double-stranded DNA molecule that is recognized and bound by one subunit of a nuclease or by one subunit of a single-stranded meganuclease.
[0343] As used herein, the term "hypervariable region" refers to a localized sequence within a meganuclease monomer or subunit that contains amino acids with relatively high variability. A hypervariable region can include about 50-60 contiguous residues, about 53-57 contiguous residues, or preferably about 56 residues. In some embodiments, the hypervariable region residues may correspond to positions 24-79 or 215-270 of any one of SEQ ID NOs: 36-59. The hypervariable region can contain one or more residues that contact DNA bases in the recognition sequence and can be modified to alter the base selectivity of the monomer or subunit. The hypervariable region can also include one or more residues that bind to the DNA backbone when the meganuclease associates with a double-stranded DNA recognition sequence. Such residues can be modified to alter the binding affinity of the meganuclease to the DNA backbone and target recognition sequence. In different embodiments of the invention, the hypervariable region may contain 1-20 residues that exhibit variability and can be modified to affect base selectivity and / or DNA binding affinity. In certain embodiments, the hypervariable region comprises about 15-20 residues that exhibit variability and can be modified to affect base selectivity and / or DNA binding affinity. In some embodiments, the variable residues within the hypervariable region are at positions 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77. In certain embodiments, the variable residues within the hypervariable region may further correspond to residues 48, 50, and 71-73 of any one of SEQ ID NOs: 36-59. In other embodiments, the variable residues within the hypervariable region are at positions 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 239 of any one of SEQ ID NOs: 36-59. , 241, 259, 261, 262, 263, 264, 266, and 268. In certain embodiments, the variable residues within the hypervariable region may further correspond to residues 239, 241, and 263-265 of any one of SEQ ID NOs: 36-59.
[0344] The term "increase" in the context of dystrophin protein or mRNA levels means at least 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, as compared to a reference level or control. Dystrophin compared to a reference level, including an increase in dystrophin protein or mRNA expression of 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 100% or more Refers to any increase in the level of protein or mRNA expression. In some embodiments, the increase in dystrophin protein or mRNA levels comprises an increase in a truncated dystrophin polypeptide or mRNA transcript, e.g., encoded by at least one exon, as compared to a wild-type dystrophin polypeptide or gene. This refers to the deletion of a part of the polypeptide (for example, the part encoded by exons 45 to 55) or the deletion of part of the mRNA corresponding to exons 45 to 55.
[0345] As used herein, the term "reference level" in the context of dystrophin protein or mRNA levels refers to, e.g., in a control cell, control cell population or control subject undergoing a control cell, control cell population or treatment. The level of dystrophin protein or mRNA measured at a previous time point in the subject (e.g., a pre-dose baseline level obtained from a control cell, control cell population or subject), or a predefined threshold level of dystrophin protein or mRNA (e.g. , the threshold level identified through previous experiments).
[0346] As used herein, the term "control" or "control cell" refers to a cell that provides a reference point for measuring genotypic or phenotypic changes in genetically modified cells. The control cells can be, for example, (a) wild-type cells, i.e. of the same genotype as the starting material for the genetic modification that resulted in the genetically modified cells; (b) cells of the same genotype as the genetically modified cells. or (c) genetically identical to the genetically modified cell, but with an altered genotype. or may include cells that have not been exposed to conditions or stimuli that induce expression of the phenotype or to further genetic modification. The control subject is, for example: a wild-type subject, i.e. a wild-type subject of the same genotype as the starting subject for the genetic modification that resulted in the genetically modified subject (e.g. a subject with the same mutation in the dystrophin gene), It can include a wild type subject that has not been exposed to conditions or stimuli or further genetic modification that induces expression of an altered genotype or phenotype in the subject.
[0347] As used herein, the terms "recombinant DNA construct", "recombinant construct", "expression cassette", "expression construct", "chimeric construct", "construct", and "recombinant DNA fragment" are used interchangeably herein and are single-stranded or double-stranded polynucleotides. Recombinant constructs include artificial combinations of nucleic acid fragments including, but not limited to, regulatory and coding sequences that are not found together in nature. For example, a recombinant DNA construct may contain regulatory and coding sequences derived from different sources, or regulatory and coding sequences derived from the same source but arranged in a manner different from that found in nature. Such constructs may be used alone or in combination with vectors.
[0348] As used herein, the term "vector" or "recombinant DNA vector" refers to a construct containing a replication system and sequences capable of transcription and translation of a polypeptide-encoding sequence in a given host cell. could be. If a vector is used, the choice of vector will depend on the method used to transform the host cell, as is well known to those skilled in the art. Vectors can include, but are not limited to, plasmid vectors and recombinant AAV vectors, or any other vector known in the art suitable for delivering genes to target cells. Those skilled in the art will appreciate the genetic elements that must be present on a vector to successfully transform, select and propagate host cells containing any of the isolated nucleotide or nucleic acid sequences of the invention. ing. In some embodiments, "vector" also refers to viral vectors. Viral vectors can include, but are not limited to, retroviral vectors, lentiviral vectors, adenoviral vectors, and AAV.
[0349] As used herein, the term "operably linked" is intended to mean a functional linkage between two or more elements. For example, an operable linkage between a nuclease-encoding nucleic acid sequence disclosed herein and a regulatory sequence (e.g., a promoter) is a functional linkage that enables expression of the nuclease-encoding nucleic acid sequence. . The operably connected elements may be continuous or discontinuous. When used to refer to the joining of two protein coding regions, operably linked intends that the coding regions are in the same reading frame.
[0350] As used herein, the term "treatment" or "treating a subject" refers to a genetically engineered meganuclease described herein, or a genetically engineered meganuclease described herein. Refers to the administration of a polynucleotide encoding a polynucleotide, or such a genetically engineered meganuclease or polynucleotide pair, to a subject with DMD for the purpose of increasing the level of dystrophin protein in the subject. In some embodiments, expression of a truncated form of the dystrophin protein (eg, lacking amino acids encoded by multiple exons) is increased. In some embodiments, expression of a version of the dystrophin protein lacking the amino acids encoded by exons 45-55 is increased. Such treatment, in some embodiments, shifts the DMD phenotype to a Becker dystrophic phenotype.
[0351] As used herein, the term "gc / kg" or "gene copies / kilogram" refers to the number of copies per kilogram of weight of a subject to whom a polynucleotide comprising a nucleic acid sequence is administered, as described herein. Refers to the copy number of a nucleic acid sequence encoding a genetically engineered meganuclease.
[0352] As used herein, the term "effective amount" or "therapeutically effective amount" refers to an amount sufficient to produce a beneficial or desired biological and / or clinical result. A therapeutically effective amount will vary depending on the formulation or composition used, the disease and its severity, and the age, weight, physical condition and responsiveness of the subject being treated. In certain embodiments, an effective amount of an engineered meganuclease or pair of engineered meganucleases described herein, or a polynucleotide or pair of polynucleotides encoding the same, or disclosed herein. The pharmaceutical compositions described herein increase the expression level of dystrophin protein (eg, a truncated dystrophin protein lacking amino acids encoded by exons 45-55) and ameliorate at least one symptom associated with DMD.
[0353] As used herein, the term "lipid nanoparticles" refers to lipid compositions having a typically spherical structure with an average diameter of 10-1000 nm. In some formulations, the lipid nanoparticles can include at least one cationic lipid, at least one non-cationic lipid, and at least one conjugated lipid. Lipid nanoparticles known in the art that are suitable for encapsulating nucleic acids such as mRNA are contemplated for use in the present invention.
[0354] As used herein, the recitation of a numerical range for a variable is intended to convey that the disclosure may be practiced with the variable equal to any value within that range. Thus, for a variable that is discrete in nature, the variable can be equal to any integer value within a numerical range that includes the endpoints of the range. Similarly, for an essentially continuous variable, the variable can be equal to any real value within a numerical range that includes the endpoints of the range. By way of example, but not limitation, a variable described as having a value between 0 and 2 may take on values of 0, 1, or 2 if the variable is discrete in nature. , if the variable is continuous in nature, can take on values of 0.0, 0.1, 0.01, 0.001, or any other real value between 0 and 2.
[0355] 2.1 Principle of the invention The present disclosure discloses, in part, that certain deletions in the dystrophin gene that give rise to the DMD phenotype have been demonstrated to utilize endonuclease pairs to restore the normal reading frame within the gene. based on the hypothesis that this can be compensated for by strategically deleting . The DMD-Leiden database shows that most of the mutations that cause DMD are deletions of one or more entire exons causing a reading frame shift. In many cases, the reading frame can be restored by removing the exon immediately before or after the mutation. As shown in Table 3, the 29 different Duchenne-causing mutations that account for approximately 65% of patients can be compensated for by deleting a single exon flanking the mutation.
[0356] [Table 3]
[0357] For example, patients with diseases due to deletion of exon 45, which occurs in approximately 7% of patients, can be treated with therapeutic agents that delete exon 46. Therapeutic agents capable of deleting exon 51 or exon 45 could be used to treat 15% and 13% of patients, respectively.
[0358] Notably, over 50% of all DMD-associated mutations within the dystrophin gene are encompassed by exons 45-55. Therefore, in certain embodiments of the invention, exons 45-55 of the dystrophin gene are removed to restore the normal reading frame of the gene. As disclosed herein, exon deletion in muscle cells or muscle progenitor cells (e.g., cardiomyocytes or skeletal muscle cells) generates a pair of cleavage sites in the intron upstream of exon 45 and downstream of exon 55. This is achieved by the expression of a pair of genetically engineered meganucleases, allowing excision of intervening genomic regions. Following this approach, genetically modified cells (e.g., muscle cells in treated subjects) can be produced with an amount of truncated dystrophin from a Becker phenotype similar to the microdystrophin approach, without the need to express a microdystrophin transgene. Proteins can be made. This truncated dystrophin may be sufficient to permanently rescue the disease, unlike other treatments that require multiple sequential treatment regimens.
[0359] It is therefore envisioned that a single treatment will permanently delete an exon from a percentage of cells in a subject. In some embodiments, these cells are myoblasts (i.e., muscle cells) or other muscle precursors that can replicate and give rise to whole myofibers that express functional (or semi-functional) dystrophin. It is a cell. However, if exon deletions are infrequent, it may be necessary to perform multiple treatments for each patient.
[0360] 2.2 Meganuclease that binds to and cleaves the recognition sequence in the dystrophin gene recognition sequence It is possible to perform DNA breaks within the genome of living cells using site-specific nucleases, and such DNA breaks can be performed via mutagenic NHEJ repair or through homologous recombination with transgenic DNA sequences. It is known in the art that permanent alterations of the genome can be effected through . NHEJ can cause mutagenesis at the cleavage site, resulting in allele inactivation. NHEJ-associated mutagenesis may inactivate alleles through the generation of early stop codons, frameshift mutations producing aberrant non-functional proteins, or may trigger mechanisms such as nonsense-mediated mRNA degradation. . The use of nucleases to induce mutagenesis via NHEJ can be used to target specific mutations or sequences present in the wild-type allele. Additionally, the use of nucleases to induce double-strand breaks at target loci is known to stimulate homologous recombination, particularly of transgenic DNA sequences flanking sequences homologous to the genomic target. In this way, exogenous polynucleotides can be inserted into the target locus. Such exogenous polynucleotides can encode any sequence or polypeptide of interest.
[0361] In certain embodiments, a genetically engineered meganuclease of the invention comprises a DMD 19-20 recognition sequence (SEQ ID NO: 6), a DMD 35-36 recognition sequence (SEQ ID NO: 10), or a DMD 37-38 recognition sequence (SEQ ID NO: 10). Number 12) is designed to join and cut. Exemplary meganucleases that bind and cleave DMD 19-20 recognition sequences are provided in SEQ ID NOs: 36-44. Exemplary meganucleases that bind and cleave DMD 35-36 recognition sequences are provided in SEQ ID NOs: 45-52. Exemplary meganucleases that bind and cleave DMD 37-38 recognition sequences are provided in SEQ ID NOs: 53-59. The sequence of each recognition sequence and the four base pair 3' overhang that results when cleaved by the engineered meganucleases described herein is provided in Table 4 below.
[0362] [Table 4]
[0363] To modify the dystrophin gene according to the present disclosure, pairs of genetically engineered meganucleases described herein are utilized together within the same cell. A pair of such genetically engineered meganucleases is designed to generate a first cleavage site in an intron upstream of exon 45 and a second cleavage site in an intron downstream of exon 55, allowing for intervening This enabled the removal of genomic sequences. Surprisingly, it was observed that excision of this genomic region from the dystrophin gene that is over 500,000 bp in size can be achieved with high efficiency. Furthermore, the meganuclease recognition sequence was selected to have a complementary 4 base pair 3' overhang after cleavage, and the dystrophin gene is frequently repaired by complete ligation of the 3' overhang of the two cleavage sites. Observed to obtain. Such fully ligated recognition sequences contemplated herein are provided in Table 5 below.
[0364] [Table 5]
[0365] These recognition sequences are further selected to be within intronic sequences that are normally spliced during post-transcriptionally modified cellular processes. This reduces the likelihood that mutations will be introduced into the dystrophin gene and encoded polypeptide.
[0366] Exemplary genetically engineered meganucleases The genetically engineered meganucleases of the invention include a first subunit that includes an HVR1 region and a second subunit that includes an HVR2 region. Additionally, the first subunit binds to a first recognition half-site in the recognition sequence (e.g., DMD 19 half-site) and the second subunit binds to a second recognition half-site in the recognition sequence (e.g., , DMD 20 half-site).
[0367] In certain embodiments, the meganuclease used to practice the invention is a single chain meganuclease. A single-chain meganuclease comprises an N-terminal subunit and a C-terminal subunit (ie, the first and second subunits described above) connected by a linker peptide. Each of the two subunits recognizes and binds to a half-site of the recognition sequence, and the site of DNA cleavage is in the center of the recognition sequence near the interface of the two subunits. As discussed, DNA strand breaks are offset by 4 base pairs such that DNA cleavage by meganucleases generates a pair of 4 base pair 3' single-stranded overhangs.
[0368] In embodiments where the engineered meganuclease is a single-chain meganuclease, the first and second subunits include the HVR1 region and the first subunit that binds to the first half-site as the N-terminal subunit. The second subunit containing the HVR2 region and binding to the second half-site can be oriented such that the second subunit is arranged as a C-terminal subunit. In an alternative embodiment, the first and second subunits are arranged as a C-terminal subunit, with the first subunit containing the HVR1 region and binding to the first half site, and the second subunit containing the HVR2 region binding to the first half site. The second subunit that binds to the site can be oriented such that it is positioned as the N-terminal subunit.
[0369] Exemplary DMD meganucleases of the invention are provided in SEQ ID NOs: 36-59 and are summarized in Tables 6-8 below.
[0370] [Table 6]
[0371] "DMD19 subunit %" and "DMD20 subunit %" are between the DMD19-binding and DMD20-binding subunit regions of each meganuclease and the DMD19-binding and DMD20-binding subunit regions of DMD 19-20x.13 meganuclease, respectively. represents the amino acid sequence identity of
[0372] [Table 7]
[0373] "DMD35 subunit %" and "DMD36 subunit %" are between the DMD35-binding and DMD36-binding subunit regions of each meganuclease and the DMD35-binding and DMD36-binding subunit regions, respectively, of DMD 35-36x.63 meganuclease. represents the amino acid sequence identity of
[0374] [Table 8]
[0375] "DMD37 subunit %" and "DMD38 subunit %" are between the DMD37-binding and DMD38-binding subunit regions of each meganuclease and the DMD37-binding and DMD38-binding subunit regions, respectively, of DMD 37-38x.15 meganuclease. represents the amino acid sequence identity of
[0376] In certain embodiments of the invention, the genetically engineered meganuclease binds to and cleaves a recognition sequence comprising SEQ ID NO: 6 within the dystrophin gene (i.e., the DMD 19-20 recognition sequence), and the genetically engineered meganuclease The nuclease includes a first subunit and a second subunit, the first subunit binds to the first recognition half site of the recognition sequence and includes the HVR1 region, and the second subunit binds to the first recognition half site of the recognition sequence; It binds to the second recognition half of the sequence and contains the HVR2 region. An exemplary DMD 19-20 meganuclease is described below.
[0377] DMD 19-20x.13 (Sequence number 36)
[0378] In some embodiments, the HVR1 region comprises at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% of the amino acid sequence corresponding to residues 24-79 of SEQ ID NO: 36. , 96%, 97%, 98%, 99% or higher sequence identity. In some embodiments, the HVR1 region corresponds to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 36. Contains one or more residues. In some embodiments, the HVR1 region corresponds to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 36. Contains residues. In some embodiments, the HVR1 region includes Y, R, K, or D at the residue corresponding to residue 66 of SEQ ID NO: 36. In some embodiments, the HVR1 region comprises residues 24-79 of SEQ ID NO: 36 with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 amino acid substitutions. . In some embodiments, the HVR1 region comprises residues 24-79 of SEQ ID NO:36.
[0379] In some embodiments, the first subunit comprises residues 7-153 of SEQ ID NO: 36 and at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the first subunit includes a G, S or A at the residue corresponding to residue 19 of SEQ ID NO: 36. In some embodiments, the first subunit includes a residue corresponding to residue 19 of SEQ ID NO:36. In some embodiments, the first subunit includes E, Q, or K at the residue corresponding to residue 80 of SEQ ID NO:36. In some embodiments, the first subunit is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, Includes residues 7-153 of SEQ ID NO: 36 with up to 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acid substitutions. In some embodiments, the first subunit comprises residues 7-153 of SEQ ID NO:36.
[0380] In some embodiments, the HVR2 region comprises at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% of the amino acid sequence corresponding to residues 215-270 of SEQ ID NO: 36. , 96%, 97%, 98%, 99% or higher sequence identity. In some embodiments, the HVR2 region corresponds to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of SEQ ID NO: 36. Contains one or more residues. In some embodiments, the HVR2 region corresponds to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of SEQ ID NO: 36. Contains residues. In some embodiments, the HVR2 region includes Y, R, K, or D at the residue corresponding to residue 257 of SEQ ID NO: 36. In some embodiments, the HVR2 region includes a residue corresponding to residue 241 of SEQ ID NO:36. In some embodiments, the HVR2 region includes a residue corresponding to residue 263 of SEQ ID NO:36. In some embodiments, the HVR2 region includes a residue corresponding to residue 264 of SEQ ID NO:36. In some embodiments, the HVR2 region comprises residues 215-270 of SEQ ID NO: 36 with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 amino acid substitutions. . In some embodiments, the HVR2 region comprises residues 215-270 of SEQ ID NO:36.
[0381] In some embodiments, the second subunit comprises residues 198-344 of SEQ ID NO: 36 and at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the second subunit includes a G, S or A at the residue corresponding to residue 210 of SEQ ID NO:36. In some embodiments, the second subunit includes an E, Q, or K at the residue corresponding to residue 271 of SEQ ID NO: 36. In some embodiments, the second subunit includes a residue corresponding to residue 271 of SEQ ID NO:36. In some embodiments, the second subunit includes a residue corresponding to residue 330 of SEQ ID NO:36. In some embodiments, the second subunit is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, Includes residues 198-344 of SEQ ID NO: 36 with up to 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acid substitutions. In some embodiments, the second subunit comprises residues 198-344 of SEQ ID NO:36.
[0382] In some embodiments, the genetically engineered meganuclease is a single chain meganuclease that includes a linker, where the linker covalently joins the first subunit and the second subunit. In some embodiments, the genetically engineered meganuclease is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, Contains amino acid sequences having 98%, 99% or higher sequence identity. In some embodiments, the genetically engineered meganuclease comprises the amino acid sequence of SEQ ID NO: 36. In some embodiments, the genetically engineered meganuclease has at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 with the nucleic acid sequence set forth in SEQ ID NO: 50. %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the genetically engineered meganuclease is encoded by the nucleic acid sequence set forth in SEQ ID NO:50.
[0383] DMD 19-20x.87 (Sequence number 37)
[0384] In some embodiments, the HVR1 region comprises at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% of the amino acid sequence corresponding to residues 24-79 of SEQ ID NO: 37. , 96%, 97%, 98%, 99% or higher sequence identity. In some embodiments, the HVR1 region corresponds to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 37. Contains one or more residues. In some embodiments, the HVR1 region corresponds to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 37. Contains residues. In some embodiments, the HVR1 region includes a Y, R, K, or D at the residue corresponding to residue 66 of SEQ ID NO:37. In some embodiments, the HVR1 region comprises residues 24-79 of SEQ ID NO: 37 with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 amino acid substitutions. . In some embodiments, the HVR1 region comprises residues 24-79 of SEQ ID NO:37.
[0385] In some embodiments, the first subunit comprises residues 7-153 of SEQ ID NO: 37 and at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the first subunit includes a G, S or A at the residue corresponding to residue 19 of SEQ ID NO: 37. In some embodiments, the first subunit includes a residue corresponding to residue 19 of SEQ ID NO: 37. In some embodiments, the first subunit includes E, Q, or K at the residue corresponding to residue 80 of SEQ ID NO: 37. In some embodiments, the first subunit is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, Includes residues 7-153 of SEQ ID NO: 37 with up to 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acid substitutions. In some embodiments, the first subunit comprises residues 7-153 of SEQ ID NO:37.
[0386] In some embodiments, the HVR2 region comprises at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% of the amino acid sequence corresponding to residues 215-270 of SEQ ID NO: 37. , 96%, 97%, 98%, 99% or higher sequence identity. In some embodiments, the HVR2 region corresponds to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of SEQ ID NO: 37. Contains one or more residues. In some embodiments, the HVR2 region corresponds to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of SEQ ID NO: 37. Contains residues. In some embodiments, the HVR2 region includes Y, R, K, or D at the residue corresponding to residue 257 of SEQ ID NO: 37. In some embodiments, the HVR2 region includes a residue corresponding to residue 239 of SEQ ID NO:37. In some embodiments, the HVR2 region includes a residue corresponding to residue 241 of SEQ ID NO:37. In some embodiments, the HVR2 region includes a residue corresponding to residue 264 of SEQ ID NO: 37. In some embodiments, the HVR2 region comprises residues 215-270 of SEQ ID NO: 37 with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 amino acid substitutions. . In some embodiments, the HVR2 region comprises residues 215-270 of SEQ ID NO:37.
[0387] In some embodiments, the second subunit comprises residues 198-344 of SEQ ID NO: 37 and at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the second subunit includes a G, S or A at the residue corresponding to residue 210 of SEQ ID NO:37. In some embodiments, the second subunit includes E, Q, or K at the residue corresponding to residue 271 of SEQ ID NO: 37. In some embodiments, the second subunit includes a residue corresponding to residue 330 of SEQ ID NO:37. In some embodiments, the second subunit is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, Includes residues 198-344 of SEQ ID NO: 37 with up to 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acid substitutions. In some embodiments, the second subunit comprises residues 198-344 of SEQ ID NO:37.
[0388] In some embodiments, the genetically engineered meganuclease is a single chain meganuclease that includes a linker, where the linker covalently joins the first subunit and the second subunit. In some embodiments, the genetically engineered meganuclease is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, Contains amino acid sequences having 98%, 99% or higher sequence identity. In some embodiments, the genetically engineered meganuclease comprises the amino acid sequence of SEQ ID NO: 37. In some embodiments, the genetically engineered meganuclease has at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 with the nuclear sequence set forth in SEQ ID NO: 51. %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the genetically engineered meganuclease is encoded by the nucleic acid sequence set forth in SEQ ID NO:51.
[0389] DMD 19-20L.249 (Sequence number 38)
[0390] In some embodiments, the HVR1 region comprises at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% of the amino acid sequence corresponding to residues 24-79 of SEQ ID NO: 38. , 96%, 97%, 98%, 99% or higher sequence identity. In some embodiments, the HVR1 region corresponds to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 38. Contains one or more residues. In some embodiments, the HVR1 region corresponds to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 38. Contains residues. In some embodiments, the HVR1 region includes Y, R, K, or D at the residue corresponding to residue 66 of SEQ ID NO: 38. In some embodiments, the HVR1 region comprises residues 24-79 of SEQ ID NO: 38 with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 amino acid substitutions. . In some embodiments, the HVR1 region comprises residues 24-79 of SEQ ID NO:38.
[0391] In some embodiments, the first subunit comprises residues 7-153 of SEQ ID NO: 38 and at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the first subunit includes a G, S or A at the residue corresponding to residue 19 of SEQ ID NO: 38. In some embodiments, the first subunit includes a residue corresponding to residue 19 of SEQ ID NO: 38. In some embodiments, the first subunit includes E, Q, or K at residue corresponding to residue 80 of SEQ ID NO: 38. In some embodiments, the first subunit includes a residue corresponding to residue 80 of SEQ ID NO:38. In some embodiments, the first subunit is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, Includes residues 7-153 of SEQ ID NO: 38 with up to 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acid substitutions. In some embodiments, the first subunit comprises residues 7-153 of SEQ ID NO: 38.
[0392] In some embodiments, the HVR2 region comprises at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% of the amino acid sequence corresponding to residues 215-270 of SEQ ID NO: 38. , 96%, 97%, 98%, 99% or higher sequence identity. In some embodiments, the HVR2 region corresponds to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of SEQ ID NO: 38. Contains one or more residues. In some embodiments, the HVR2 region corresponds to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of SEQ ID NO: 38. Contains residues. In some embodiments, the HVR2 region includes Y, R, K, or D at residue corresponding to residue 257 of SEQ ID NO: 38. In some embodiments, the HVR2 region includes a residue corresponding to residue 264 of SEQ ID NO: 38. In some embodiments, the HVR2 region comprises residues 215-270 of SEQ ID NO: 38 with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 amino acid substitutions. . In some embodiments, the HVR2 region comprises residues 215-270 of SEQ ID NO:38.
[0393] In some embodiments, the second subunit comprises residues 198-344 of SEQ ID NO: 38 and at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the second subunit includes a G, S or A at the residue corresponding to residue 210 of SEQ ID NO: 38. In some embodiments, the second subunit includes E, Q, or K at the residue corresponding to residue 271 of SEQ ID NO: 38. In some embodiments, the second subunit includes a residue corresponding to residue 330 of SEQ ID NO: 38. In some embodiments, the second subunit is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, Includes residues 198-344 of SEQ ID NO: 38 with up to 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acid substitutions. In some embodiments, the second subunit comprises residues 198-344 of SEQ ID NO:38.
[0394] In some embodiments, the genetically engineered meganuclease is a single chain meganuclease that includes a linker, where the linker covalently joins the first subunit and the second subunit. In some embodiments, the genetically engineered meganuclease is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, Contains amino acid sequences having 98%, 99% or higher sequence identity. In some embodiments, the genetically engineered meganuclease comprises the amino acid sequence of SEQ ID NO: 38. In some embodiments, the genetically engineered meganuclease has at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 with the nucleic acid sequence set forth in SEQ ID NO: 52. %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the genetically engineered meganuclease is encoded by the nucleic acid sequence set forth in SEQ ID NO: 52.
[0395] DMD 19-20L.302 (Sequence number 39)
[0396] In some embodiments, the HVR1 region comprises at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% of the amino acid sequence corresponding to residues 24-79 of SEQ ID NO: 39. , 96%, 97%, 98%, 99% or higher sequence identity. In some embodiments, the HVR1 region corresponds to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 39. Contains one or more residues. In some embodiments, the HVR1 region corresponds to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 39. Contains residues. In some embodiments, the HVR1 region includes a Y, R, K, or D at the residue corresponding to residue 66 of SEQ ID NO: 39. In some embodiments, the HVR1 region comprises residues 24-79 of SEQ ID NO: 39 with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 amino acid substitutions. . In some embodiments, the HVR1 region comprises residues 24-79 of SEQ ID NO:39.
[0397] In some embodiments, the first subunit comprises residues 7-153 of SEQ ID NO: 39 and at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the first subunit includes a G, S or A at the residue corresponding to residue 19 of SEQ ID NO: 39. In some embodiments, the first subunit includes a residue corresponding to residue 19 of SEQ ID NO: 39. In some embodiments, the first subunit includes E, Q, or K at the residue corresponding to residue 80 of SEQ ID NO: 39. In some embodiments, the first subunit includes a residue corresponding to residue 80 of SEQ ID NO: 39. In some embodiments, the first subunit is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, Includes residues 7-153 of SEQ ID NO: 39 with up to 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acid substitutions. In some embodiments, the first subunit comprises residues 7-153 of SEQ ID NO:39.
[0398] In some embodiments, the HVR2 region comprises at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% of the amino acid sequence corresponding to residues 215-270 of SEQ ID NO: 39. , 96%, 97%, 98%, 99% or higher sequence identity. In some embodiments, the HVR2 region corresponds to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of SEQ ID NO: 39. Contains one or more residues. In some embodiments, the HVR2 region corresponds to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of SEQ ID NO: 39. Contains residues. In some embodiments, the HVR2 region includes Y, R, K, or D at the residue corresponding to residue 257 of SEQ ID NO: 39. In some embodiments, the HVR2 region includes a residue corresponding to residue 236 of SEQ ID NO: 39. In some embodiments, the HVR2 region includes a residue corresponding to residue 264 of SEQ ID NO: 39. In some embodiments, the HVR2 region comprises residues 215-270 of SEQ ID NO: 39 with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 amino acid substitutions. . In some embodiments, the HVR2 region comprises residues 215-270 of SEQ ID NO: 39.
[0399] In some embodiments, the second subunit comprises residues 198-344 of SEQ ID NO: 39 and at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the second subunit includes a G, S or A at the residue corresponding to residue 210 of SEQ ID NO: 39. In some embodiments, the second subunit includes an E, Q, or K at the residue corresponding to residue 271 of SEQ ID NO: 39. In some embodiments, the second subunit includes a residue corresponding to residue 271 of SEQ ID NO: 39. In some embodiments, the second subunit is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, Includes residues 198-344 of SEQ ID NO: 39 with up to 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acid substitutions. In some embodiments, the second subunit comprises residues 198-344 of SEQ ID NO: 39.
[0400] In some embodiments, the genetically engineered meganuclease is a single chain meganuclease that includes a linker, where the linker covalently joins the first subunit and the second subunit. In some embodiments, the engineered meganuclease is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, Contains amino acid sequences having 98%, 99% or higher sequence identity. In some embodiments, the genetically engineered meganuclease comprises the amino acid sequence of SEQ ID NO: 39. In some embodiments, the genetically engineered meganuclease has at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 with the nuclear sequence set forth in SEQ ID NO: 53. %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the genetically engineered meganuclease is encoded by the nucleic acid sequence set forth in SEQ ID NO: 53.
[0401] DMD 19-20L.329 (Sequence number 40)
[0402] In some embodiments, the HVR1 region comprises at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% of the amino acid sequence corresponding to residues 24-79 of SEQ ID NO: 40. , 96%, 97%, 98%, 99% or higher sequence identity. In some embodiments, the HVR1 region corresponds to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 40. Contains one or more residues. In some embodiments, the HVR1 region corresponds to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 40. Contains residues. In some embodiments, the HVR1 region includes a Y, R, K, or D at the residue corresponding to residue 66 of SEQ ID NO:40. In some embodiments, the HVR1 region comprises residues 24-79 of SEQ ID NO: 40 with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 amino acid substitutions. . In some embodiments, the HVR1 region comprises residues 24-79 of SEQ ID NO:40.
[0403] In some embodiments, the first subunit comprises residues 7-153 of SEQ ID NO: 40 and at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the first subunit includes a G, S or A at the residue corresponding to residue 19 of SEQ ID NO:40. In some embodiments, the first subunit includes a residue corresponding to residue 19 of SEQ ID NO:40. In some embodiments, the first subunit includes E, Q, or K at the residue corresponding to residue 80 of SEQ ID NO:40. In some embodiments, the first subunit is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, Includes residues 7-153 of SEQ ID NO: 40 with up to 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acid substitutions. In some embodiments, the first subunit comprises residues 7-153 of SEQ ID NO:40.
[0404] In some embodiments, the HVR2 region comprises at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% of the amino acid sequence corresponding to residues 215-270 of SEQ ID NO: 40. , 96%, 97%, 98%, 99% or higher sequence identity. In some embodiments, the HVR2 region corresponds to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of SEQ ID NO: 40. Contains one or more residues. In some embodiments, the HVR2 region corresponds to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of SEQ ID NO: 40. Contains residues. In some embodiments, the HVR2 region includes Y, R, K, or D at the residue corresponding to residue 257 of SEQ ID NO: 40. In some embodiments, the HVR2 region includes a residue corresponding to residue 264 of SEQ ID NO:40. In some embodiments, the HVR2 region comprises residues 215-270 of SEQ ID NO: 40 with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 amino acid substitutions. . In some embodiments, the HVR2 region comprises residues 215-270 of SEQ ID NO:40.
[0405] In some embodiments, the second subunit comprises residues 198-344 of SEQ ID NO: 40 and at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the second subunit includes a G, S or A at the residue corresponding to residue 210 of SEQ ID NO:40. In some embodiments, the second subunit includes an E, Q, or K at the residue corresponding to residue 271 of SEQ ID NO:40. In some embodiments, the second subunit includes a residue corresponding to residue 271 of SEQ ID NO:40. In some embodiments, the second subunit includes a residue corresponding to residue 330 of SEQ ID NO:40. In some embodiments, the second subunit is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, Includes residues 198-344 of SEQ ID NO: 40 with up to 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acid substitutions. In some embodiments, the second subunit comprises residues 198-344 of SEQ ID NO:40.
[0406] In some embodiments, the genetically engineered meganuclease is a single chain meganuclease that includes a linker, where the linker covalently joins the first subunit and the second subunit. In some embodiments, the genetically engineered meganuclease is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, Contains amino acid sequences having 98%, 99% or higher sequence identity. In some embodiments, the genetically engineered meganuclease comprises the amino acid sequence of SEQ ID NO:40. In some embodiments, the genetically engineered meganuclease has at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 with the nucleic acid sequence set forth in SEQ ID NO: 54. %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the genetically engineered meganuclease is encoded by the nucleic acid sequence set forth in SEQ ID NO:54.
[0407] DMD 19-20L.374 (Sequence number 41)
[0408] In some embodiments, the HVR1 region comprises at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% of the amino acid sequence corresponding to residues 24-79 of SEQ ID NO: 41. , 96%, 97%, 98%, 99% or higher sequence identity. In some embodiments, the HVR1 region corresponds to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 41. Contains one or more residues. In some embodiments, the HVR1 region corresponds to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 41. Contains residues. In some embodiments, the HVR1 region includes a Y, R, K, or D at the residue corresponding to residue 66 of SEQ ID NO:40. In some embodiments, the HVR1 region comprises residues 24-79 of SEQ ID NO: 41 with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 amino acid substitutions. . In some embodiments, the HVR1 region comprises residues 24-79 of SEQ ID NO:41.
[0409] In some embodiments, the first subunit comprises residues 7-153 of SEQ ID NO: 41 and at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the first subunit includes a G, S or A at the residue corresponding to residue 19 of SEQ ID NO:41. In some embodiments, the first subunit includes a residue corresponding to residue 19 of SEQ ID NO: 41. In some embodiments, the first subunit includes E, Q, or K at the residue corresponding to residue 80 of SEQ ID NO:41. In some embodiments, the first subunit is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, Includes residues 7-153 of SEQ ID NO: 41 with up to 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acid substitutions. In some embodiments, the first subunit comprises residues 7-153 of SEQ ID NO:41.
[0410] In some embodiments, the HVR2 region comprises at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% of the amino acid sequence corresponding to residues 215-270 of SEQ ID NO: 41. , 96%, 97%, 98%, 99% or higher sequence identity. In some embodiments, the HVR2 region corresponds to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of SEQ ID NO: 41. Contains one or more residues. In some embodiments, the HVR2 region corresponds to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of SEQ ID NO: 41. Contains residues. In some embodiments, the HVR2 region includes Y, R, K, or D at the residue corresponding to residue 257 of SEQ ID NO: 41. In some embodiments, the HVR2 region includes a residue corresponding to residue 264 of SEQ ID NO:41. In some embodiments, the HVR2 region comprises residues 215-270 of SEQ ID NO: 41 with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 amino acid substitutions. . In some embodiments, the HVR2 region comprises residues 215-270 of SEQ ID NO:41.
[0411] In some embodiments, the second subunit comprises residues 198-344 of SEQ ID NO: 41 and at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the second subunit includes a G, S or A at the residue corresponding to residue 210 of SEQ ID NO: 41. In some embodiments, the second subunit includes an E, Q, or K at the residue corresponding to residue 271 of SEQ ID NO: 41. In some embodiments, the second subunit includes a residue corresponding to residue 330 of SEQ ID NO:41. In some embodiments, the second subunit is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, Includes residues 198-344 of SEQ ID NO: 41 with up to 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acid substitutions. In some embodiments, the second subunit comprises residues 198-344 of SEQ ID NO:41.
[0412] In some embodiments, the genetically engineered meganuclease is a single chain meganuclease that includes a linker, where the linker covalently joins the first subunit and the second subunit. In some embodiments, the engineered meganuclease is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, Contains amino acid sequences having 98%, 99% or higher sequence identity. In some embodiments, the genetically engineered meganuclease comprises the amino acid sequence of SEQ ID NO:41. In some embodiments, the genetically engineered meganuclease has at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 with the nucleic acid sequence set forth in SEQ ID NO: 65. %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the genetically engineered meganuclease is encoded by the nucleic acid sequence set forth in SEQ ID NO: 65.
[0413] DMD 19-20L.375 (Sequence number 42)
[0414] In some embodiments, the HVR1 region comprises at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% of the amino acid sequence corresponding to residues 24-79 of SEQ ID NO: 42. , 96%, 97%, 98%, 99% or higher sequence identity. In some embodiments, the HVR1 region corresponds to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 42. Contains one or more residues. In some embodiments, the HVR1 region corresponds to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 42. Contains residues. In some embodiments, the HVR1 region includes Y, R, K, or D at the residue corresponding to residue 66 of SEQ ID NO: 42. In some embodiments, the HVR1 region comprises residues 24-79 of SEQ ID NO: 42 with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 amino acid substitutions. . In some embodiments, the HVR1 region comprises residues 24-79 of SEQ ID NO:42.
[0415] In some embodiments, the first subunit comprises residues 7-153 of SEQ ID NO: 42 and at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the first subunit includes a G, S or A at the residue corresponding to residue 19 of SEQ ID NO: 42. In some embodiments, the first subunit includes a residue corresponding to residue 19 of SEQ ID NO: 42. In some embodiments, the first subunit includes E, Q, or K at the residue corresponding to residue 80 of SEQ ID NO: 42. In some embodiments, the first subunit is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, Includes residues 7-153 of SEQ ID NO: 42 with up to 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acid substitutions. In some embodiments, the first subunit comprises residues 7-153 of SEQ ID NO: 42.
[0416] In some embodiments, the HVR2 region comprises at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% of the amino acid sequence corresponding to residues 215-270 of SEQ ID NO: 42. , 96%, 97%, 98%, 99% or higher sequence identity. In some embodiments, the HVR2 region corresponds to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of SEQ ID NO: 42. Contains one or more residues. In some embodiments, the HVR2 region corresponds to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of SEQ ID NO: 42. Contains residues. In some embodiments, the HVR2 region includes Y, R, K, or D at the residue corresponding to residue 257 of SEQ ID NO: 42. In some embodiments, the HVR2 region includes a residue corresponding to residue 264 of SEQ ID NO: 42. In some embodiments, the HVR2 region comprises residues 215-270 of SEQ ID NO: 42 with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 amino acid substitutions. . In some embodiments, the HVR2 region comprises residues 215-270 of SEQ ID NO: 42.
[0417] In some embodiments, the second subunit comprises residues 198-344 of SEQ ID NO: 42 and at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the second subunit includes a G, S, or A at the residue corresponding to residue 210 of SEQ ID NO: 42. In some embodiments, the second subunit includes an E, Q, or K at the residue corresponding to residue 271 of SEQ ID NO: 42. In some embodiments, the second subunit includes a residue corresponding to residue 330 of SEQ ID NO: 42. In some embodiments, the second subunit is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, Includes residues 198-344 of SEQ ID NO: 42 with up to 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acid substitutions. In some embodiments, the second subunit comprises residues 198-344 of SEQ ID NO: 42. In some embodiments, the genetically engineered meganuclease is a single chain meganuclease that includes a linker, where the linker covalently joins the first subunit and the second subunit. In some embodiments, the engineered meganuclease is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, Contains amino acid sequences having 98%, 99% or higher sequence identity. In some embodiments, the genetically engineered meganuclease comprises the amino acid sequence of SEQ ID NO: 42. In some embodiments, the genetically engineered meganuclease is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 with the nucleic acid sequence set forth in SEQ ID NO: 66. %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the genetically engineered meganuclease is encoded by the nucleic acid sequence set forth in SEQ ID NO: 66.
[0418] DMD 19-20L.431 (Sequence number 43)
[0419] In some embodiments, the HVR1 region comprises at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% of the amino acid sequence corresponding to residues 24-79 of SEQ ID NO: 43. , 96%, 97%, 98%, 99% or higher sequence identity. In some embodiments, the HVR1 region corresponds to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 43. Contains one or more residues. In some embodiments, the HVR1 region corresponds to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 43. Contains residues. In some embodiments, the HVR1 region includes a Y, R, K, or D at the residue corresponding to residue 66 of SEQ ID NO: 43. In some embodiments, the HVR1 region comprises residues 24-79 of SEQ ID NO: 43 with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 amino acid substitutions. . In some embodiments, the HVR1 region comprises residues 24-79 of SEQ ID NO:43.
[0420] In some embodiments, the first subunit comprises residues 7-153 of SEQ ID NO: 43 and at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the first subunit includes a G, S or A at the residue corresponding to residue 19 of SEQ ID NO: 43. In some embodiments, the first subunit includes a residue corresponding to residue 19 of SEQ ID NO: 43. In some embodiments, the first subunit includes E, Q, or K at the residue corresponding to residue 80 of SEQ ID NO: 43. In some embodiments, the first subunit includes a residue corresponding to residue 80 of SEQ ID NO: 43. In some embodiments, the first subunit is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, Includes residues 7-153 of SEQ ID NO: 43 with up to 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acid substitutions. In some embodiments, the first subunit comprises residues 7-153 of SEQ ID NO: 43.
[0421] In some embodiments, the HVR2 region comprises at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% of the amino acid sequence corresponding to residues 215-270 of SEQ ID NO: 43. , 96%, 97%, 98%, 99% or higher sequence identity. In some embodiments, the HVR2 region corresponds to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of SEQ ID NO: 43. Contains one or more residues. In some embodiments, the HVR2 region corresponds to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of SEQ ID NO: 43. Contains residues. In some embodiments, the HVR2 region includes Y, R, K, or D at the residue corresponding to residue 257 of SEQ ID NO: 43. In some embodiments, the HVR2 region includes a residue corresponding to residue 264 of SEQ ID NO: 43. In some embodiments, the HVR2 region comprises residues 215-270 of SEQ ID NO: 43 with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 amino acid substitutions. . In some embodiments, the HVR2 region comprises residues 215-270 of SEQ ID NO: 43.
[0422] In some embodiments, the second subunit comprises residues 198-344 of SEQ ID NO: 43 and at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the second subunit includes a G, S or A at the residue corresponding to residue 210 of SEQ ID NO: 43. In some embodiments, the second subunit includes an E, Q, or K at the residue corresponding to residue 271 of SEQ ID NO: 43. In some embodiments, the second subunit includes a residue corresponding to residue 271 of SEQ ID NO: 43. In some embodiments, the second subunit includes a residue corresponding to residue 330 of SEQ ID NO: 43. In some embodiments, the second subunit is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, Includes residues 198-344 of SEQ ID NO: 43 with up to 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acid substitutions. In some embodiments, the second subunit comprises residues 198-344 of SEQ ID NO: 43.
[0423] In some embodiments, the genetically engineered meganuclease is a single chain meganuclease that includes a linker, where the linker covalently joins the first subunit and the second subunit. In some embodiments, the engineered meganuclease is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, Contains amino acid sequences having 98%, 99% or higher sequence identity. In some embodiments, the genetically engineered meganuclease comprises the amino acid sequence of SEQ ID NO: 43. In some embodiments, the engineered meganuclease has at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the genetically engineered meganuclease is encoded by the nucleic acid sequence set forth in SEQ ID NO: 67.
[0424] DMD 19-20L.458 (Sequence number 44)
[0425] In some embodiments, the HVR1 region comprises at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% of the amino acid sequence corresponding to residues 24-79 of SEQ ID NO: 44. , 96%, 97%, 98%, 99% or higher sequence identity. In some embodiments, the HVR1 region corresponds to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 44. Contains one or more residues. In some embodiments, the HVR1 region corresponds to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 44. Contains residues. In some embodiments, the HVR1 region includes Y, R, K, or D at the residue corresponding to residue 66 of SEQ ID NO: 44. In some embodiments, the HVR1 region comprises residues 24-79 of SEQ ID NO: 44 with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 amino acid substitutions. . In some embodiments, the HVR1 region comprises residues 24-79 of SEQ ID NO:44.
[0426] In some embodiments, the first subunit comprises residues 7-153 of SEQ ID NO: 44 and at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the first subunit includes a G, S or A at the residue corresponding to residue 19 of SEQ ID NO: 44. In some embodiments, the first subunit includes a residue corresponding to residue 19 of SEQ ID NO: 44. In some embodiments, the first subunit includes E, Q, or K at the residue corresponding to residue 80 of SEQ ID NO: 44. In some embodiments, the first subunit is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, Includes residues 7-153 of SEQ ID NO: 44 with up to 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acid substitutions. In some embodiments, the first subunit comprises residues 7-153 of SEQ ID NO:44.
[0427] In some embodiments, the HVR2 region comprises at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% of the amino acid sequence corresponding to residues 215-270 of SEQ ID NO: 44. , 96%, 97%, 98%, 99% or higher sequence identity. In some embodiments, the HVR2 region corresponds to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of SEQ ID NO: 44. Contains one or more residues. In some embodiments, the HVR2 region corresponds to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of SEQ ID NO: 44. Contains residues. In some embodiments, the HVR2 region includes Y, R, K, or D at the residue corresponding to residue 257 of SEQ ID NO: 44. In some embodiments, the HVR2 region includes a residue corresponding to residue 264 of SEQ ID NO: 44. In some embodiments, the HVR2 region comprises residues 215-270 of SEQ ID NO: 44 with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 amino acid substitutions. . In some embodiments, the HVR2 region comprises residues 215-270 of SEQ ID NO:44.
[0428] In some embodiments, the second subunit comprises residues 198-344 of SEQ ID NO: 44 and at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the second subunit includes a G, S or A at the residue corresponding to residue 210 of SEQ ID NO: 44. In some embodiments, the second subunit includes an E, Q, or K at the residue corresponding to residue 271 of SEQ ID NO: 44. In some embodiments, the second subunit includes a residue corresponding to residue 271 of SEQ ID NO: 44. In some embodiments, the second subunit includes a residue corresponding to residue 330 of SEQ ID NO: 44. In some embodiments, the second subunit is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, Includes residues 198-344 of SEQ ID NO: 44 with up to 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acid substitutions. In some embodiments, the second subunit comprises residues 198-344 of SEQ ID NO: 44.
[0429] In some embodiments, the genetically engineered meganuclease is a single chain meganuclease that includes a linker, where the linker covalently joins the first subunit and the second subunit. In some embodiments, the engineered meganuclease is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, Contains amino acid sequences having 98%, 99% or higher sequence identity. In some embodiments, the genetically engineered meganuclease comprises the amino acid sequence of SEQ ID NO: 44. In some embodiments, the genetically engineered meganuclease has at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 with the nucleic acid sequence set forth in SEQ ID NO: 68. %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the genetically engineered meganuclease is encoded by the nucleic acid sequence set forth in SEQ ID NO: 68.
[0430] In certain embodiments of the invention, the genetically engineered meganuclease binds to and cleaves a recognition sequence comprising SEQ ID NO: 10 within the dystrophin gene (i.e., the DMD 35-36 recognition sequence), and the genetically engineered meganuclease The nuclease includes a first subunit and a second subunit, the first subunit binds to a first recognition half site of a recognition sequence and includes a first hypervariable (HVR1) region; Two subunits bind to the second recognition half site of the recognition sequence and include the second hypervariable (HVR2) region. An exemplary DMD 35-36 meganuclease is described below.
[0431] DMD 35-36x.63 (Sequence number 45)
[0432] In some embodiments, the HVR1 region comprises at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% of the amino acid sequence corresponding to residues 24-79 of SEQ ID NO: 45. , 96%, 97%, 98%, 99% or higher sequence identity. In some embodiments, the HVR1 region corresponds to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 45. Contains one or more residues. In some embodiments, the HVR1 region corresponds to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 45. Contains residues. In some embodiments, the HVR1 region includes a Y, R, K, or D at the residue corresponding to residue 66 of SEQ ID NO: 45. In some embodiments, the HVR1 region comprises residues 24-79 of SEQ ID NO: 45 with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 amino acid substitutions. . In some embodiments, the HVR1 region comprises residues 24-79 of SEQ ID NO:45.
[0433] In some embodiments, the first subunit comprises residues 7-153 of SEQ ID NO: 45 and at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the first subunit includes a G, S or A at the residue corresponding to residue 19 of SEQ ID NO: 45. In some embodiments, the first subunit includes a residue corresponding to residue 19 of SEQ ID NO: 45. In some embodiments, the first subunit includes E, Q, or K at residue corresponding to residue 80 of SEQ ID NO: 45. In some embodiments, the first subunit includes a residue corresponding to residue 80 of SEQ ID NO: 45. In some embodiments, the first subunit is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, Includes residues 7-153 of SEQ ID NO: 45 with up to 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acid substitutions. In some embodiments, the first subunit comprises residues 7-153 of SEQ ID NO:45.
[0434] In some embodiments, the HVR2 region comprises at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% of the amino acid sequence corresponding to residues 215-270 of SEQ ID NO: 45. , 96%, 97%, 98%, 99% or higher sequence identity. In some embodiments, the HVR2 region corresponds to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of SEQ ID NO: 45. Contains one or more residues. In some embodiments, the HVR2 region corresponds to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of SEQ ID NO: 45. Contains residues. In some embodiments, the HVR2 region includes Y, R, K, or D at the residue corresponding to residue 257 of SEQ ID NO: 45. In some embodiments, the HVR2 region includes a residue corresponding to residue 239 of SEQ ID NO: 45. In some embodiments, the HVR2 region includes a residue corresponding to residue 241 of SEQ ID NO: 45. In some embodiments, the HVR2 region includes residues corresponding to residue 250 of SEQ ID NO:45. In some embodiments, the HVR2 region includes a residue corresponding to residue 263 of SEQ ID NO:45. In some embodiments, the HVR2 region includes a residue corresponding to residue 264 of SEQ ID NO: 45. In some embodiments, the HVR2 region comprises residues 215-270 of SEQ ID NO: 45 with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 amino acid substitutions. . In some embodiments, the HVR2 region comprises residues 215-270 of SEQ ID NO: 45. In some embodiments, the second subunit comprises residues 198-344 of SEQ ID NO: 45 and at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the second subunit includes a G, S or A at the residue corresponding to residue 210 of SEQ ID NO: 45. In some embodiments, the second subunit includes an E, Q, or K at the residue corresponding to residue 271 of SEQ ID NO: 45. In some embodiments, the second subunit includes a residue corresponding to residue 330 of SEQ ID NO: 45. In some embodiments, the second subunit is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, Includes residues 198-344 of SEQ ID NO: 45 with up to 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acid substitutions. In some embodiments, the second subunit comprises residues 198-344 of SEQ ID NO: 45.
[0435] In some embodiments, the genetically engineered meganuclease is a single chain meganuclease that includes a linker, where the linker covalently joins the first subunit and the second subunit. In some embodiments, the genetically engineered meganuclease is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, Contains amino acid sequences having 98%, 99% or higher sequence identity. In some embodiments, the genetically engineered meganuclease comprises the amino acid sequence of SEQ ID NO: 45. In some embodiments, the genetically engineered meganuclease has at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 with the nucleic acid sequence set forth in SEQ ID NO: 69. %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the genetically engineered meganuclease is encoded by the nucleic acid sequence set forth in SEQ ID NO: 69.
[0436] DMD 35-36x.81 (Sequence number 46)
[0437] In some embodiments, the HVR1 region comprises at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% of the amino acid sequence corresponding to residues 24-79 of SEQ ID NO: 46. , 96%, 97%, 98%, 99% or higher sequence identity. In some embodiments, the HVR1 region corresponds to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 46. Contains one or more residues. In some embodiments, the HVR1 region corresponds to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 46. Contains residues. In some embodiments, the HVR1 region includes Y, R, K, or D at the residue corresponding to residue 66 of SEQ ID NO: 46. In some embodiments, the HVR1 region comprises residues 24-79 of SEQ ID NO: 46 with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 amino acid substitutions. . In some embodiments, the HVR1 region comprises residues 24-79 of SEQ ID NO:46.
[0438] In some embodiments, the first subunit comprises residues 7-153 of SEQ ID NO: 46 and at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the first subunit includes a G, S or A at the residue corresponding to residue 19 of SEQ ID NO: 46. In some embodiments, the first subunit includes a residue corresponding to residue 19 of SEQ ID NO: 46. In some embodiments, the first subunit includes E, Q, or K at the residue corresponding to residue 80 of SEQ ID NO: 46. In some embodiments, the first subunit includes a residue corresponding to residue 80 of SEQ ID NO: 46. In some embodiments, the first subunit is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, Includes residues 7-153 of SEQ ID NO: 46 with up to 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acid substitutions. In some embodiments, the first subunit comprises residues 7-153 of SEQ ID NO:46.
[0439] In some embodiments, the HVR2 region comprises at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% of the amino acid sequence corresponding to residues 215-270 of SEQ ID NO: 46. , 96%, 97%, 98%, 99% or higher sequence identity. In some embodiments, the HVR2 region corresponds to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of SEQ ID NO: 46. Contains one or more residues. In some embodiments, the HVR2 region corresponds to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of SEQ ID NO: 46. Contains residues. In some embodiments, the HVR2 region includes Y, R, K, or D at the residue corresponding to residue 257 of SEQ ID NO: 46. In some embodiments, the HVR2 region includes a residue corresponding to residue 239 of SEQ ID NO: 46. In some embodiments, the HVR2 region includes a residue corresponding to residue 241 of SEQ ID NO: 46. In some embodiments, the HVR2 region includes a residue corresponding to residue 263 of SEQ ID NO: 46. In some embodiments, the HVR2 region includes a residue corresponding to residue 264 of SEQ ID NO: 46. In some embodiments, the HVR2 region comprises residues 215-270 of SEQ ID NO: 46 with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 amino acid substitutions. . In some embodiments, the HVR2 region comprises residues 215-270 of SEQ ID NO: 46.
[0440] In some embodiments, the second subunit comprises residues 198-344 of SEQ ID NO: 46 and at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the second subunit includes a G, S or A at the residue corresponding to residue 210 of SEQ ID NO: 46. In some embodiments, the second subunit includes an E, Q, or K at the residue corresponding to residue 271 of SEQ ID NO: 46. In some embodiments, the second subunit includes a residue corresponding to residue 330 of SEQ ID NO: 46. In some embodiments, the second subunit is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, Includes residues 198-344 of SEQ ID NO: 46 with up to 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acid substitutions. In some embodiments, the second subunit comprises residues 198-344 of SEQ ID NO: 46.
[0441] In some embodiments, the genetically engineered meganuclease is a single chain meganuclease that includes a linker, where the linker covalently joins the first subunit and the second subunit. In some embodiments, the engineered meganuclease is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, Contains amino acid sequences having 98%, 99% or higher sequence identity. In some embodiments, the genetically engineered meganuclease comprises the amino acid sequence of SEQ ID NO: 46. In some embodiments, the genetically engineered meganuclease has at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 with the nucleic acid sequence set forth in SEQ ID NO: 70. %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the engineered meganuclease is encoded by the nucleic acid sequence set forth in SEQ ID NO:70.
[0442] DMD 35-36L.195 (Sequence number 47)
[0443] In some embodiments, the HVR1 region comprises at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% of the amino acid sequence corresponding to residues 24-79 of SEQ ID NO: 47. , 96%, 97%, 98%, 99% or higher sequence identity. In some embodiments, the HVR1 region corresponds to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 47. Contains one or more residues. In some embodiments, the HVR1 region corresponds to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 47. Contains residues. In some embodiments, the HVR1 region includes Y, R, K, or D at the residue corresponding to residue 66 of SEQ ID NO: 47. In some embodiments, the HVR1 region comprises residues 24-79 of SEQ ID NO: 47 with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 amino acid substitutions. . In some embodiments, the HVR1 region comprises residues 24-79 of SEQ ID NO:47.
[0444] In some embodiments, the first subunit comprises residues 7-153 of SEQ ID NO: 47 and at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the first subunit includes a G, S or A at the residue corresponding to residue 19 of SEQ ID NO: 47. In some embodiments, the first subunit includes a residue corresponding to residue 19 of SEQ ID NO: 47. In some embodiments, the first subunit includes E, Q, or K at the residue corresponding to residue 80 of SEQ ID NO: 47. In some embodiments, the first subunit includes a residue corresponding to residue 80 of SEQ ID NO: 47. In some embodiments, the first subunit is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, Includes residues 7-153 of SEQ ID NO: 47 with up to 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acid substitutions. In some embodiments, the first subunit comprises residues 7-153 of SEQ ID NO:47.
[0445] In some embodiments, the HVR2 region comprises at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% of the amino acid sequence corresponding to residues 215-270 of SEQ ID NO: 47. , 96%, 97%, 98%, 99% or higher sequence identity. In some embodiments, the HVR2 region corresponds to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of SEQ ID NO: 47. Contains one or more residues. In some embodiments, the HVR2 region corresponds to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of SEQ ID NO: 47. Contains residues. In some embodiments, the HVR2 region includes Y, R, K, or D at the residue corresponding to residue 257 of SEQ ID NO: 47. In some embodiments, the HVR2 region includes a residue corresponding to residue 239 of SEQ ID NO: 47. In some embodiments, the HVR2 region includes a residue corresponding to residue 241 of SEQ ID NO: 47. In some embodiments, the HVR2 region includes a residue corresponding to residue 264 of SEQ ID NO: 47. In some embodiments, the HVR2 region comprises residues 215-270 of SEQ ID NO: 47 with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 amino acid substitutions. . In some embodiments, the HVR2 region comprises residues 215-270 of SEQ ID NO: 47.
[0446] In some embodiments, the second subunit comprises residues 198-344 of SEQ ID NO: 47 and at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the second subunit includes a G, S or A at the residue corresponding to residue 210 of SEQ ID NO: 47. In some embodiments, the second subunit includes an E, Q, or K at the residue corresponding to residue 271 of SEQ ID NO: 47. In some embodiments, the second subunit includes a residue corresponding to residue 330 of SEQ ID NO: 47. In some embodiments, the second subunit is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, Includes residues 198-344 of SEQ ID NO: 47 with up to 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acid substitutions. In some embodiments, the second subunit comprises residues 198-344 of SEQ ID NO: 47.
[0447] In some embodiments, the genetically engineered meganuclease is a single chain meganuclease that includes a linker, where the linker covalently joins the first subunit and the second subunit. In some embodiments, the engineered meganuclease is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, Contains amino acid sequences having 98%, 99% or higher sequence identity. In some embodiments, the genetically engineered meganuclease comprises the amino acid sequence of SEQ ID NO: 47. In some embodiments, the genetically engineered meganuclease has at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 with the nucleic acid sequence set forth in SEQ ID NO: 71. %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the engineered meganuclease is encoded by the nucleic acid sequence set forth in SEQ ID NO:71.
[0448] DMD 35-36L.282 (Sequence number 48)
[0449] In some embodiments, the HVR1 region comprises at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% of the amino acid sequence corresponding to residues 24-79 of SEQ ID NO: 48. , 96%, 97%, 98%, 99% or higher sequence identity. In some embodiments, the HVR1 region corresponds to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 48. Contains one or more residues. In some embodiments, the HVR1 region corresponds to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 48. Contains residues. In some embodiments, the HVR1 region includes a Y, R, K, or D at the residue corresponding to residue 66 of SEQ ID NO: 48. In some embodiments, the HVR1 region comprises residues 24-79 of SEQ ID NO: 48 with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 amino acid substitutions. . In some embodiments, the HVR1 region comprises residues 24-79 of SEQ ID NO: 48.
[0450] In some embodiments, the first subunit comprises residues 7-153 of SEQ ID NO: 48 and at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the first subunit includes a G, S or A at the residue corresponding to residue 19 of SEQ ID NO: 48. In some embodiments, the first subunit includes a residue corresponding to residue 19 of SEQ ID NO: 48. In some embodiments, the first subunit includes E, Q, or K at residue corresponding to residue 80 of SEQ ID NO: 48. In some embodiments, the first subunit includes a residue corresponding to residue 80 of SEQ ID NO: 48. In some embodiments, the first subunit is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, Includes residues 7-153 of SEQ ID NO: 48 with up to 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acid substitutions. In some embodiments, the first subunit comprises residues 7-153 of SEQ ID NO: 48.
[0451] In some embodiments, the HVR2 region comprises at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% of the amino acid sequence corresponding to residues 215-270 of SEQ ID NO: 48. , 96%, 97%, 98%, 99% or higher sequence identity. In some embodiments, the HVR2 region corresponds to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of SEQ ID NO: 48. Contains one or more residues. In some embodiments, the HVR2 region corresponds to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of SEQ ID NO: 48. Contains residues. In some embodiments, the HVR2 region includes Y, R, K, or D at residue corresponding to residue 257 of SEQ ID NO: 48. In some embodiments, the HVR2 region includes a residue corresponding to residue 239 of SEQ ID NO: 48. In some embodiments, the HVR2 region includes a residue corresponding to residue 241 of SEQ ID NO: 48. In some embodiments, the HVR2 region includes a residue corresponding to residue 264 of SEQ ID NO: 48. In some embodiments, the HVR2 region comprises residues 215-270 of SEQ ID NO: 48 with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 amino acid substitutions. . In some embodiments, the HVR2 region comprises residues 215-270 of SEQ ID NO: 48.
[0452] In some embodiments, the second subunit comprises residues 198-344 of SEQ ID NO: 48 and at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the second subunit includes a G, S or A at the residue corresponding to residue 210 of SEQ ID NO: 48. In some embodiments, the second subunit includes an E, Q, or K at the residue corresponding to residue 271 of SEQ ID NO: 48. In some embodiments, the second subunit includes a residue corresponding to residue 330 of SEQ ID NO: 48. In some embodiments, the second subunit is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, Includes residues 198-344 of SEQ ID NO: 48 with up to 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acid substitutions. In some embodiments, the second subunit comprises residues 198-344 of SEQ ID NO: 48.
[0453] In some embodiments, the genetically engineered meganuclease is a single chain meganuclease that includes a linker, where the linker covalently joins the first subunit and the second subunit. In some embodiments, the genetically engineered meganuclease is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, Contains amino acid sequences having 98%, 99% or higher sequence identity. In some embodiments, the genetically engineered meganuclease comprises the amino acid sequence of SEQ ID NO: 48. In some embodiments, the genetically engineered meganuclease has at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 with the nucleic acid sequence set forth in SEQ ID NO: 72. %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the genetically engineered meganuclease is encoded by the nucleic acid sequence set forth in SEQ ID NO:72.
[0454] DMD 35-36L.349 (Sequence number 49)
[0455] In some embodiments, the HVR1 region comprises at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% of the amino acid sequence corresponding to residues 24-79 of SEQ ID NO: 49. , 96%, 97%, 98%, 99% or higher sequence identity. In some embodiments, the HVR1 region corresponds to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 49. Contains one or more residues. In some embodiments, the HVR1 region corresponds to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 49. Contains residues. In some embodiments, the HVR1 region includes a Y, R, K, or D at the residue corresponding to residue 66 of SEQ ID NO: 49. In some embodiments, the HVR1 region comprises residues 24-79 of SEQ ID NO: 49 with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 amino acid substitutions. . In some embodiments, the HVR1 region comprises residues 24-79 of SEQ ID NO: 49.
[0456] In some embodiments, the first subunit comprises residues 7-153 of SEQ ID NO: 49 and at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the first subunit includes a G, S or A at the residue corresponding to residue 19 of SEQ ID NO: 49. In some embodiments, the first subunit includes a residue corresponding to residue 19 of SEQ ID NO: 49. In some embodiments, the first subunit includes an E, Q, or K at the residue corresponding to residue 80 of SEQ ID NO: 49. In some embodiments, the first subunit includes a residue corresponding to residue 80 of SEQ ID NO: 49. In some embodiments, the first subunit is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, Includes residues 7-153 of SEQ ID NO: 49 with up to 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acid substitutions. In some embodiments, the first subunit comprises residues 7-153 of SEQ ID NO: 49.
[0457] In some embodiments, the HVR2 region comprises at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% of the amino acid sequence corresponding to residues 215-270 of SEQ ID NO: 49. , 96%, 97%, 98%, 99% or higher sequence identity. In some embodiments, the HVR2 region corresponds to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of SEQ ID NO: 49. Contains one or more residues. In some embodiments, the HVR2 region corresponds to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of SEQ ID NO: 49. Contains residues. In some embodiments, the HVR2 region includes Y, R, K, or D at the residue corresponding to residue 257 of SEQ ID NO: 49. In some embodiments, the HVR2 region includes a residue corresponding to residue 239 of SEQ ID NO: 49. In some embodiments, the HVR2 region includes a residue corresponding to residue 241 of SEQ ID NO: 49. In some embodiments, the HVR2 region includes a residue corresponding to residue 264 of SEQ ID NO: 49. In some embodiments, the HVR2 region comprises residues 215-270 of SEQ ID NO: 49 with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 amino acid substitutions. . In some embodiments, the HVR2 region comprises residues 215-270 of SEQ ID NO: 49.
[0458] In some embodiments, the second subunit comprises residues 198-344 of SEQ ID NO: 49 and at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the second subunit includes a G, S or A at the residue corresponding to residue 210 of SEQ ID NO: 49. In some embodiments, the second subunit includes an E, Q, or K at the residue corresponding to residue 271 of SEQ ID NO: 49. In some embodiments, the second subunit includes a residue corresponding to residue 330 of SEQ ID NO: 49. In some embodiments, the second subunit is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, Includes residues 198-344 of SEQ ID NO: 49 with up to 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acid substitutions. In some embodiments, the second subunit comprises residues 198-344 of SEQ ID NO: 49.
[0459] In some embodiments, the genetically engineered meganuclease is a single chain meganuclease that includes a linker, where the linker covalently joins the first subunit and the second subunit. In some embodiments, the genetically engineered meganuclease is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, Contains amino acid sequences having 98%, 99% or higher sequence identity. In some embodiments, the genetically engineered meganuclease comprises the amino acid sequence of SEQ ID NO: 49. In some embodiments, the genetically engineered meganuclease has at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 with the nucleic acid sequence set forth in SEQ ID NO: 73. %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the genetically engineered meganuclease is encoded by the nucleic acid sequence set forth in SEQ ID NO:73.
[0460] DMD 35-36L.376 (Sequence number 50)
[0461] In some embodiments, the HVR1 region comprises at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% of the amino acid sequence corresponding to residues 24-79 of SEQ ID NO: 50. , 96%, 97%, 98%, 99% or higher sequence identity. In some embodiments, the HVR1 region corresponds to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 50. Contains one or more residues. In some embodiments, the HVR1 region corresponds to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 50. Contains residues. In some embodiments, the HVR1 region includes a Y, R, K, or D at the residue corresponding to residue 66 of SEQ ID NO: 50. In some embodiments, the HVR1 region comprises residues 24-79 of SEQ ID NO: 50 with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 amino acid substitutions. . In some embodiments, the HVR1 region comprises residues 24-79 of SEQ ID NO:50.
[0462] In some embodiments, the first subunit comprises residues 7-153 of SEQ ID NO: 50 and at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the first subunit includes a G, S or A at the residue corresponding to residue 19 of SEQ ID NO: 50. In some embodiments, the first subunit includes a residue corresponding to residue 19 of SEQ ID NO:50. In some embodiments, the first subunit includes E, Q, or K at residue corresponding to residue 80 of SEQ ID NO:50. In some embodiments, the first subunit includes a residue corresponding to residue 80 of SEQ ID NO:50. In some embodiments, the first subunit is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, Includes residues 7-153 of SEQ ID NO: 50 with up to 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acid substitutions. In some embodiments, the first subunit comprises residues 7-153 of SEQ ID NO:50.
[0463] In some embodiments, the HVR2 region comprises at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% of the amino acid sequence corresponding to residues 215-270 of SEQ ID NO: 50. , 96%, 97%, 98%, 99% or higher sequence identity. In some embodiments, the HVR2 region corresponds to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of SEQ ID NO: 50. Contains one or more residues. In some embodiments, the HVR2 region corresponds to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of SEQ ID NO: 50. Contains residues. In some embodiments, the HVR2 region includes Y, R, K or D at residue corresponding to residue 257 of SEQ ID NO:50. In some embodiments, the HVR2 region includes a residue corresponding to residue 239 of SEQ ID NO:50. In some embodiments, the HVR2 region includes a residue corresponding to residue 241 of SEQ ID NO:50. In some embodiments, the HVR2 region includes a residue corresponding to residue 264 of SEQ ID NO:50. In some embodiments, the HVR2 region comprises residues 215-270 of SEQ ID NO: 50 with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 amino acid substitutions. . In some embodiments, the HVR2 region comprises residues 215-270 of SEQ ID NO:50.
[0464] In some embodiments, the second subunit comprises residues 198-344 of SEQ ID NO: 50 and at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the second subunit includes a G, S or A at the residue corresponding to residue 210 of SEQ ID NO:50. In some embodiments, the second subunit includes an E, Q, or K at the residue corresponding to residue 271 of SEQ ID NO: 50. In some embodiments, the second subunit includes a residue corresponding to residue 330 of SEQ ID NO:50. In some embodiments, the second subunit is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, Includes residues 198-344 of SEQ ID NO: 50 with up to 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acid substitutions. In some embodiments, the second subunit comprises residues 198-344 of SEQ ID NO:50.
[0465] In some embodiments, the genetically engineered meganuclease is a single chain meganuclease that includes a linker, where the linker covalently joins the first subunit and the second subunit. In some embodiments, the genetically engineered meganuclease is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, Contains amino acid sequences having 98%, 99% or higher sequence identity. In some embodiments, the genetically engineered meganuclease comprises the amino acid sequence of SEQ ID NO:50. In some embodiments, the genetically engineered meganuclease has at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the genetically engineered meganuclease is encoded by the nucleic acid sequence set forth in SEQ ID NO:74.
[0466] DMD 35-36L.457 (Sequence number 51)
[0467] In some embodiments, the HVR1 region comprises at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% of the amino acid sequence corresponding to residues 24-79 of SEQ ID NO: 51. , 96%, 97%, 98%, 99% or higher sequence identity. In some embodiments, the HVR1 region corresponds to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 51. Contains one or more residues. In some embodiments, the HVR1 region corresponds to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 51. Contains residues. In some embodiments, the HVR1 region includes Y, R, K, or D at the residue corresponding to residue 66 of SEQ ID NO: 51. In some embodiments, the HVR1 region comprises residues 24-79 of SEQ ID NO: 51 with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 amino acid substitutions. . In some embodiments, the HVR1 region comprises residues 24-79 of SEQ ID NO:51.
[0468] In some embodiments, the first subunit comprises residues 7-153 of SEQ ID NO: 51 and at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the first subunit includes a G, S or A at the residue corresponding to residue 19 of SEQ ID NO:51. In some embodiments, the first subunit includes a residue corresponding to residue 19 of SEQ ID NO:51. In some embodiments, the first subunit includes E, Q, or K at the residue corresponding to residue 80 of SEQ ID NO:51. In some embodiments, the first subunit includes a residue corresponding to residue 80 of SEQ ID NO:51. In some embodiments, the first subunit is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, Includes residues 7-153 of SEQ ID NO: 51 with up to 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acid substitutions. In some embodiments, the first subunit comprises residues 7-153 of SEQ ID NO:51.
[0469] In some embodiments, the HVR2 region comprises at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% of the amino acid sequence corresponding to residues 215-270 of SEQ ID NO: 51. , 96%, 97%, 98%, 99% or higher sequence identity. In some embodiments, the HVR2 region corresponds to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of SEQ ID NO: 51. Contains one or more residues. In some embodiments, the HVR2 region corresponds to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of SEQ ID NO: 51. Contains residues. In some embodiments, the HVR2 region includes Y, R, K, or D at the residue corresponding to residue 257 of SEQ ID NO: 51. In some embodiments, the HVR2 region includes a residue corresponding to residue 239 of SEQ ID NO:51. In some embodiments, the HVR2 region includes a residue corresponding to residue 241 of SEQ ID NO:51. In some embodiments, the HVR2 region includes a residue corresponding to residue 264 of SEQ ID NO:51. In some embodiments, the HVR2 region comprises residues 215-270 of SEQ ID NO: 51 with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 amino acid substitutions. . In some embodiments, the HVR2 region comprises residues 215-270 of SEQ ID NO:51.
[0470] In some embodiments, the second subunit comprises residues 198-344 of SEQ ID NO: 51 and at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the second subunit includes a G, S or A at the residue corresponding to residue 210 of SEQ ID NO:51. In some embodiments, the second subunit includes an E, Q, or K at the residue corresponding to residue 271 of SEQ ID NO:51. In some embodiments, the second subunit includes a residue corresponding to residue 330 of SEQ ID NO:51. In some embodiments, the second subunit is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, Includes residues 198-344 of SEQ ID NO: 51 with up to 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acid substitutions. In some embodiments, the second subunit comprises residues 198-344 of SEQ ID NO:51.
[0471] In some embodiments, the genetically engineered meganuclease is a single chain meganuclease that includes a linker, where the linker covalently joins the first subunit and the second subunit. In some embodiments, the engineered meganuclease is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, Contains amino acid sequences having 98%, 99% or higher sequence identity. In some embodiments, the genetically engineered meganuclease comprises the amino acid sequence of SEQ ID NO:51. In some embodiments, the genetically engineered meganuclease has at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 with the nucleic acid sequence set forth in SEQ ID NO: 75. %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the genetically engineered meganuclease is encoded by the nucleic acid sequence set forth in SEQ ID NO:75.
[0472] DMD 35-36L.469 (Sequence number 52)
[0473] In some embodiments, the HVR1 region comprises at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% of the amino acid sequence corresponding to residues 24-79 of SEQ ID NO: 52. , 96%, 97%, 98%, 99% or higher sequence identity. In some embodiments, the HVR1 region corresponds to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 52. Contains one or more residues. In some embodiments, the HVR1 region corresponds to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 52. Contains residues. In some embodiments, the HVR1 region includes Y, R, K, or D at the residue corresponding to residue 66 of SEQ ID NO: 52. In some embodiments, the HVR1 region comprises residues 24-79 of SEQ ID NO: 52 with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 amino acid substitutions. . In some embodiments, the HVR1 region comprises residues 24-79 of SEQ ID NO:52.
[0474] In some embodiments, the first subunit comprises residues 7-153 of SEQ ID NO: 52 and at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the first subunit includes a G, S or A at the residue corresponding to residue 19 of SEQ ID NO: 52. In some embodiments, the first subunit includes a residue corresponding to residue 19 of SEQ ID NO: 52. In some embodiments, the first subunit includes E, Q, or K at the residue corresponding to residue 80 of SEQ ID NO: 52. In some embodiments, the first subunit is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, Includes residues 7-153 of SEQ ID NO: 52 with up to 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acid substitutions. In some embodiments, the first subunit comprises residues 7-153 of SEQ ID NO:52.
[0475] In some embodiments, the HVR2 region comprises at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% of the amino acid sequence corresponding to residues 215-270 of SEQ ID NO: 52. , 96%, 97%, 98%, 99% or higher sequence identity. In some embodiments, the HVR2 region corresponds to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of SEQ ID NO: 52. Contains one or more residues. In some embodiments, the HVR2 region corresponds to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of SEQ ID NO: 52. Contains residues. In some embodiments, the HVR2 region includes Y, R, K, or D at residue corresponding to residue 257 of SEQ ID NO: 52. In some embodiments, the HVR2 region includes a residue corresponding to residue 239 of SEQ ID NO: 52. In some embodiments, the HVR2 region includes a residue corresponding to residue 241 of SEQ ID NO: 52. In some embodiments, the HVR2 region includes a residue corresponding to residue 264 of SEQ ID NO: 52. In some embodiments, the HVR2 region comprises residues 215-270 of SEQ ID NO: 52 with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 amino acid substitutions. . In some embodiments, the HVR2 region comprises residues 215-270 of SEQ ID NO:52.
[0476] In some embodiments, the second subunit comprises residues 198-344 of SEQ ID NO: 52 and at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the second subunit includes a G, S or A at the residue corresponding to residue 210 of SEQ ID NO: 52. In some embodiments, the second subunit includes an E, Q, or K at the residue corresponding to residue 271 of SEQ ID NO: 52. In some embodiments, the second subunit includes a residue corresponding to residue 271 of SEQ ID NO: 52. In some embodiments, the second subunit includes a residue corresponding to residue 330 of SEQ ID NO: 52. In some embodiments, the second subunit is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, Includes residues 198-344 of SEQ ID NO: 52 with up to 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acid substitutions. In some embodiments, the second subunit comprises residues 198-344 of SEQ ID NO: 52.
[0477] In some embodiments, the genetically engineered meganuclease is a single chain meganuclease that includes a linker, where the linker covalently joins the first subunit and the second subunit. In some embodiments, the engineered meganuclease is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, Contains amino acid sequences having 98%, 99% or higher sequence identity. In some embodiments, the genetically engineered meganuclease comprises the amino acid sequence of SEQ ID NO: 52. In some embodiments, the genetically engineered meganuclease is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 with the nucleic acid sequence set forth in SEQ ID NO: 76. %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the genetically engineered meganuclease is encoded by the nucleic acid sequence set forth in SEQ ID NO:76.
[0478] In certain embodiments of the invention, the genetically engineered meganuclease binds to and cleaves a recognition sequence comprising SEQ ID NO: 12 within the dystrophin gene (i.e., the DMD 37-38 recognition sequence), and the genetically engineered meganuclease The nuclease includes a first subunit and a second subunit, the first subunit binds to a first recognition half site of a recognition sequence and includes a first hypervariable (HVR1) region; Two subunits bind to the second recognition half site of the recognition sequence and include the second hypervariable (HVR2) region. An exemplary DMD 37-38 meganuclease is described below.
[0479] DMD 37-38x.15 (Sequence number 53)
[0480] In some embodiments, the HVR1 region comprises at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% of the amino acid sequence corresponding to residues 24-79 of SEQ ID NO: 53. , 96%, 97%, 98%, 99% or higher sequence identity. In some embodiments, the HVR1 region corresponds to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 53. Contains one or more residues. In some embodiments, the HVR1 region corresponds to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 53. Contains residues. In some embodiments, the HVR1 region includes a Y, R, K, or D at the residue corresponding to residue 66 of SEQ ID NO: 53. In some embodiments, the HVR1 region comprises residues 24-79 of SEQ ID NO: 53 with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 amino acid substitutions. . In some embodiments, the HVR1 region comprises residues 24-79 of SEQ ID NO:53.
[0481] In some embodiments, the first subunit comprises residues 7-153 of SEQ ID NO: 53 and at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the first subunit includes a G, S or A at the residue corresponding to residue 19 of SEQ ID NO: 53. In some embodiments, the first subunit includes a residue corresponding to residue 19 of SEQ ID NO: 53. In some embodiments, the first subunit includes E, Q, or K at residue corresponding to residue 80 of SEQ ID NO: 53. In some embodiments, the first subunit includes a residue corresponding to residue 80 of SEQ ID NO: 53. In some embodiments, the first subunit is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, Includes residues 7-153 of SEQ ID NO: 53 with up to 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acid substitutions. In some embodiments, the first subunit comprises residues 7-153 of SEQ ID NO:53.
[0482] In some embodiments, the HVR2 region comprises at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% of the amino acid sequence corresponding to residues 215-270 of SEQ ID NO: 53. , 96%, 97%, 98%, 99% or higher sequence identity. In some embodiments, the HVR2 region corresponds to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of SEQ ID NO: 53. Contains one or more residues. In some embodiments, the HVR2 region corresponds to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of SEQ ID NO: 53. Contains residues. In some embodiments, the HVR2 region includes Y, R, K, or D at residue corresponding to residue 257 of SEQ ID NO: 53. In some embodiments, the HVR2 region includes a residue corresponding to residue 239 of SEQ ID NO: 53. In some embodiments, the HVR2 region includes a residue corresponding to residue 241 of SEQ ID NO: 53. In some embodiments, the HVR2 region includes a residue corresponding to residue 264 of SEQ ID NO: 53. In some embodiments, the HVR2 region comprises residues 215-270 of SEQ ID NO: 53 with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 amino acid substitutions. . In some embodiments, the HVR2 region comprises residues 215-270 of SEQ ID NO:53.
[0483] In some embodiments, the second subunit comprises residues 198-344 of SEQ ID NO: 53 and at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the second subunit includes a G, S or A at the residue corresponding to residue 210 of SEQ ID NO: 53. In some embodiments, the second subunit includes an E, Q, or K at the residue corresponding to residue 271 of SEQ ID NO: 53. In some embodiments, the second subunit includes a residue corresponding to residue 271 of SEQ ID NO: 53. In some embodiments, the second subunit is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, Includes residues 198-344 of SEQ ID NO: 53 with up to 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acid substitutions. In some embodiments, the second subunit comprises residues 198-344 of SEQ ID NO: 53.
[0484] In some embodiments, the genetically engineered meganuclease is a single chain meganuclease that includes a linker, where the linker covalently joins the first subunit and the second subunit. In some embodiments, the genetically engineered meganuclease is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, Contains amino acid sequences having 98%, 99% or higher sequence identity. In some embodiments, the genetically engineered meganuclease comprises the amino acid sequence of SEQ ID NO: 53. In some embodiments, the genetically engineered meganuclease has at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 with the nucleic acid sequence set forth in SEQ ID NO: 77. %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the genetically engineered meganuclease is encoded by the nuclear sequence set forth in SEQ ID NO:77.
[0485] DMD 37-38x.66 (Sequence number 54)
[0486] In some embodiments, the HVR1 region comprises at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% of the amino acid sequence corresponding to residues 24-79 of SEQ ID NO: 54. , 96%, 97%, 98%, 99% or higher sequence identity. In some embodiments, the HVR1 region corresponds to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 54. Contains one or more residues. In some embodiments, the HVR1 region corresponds to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 54. Contains residues. In some embodiments, the HVR1 region includes a Y, R, K, or D at the residue corresponding to residue 66 of SEQ ID NO: 54. In some embodiments, the HVR1 region includes a residue corresponding to residue 64 of SEQ ID NO:54. In some embodiments, the HVR1 region comprises residues 24-79 of SEQ ID NO: 54 with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 amino acid substitutions. . In some embodiments, the HVR1 region comprises residues 24-79 of SEQ ID NO:54.
[0487] In some embodiments, the first subunit comprises residues 7-153 of SEQ ID NO: 54 and at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the first subunit includes a G, S or A at the residue corresponding to residue 19 of SEQ ID NO: 54. In some embodiments, the first subunit includes a residue corresponding to residue 19 of SEQ ID NO: 54. In some embodiments, the first subunit includes E, Q, or K at residue corresponding to residue 80 of SEQ ID NO: 54. In some embodiments, the first subunit includes a residue corresponding to residue 80 of SEQ ID NO:54. In some embodiments, the first subunit is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, Includes residues 7-153 of SEQ ID NO: 54 with up to 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acid substitutions. In some embodiments, the first subunit comprises residues 7-153 of SEQ ID NO:54.
[0488] In some embodiments, the HVR2 region comprises at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% of the amino acid sequence corresponding to residues 215-270 of SEQ ID NO: 54. , 96%, 97%, 98%, 99% or higher sequence identity. In some embodiments, the HVR2 region corresponds to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of SEQ ID NO: 54. Contains one or more residues. In some embodiments, the HVR2 region corresponds to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of SEQ ID NO: 54. Contains residues. In some embodiments, the HVR2 region includes Y, R, K or D at residue corresponding to residue 257 of SEQ ID NO: 54. In some embodiments, the HVR2 region includes a residue corresponding to residue 241 of SEQ ID NO:54. In some embodiments, the HVR2 region includes a residue corresponding to residue 264 of SEQ ID NO:54. In some embodiments, the HVR2 region comprises residues 215-270 of SEQ ID NO: 54 with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 amino acid substitutions. . In some embodiments, the HVR2 region comprises residues 215-270 of SEQ ID NO:54.
[0489] In some embodiments, the second subunit comprises residues 198-344 of SEQ ID NO: 54 and at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the second subunit includes a G, S or A at the residue corresponding to residue 210 of SEQ ID NO:54. In some embodiments, the second subunit includes an E, Q, or K at the residue corresponding to residue 271 of SEQ ID NO: 54. In some embodiments, the second subunit includes a residue corresponding to residue 330 of SEQ ID NO:54. In some embodiments, the second subunit is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, Includes residues 198-344 of SEQ ID NO: 54 with up to 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acid substitutions. In some embodiments, the second subunit comprises residues 198-344 of SEQ ID NO:54.
[0490] In some embodiments, the genetically engineered meganuclease is a single chain meganuclease that includes a linker, where the linker covalently joins the first subunit and the second subunit. In some embodiments, the engineered meganuclease is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, Contains amino acid sequences having 98%, 99% or higher sequence identity. In some embodiments, the genetically engineered meganuclease comprises the amino acid sequence of SEQ ID NO: 54. In some embodiments, the genetically engineered meganuclease has at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 with the nucleic acid sequence set forth in SEQ ID NO: 78. %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the genetically engineered meganuclease is encoded by the nuclear sequence set forth in SEQ ID NO:78.
[0491] DMD 37-38x.79 (Sequence number 55)
[0492] In some embodiments, the HVR1 region comprises at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% of the amino acid sequence corresponding to residues 24-79 of SEQ ID NO: 55. , 96%, 97%, 98%, 99% or higher sequence identity. In some embodiments, the HVR1 region corresponds to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 55. Contains one or more residues. In some embodiments, the HVR1 region corresponds to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 55. Contains residues. In some embodiments, the HVR1 region includes a Y, R, K, or D at the residue corresponding to residue 66 of SEQ ID NO: 55. In some embodiments, the HVR1 region comprises residues 24-79 of SEQ ID NO: 55 with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 amino acid substitutions. . In some embodiments, the HVR1 region comprises residues 24-79 of SEQ ID NO:55.
[0493] In some embodiments, the first subunit comprises residues 7-153 of SEQ ID NO: 55 and at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the first subunit includes a G, S or A at the residue corresponding to residue 19 of SEQ ID NO: 55. In some embodiments, the first subunit includes a residue corresponding to residue 19 of SEQ ID NO: 55. In some embodiments, the first subunit includes E, Q, or K at residue corresponding to residue 80 of SEQ ID NO: 55. In some embodiments, the first subunit includes a residue corresponding to residue 80 of SEQ ID NO: 55. In some embodiments, the first subunit is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, Includes residues 7-153 of SEQ ID NO: 55 with up to 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acid substitutions. In some embodiments, the first subunit comprises residues 7-153 of SEQ ID NO:55.
[0494] In some embodiments, the HVR2 region comprises at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% of the amino acid sequence corresponding to residues 215-270 of SEQ ID NO: 55. , 96%, 97%, 98%, 99% or higher sequence identity. In some embodiments, the HVR2 region corresponds to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of SEQ ID NO: 55. Contains one or more residues. In some embodiments, the HVR2 region corresponds to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of SEQ ID NO: 55. Contains residues. In some embodiments, the HVR2 region includes Y, R, K, or D at residue corresponding to residue 257 of SEQ ID NO: 55. In some embodiments, the HVR2 region includes a residue corresponding to residue 239 of SEQ ID NO: 55. In some embodiments, the HVR2 region includes a residue corresponding to residue 241 of SEQ ID NO: 55. In some embodiments, the HVR2 region includes a residue corresponding to residue 255 of SEQ ID NO: 55. In some embodiments, the HVR2 region includes a residue corresponding to residue 264 of SEQ ID NO: 55. In some embodiments, the HVR2 region comprises residues 215-270 of SEQ ID NO: 55 with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 amino acid substitutions. . In some embodiments, the HVR2 region comprises residues 215-270 of SEQ ID NO: 55.
[0495] In some embodiments, the second subunit comprises residues 198-344 of SEQ ID NO: 55 and at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the second subunit includes a G, S or A at the residue corresponding to residue 210 of SEQ ID NO: 55. In some embodiments, the second subunit includes an E, Q, or K at the residue corresponding to residue 271 of SEQ ID NO: 55. In some embodiments, the second subunit includes a residue corresponding to residue 271 of SEQ ID NO: 55. In some embodiments, the second subunit includes a residue corresponding to residue 330 of SEQ ID NO: 55. In some embodiments, the second subunit is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, Includes residues 198-344 of SEQ ID NO: 55 with up to 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acid substitutions. In some embodiments, the second subunit comprises residues 198-344 of SEQ ID NO: 55.
[0496] In some embodiments, the genetically engineered meganuclease is a single chain meganuclease that includes a linker, where the linker covalently joins the first subunit and the second subunit. In some embodiments, the genetically engineered meganuclease is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, Contains amino acid sequences having 98%, 99% or higher sequence identity. In some embodiments, the genetically engineered meganuclease comprises the amino acid sequence of SEQ ID NO: 55. In some embodiments, the genetically engineered meganuclease has at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 with the nucleic acid sequence set forth in SEQ ID NO: 79. %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the genetically engineered meganuclease is encoded by the nucleic acid sequence set forth in SEQ ID NO:79.
[0497] DMD 37-38L.166 (Sequence number 56)
[0498] In some embodiments, the HVR1 region comprises at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% of the amino acid sequence corresponding to residues 24-79 of SEQ ID NO: 56. , 96%, 97%, 98%, 99% or higher sequence identity. In some embodiments, the HVR1 region corresponds to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 56. Contains one or more residues. In some embodiments, the HVR1 region corresponds to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of SEQ ID NO: 56. Contains residues. In some embodiments, the HVR1 region includes a Y, R, K, or D at the residue corresponding to residue 66 of SEQ ID NO: 56. In some embodiments, the HVR1 region comprises residues 24-79 of SEQ ID NO: 56 with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 amino acid substitutions. . In some embodiments, the HVR1 region comprises residues 24-79 of SEQ ID NO:56.
[0499] In some embodiments, the first subunit comprises residues 7-153 of SEQ ID NO: 56 and at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the first subunit includes a G, S or A at the residue corresponding to residue 19 of SEQ ID NO: 56. In some embodiments, the first subunit includes a residue corresponding to residue 19 of SEQ ID NO: 56. In some embodiments, the first subunit includes E, Q, or K at residue corresponding to residue 80 of SEQ ID NO: 56. In some embodiments, the first subunit is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, Includes residues 7-153 of SEQ ID NO: 56 with up to 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acid substitutions. In some embodiments, the first subunit comprises residues 7-153 of SEQ ID NO:56.
[0500] In some embodiments, the HVR2 region comprises at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% of the amino acid sequence corresponding to residues 215-270 of SEQ ID NO: 56. , 96%, 97%, 98%, 99% or higher sequence identity. In some embodiments, the HVR2 region corresponds to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of SEQ ID NO: 56. Contains one or more residues. In some embodiments, the HVR2 region corresponds to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of SEQ ID NO: 56. Contains residues. In some embodiments, the HVR2 region includes Y, R, K, or D at residue corresponding to residue 257 of SEQ ID NO: 56. In some embodiments, the HVR2 region includes a residue corresponding to residue 263 of SEQ ID NO:56. In some embodiments, the HVR2 region includes a residue corresponding to residue 264 of SEQ ID NO:56. In some embodiments, the HVR2 region comprises residues 215-270 of SEQ ID NO: 56 with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 amino acid substitutions. . In some embodiments, the HVR2 region comprises residues 215-270 of SEQ ID NO:56.
[0501] In some embodiments, the second subunit comprises residues 198-344 of SEQ ID NO: 56 and at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 %, 97%, 98%, 99% or higher sequence identity. In some embodiments, the second subunit includes a G, S or A at the residue corresponding to residue 210 of SEQ ID NO: 56. In some embodiments, the second subunit includes an E, Q, or K at the residue corresponding to residue 271 of SEQ ID NO: 56. In some embodiments, the second subunit includes a residue corresponding to residue 271 of SEQ ID NO: 56. In some embodiments, the second subunit includes a residue corresponding to residue 330 of SEQ ID NO:56. In some embodiments, the second subunit is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, Includes residues 198-344 of SEQ ID NO: 56 with up to 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acid substitutions. In some embodiments, the second subunit comprises residues 198-344 of SEQ ID NO: 56.
[0502] In some embodiments, the genetically engineered meganuclease is a single chain meganuclease that includes a linker, wher...
Claims
1. comprising a nucleic acid sequence encoding an engineered meganuclease, The engineered meganuclease is a polynucleotide that comprises the amino acid sequence of SEQ ID NO:43 and binds to and cleaves nucleic acid at a site that contains a recognition sequence consisting of the nucleic acid sequence of SEQ ID NO:6 within the dystrophin gene.
2. The polynucleotide described in claim 1, wherein the polynucleotide comprises a promoter operably linked to the nucleic acid sequence encoding the genetically engineered meganuclease.
3. The polynucleotide described in claim 2, wherein the promoter is a muscle cell-specific promoter.
4. The polynucleotide of claim 1 , wherein the polynucleotide is an mRNA.
5. a polynucleotide comprising a nucleic acid sequence encoding an engineered meganuclease, A recombinant DNA construct, wherein the engineered meganuclease comprises the amino acid sequence of SEQ ID NO:43 and binds to and cleaves nucleic acid at a site comprising a recognition sequence consisting of the nucleic acid sequence of SEQ ID NO:6 within the dystrophin gene.
6. 6. The recombinant DNA construct of claim 5, wherein said polynucleotide comprises a promoter operably linked to said nucleic acid sequence encoding said engineered meganuclease.
7. The recombinant DNA construct of claim 6 , wherein the promoter is a muscle cell-specific promoter.
8. a polynucleotide comprising a nucleic acid sequence encoding an engineered meganuclease, A recombinant virus, wherein the engineered meganuclease comprises the amino acid sequence of SEQ ID NO:43 and binds to and cleaves nucleic acid at a site comprising a recognition sequence consisting of the nucleic acid sequence of SEQ ID NO:6 within the dystrophin gene.
9. The recombinant virus of claim 8, wherein the recombinant virus is a recombinant adeno-associated virus (AAV).
10. The recombinant virus described in claim 9, wherein the recombinant AAV has a capsid comprising the amino acid sequence of SEQ ID NO: 182 or a capsid comprising the amino acid sequence of SEQ ID NO:
183.
11. The recombinant virus of any one of claims 8 to 10, wherein the polynucleotide comprises a promoter operably linked to the nucleic acid sequence encoding the engineered meganuclease.
12. The recombinant virus of claim 11 , wherein the promoter is a muscle cell-specific promoter.
13. A method for producing a method for the production of a gene comprising the steps of: The engineered meganuclease is a polynucleotide that comprises the amino acid sequence of SEQ ID NO:51 and binds to and cleaves nucleic acid at a site that comprises a recognition sequence consisting of the nucleic acid sequence of SEQ ID NO:10 within the dystrophin gene.
14. The polynucleotide of claim 13, wherein the polynucleotide comprises a promoter operably linked to the nucleic acid sequence encoding the engineered meganuclease.
15. The polynucleotide of claim 14, wherein the promoter is a muscle cell-specific promoter.
16. The polynucleotide described in claim 13, wherein the polynucleotide is mRNA.
17. A method for producing a method for the production of a polypeptide comprising the steps of: A recombinant DNA construct, wherein the engineered meganuclease comprises the amino acid sequence of SEQ ID NO:51 and binds to and cleaves nucleic acid at a site comprising a recognition sequence consisting of the nucleic acid sequence of SEQ ID NO:10 within the dystrophin gene.
18. The recombinant DNA construct of claim 17, wherein the polynucleotide comprises a promoter operably linked to the nucleic acid sequence encoding the engineered meganuclease.
19. The recombinant DNA construct of claim 18, wherein the promoter is a muscle cell-specific promoter.
20. A method for producing a method for the production of a polypeptide comprising the steps of: A recombinant virus, wherein the engineered meganuclease comprises the amino acid sequence of SEQ ID NO:51 and binds to and cleaves nucleic acid at a site comprising a recognition sequence consisting of the nucleic acid sequence of SEQ ID NO:10 within the dystrophin gene.
21. The recombinant virus described in claim 20, wherein the recombinant virus is a recombinant AAV.
22. The recombinant virus described in claim 21, wherein the recombinant AAV has a capsid comprising the amino acid sequence of SEQ ID NO: 182 or a capsid comprising the amino acid sequence of SEQ ID NO:
183.
23. A recombinant virus described in any one of claims 20 to 22, wherein the polynucleotide comprises a promoter operably linked to the nucleic acid sequence encoding the engineered meganuclease.
24. The recombinant virus described in claim 23, wherein the promoter is a muscle cell-specific promoter.
25. A polynucleotide comprising a first nucleic acid sequence encoding a first engineered meganuclease and a second nucleic acid sequence encoding a second engineered meganuclease, the first engineered meganuclease comprises the amino acid sequence of SEQ ID NO: 43 and binds to and cleaves nucleic acid at a site in the dystrophin gene that comprises a recognition sequence consisting of the nucleic acid sequence of SEQ ID NO: 6; A polynucleotide, wherein the second engineered meganuclease is a meganuclease that comprises the amino acid sequence of SEQ ID NO:51 and binds to and cleaves nucleic acid at a site that comprises a recognition sequence consisting of the nucleic acid sequence of SEQ ID NO:10 within the dystrophin gene.
26. 26. The polynucleotide of claim 25, wherein the first and second nucleic acid sequences are separated by an internal ribosome entry site (IRES) sequence or a nucleic acid sequence encoding a 2A peptide.
27. 26. A recombinant DNA construct comprising the polynucleotide of claim 25.
28. 28. The recombinant DNA construct of claim 27, wherein the first nucleic acid sequence and the second nucleic acid sequence are separated by an IRES sequence or a nucleic acid sequence encoding a 2A peptide.
29. 30. The recombinant DNA construct of claim 28, wherein said polynucleotide comprises a muscle cell-specific promoter operably linked to said first nucleic acid sequence and said second nucleic acid sequence.
30. A recombinant AAV comprising the polynucleotide of claim 25.
31. 31. The recombinant AAV of claim 30, wherein the first nucleic acid sequence and the second nucleic acid sequence are separated by an IRES sequence or a nucleic acid sequence encoding a 2A peptide.
32. 32. The recombinant AAV of claim 31 , wherein the polynucleotide comprises a muscle cell-specific promoter operably linked to the first nucleic acid sequence and the second nucleic acid sequence.
33. A recombinant AAV described in any one of claims 30 to 32, wherein the recombinant AAV has a capsid comprising the amino acid sequence of SEQ ID NO: 182 or a capsid comprising the amino acid sequence of SEQ ID NO: 183.
